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                           Abstract 
 	  
Smallpox eradication through the use of a live-virus vaccine is one of the most 
successful public health endeavors of modern medicine. Humoral immunity against the 
smallpox virus, characterized by neutralizing antiviral antibody response, is stable, lasts 
for decades, and is considered a valuable benchmark of the functional attributes of a 
good vaccine. Indeed, neutralizing antibody is the best correlate of long-term protective 
immunity for all the currently licensed clinically effective viral vaccines. In this thesis, 
we investigated the contribution of host and viral factors that are responsible for the 
induction of long-lived antiviral humoral immunity. Crosstalk between T follicular 
helper (TFH) cells, T follicular regulatory (TFR) cells and B cells is essential for 
induction of optimal germinal center (GC) responses and subsequent high affinity 
antibody generation. We hypothesized that the escalating concentrations of replicating 
virus (antigens) provide important cues to these immune cell subsets in the GC 
response, and these are critical for induction and maintenance of robust, long-lived 
humoral immunity. To test this, we used mousepox, the disease caused by ectromelia 
virus (ECTV) in mice and an excellent surrogate small animal model for smallpox and 
generalized viral infections. 
 
We found that replication-competent wild type ECTV induced more robust TFH and GC 
responses, contemporaneous with significantly higher neutralizing antibody titers, 
compared with a poorly replicating ECTV strain. We were able to demonstrate via 
passive transfer-challenge experiments, that antibodies generated following infection 
with the poorly replicating strain were not as effective in controlling a secondary 
challenge as compared to antibodies generated following infection with a replication-
competent virus. Similar differences were observed between replicating and non-
	   vi 
replicating strains of both Vaccinia virus (VACV), vaccine-strain Modified Vaccinia 
Ankara (MVA) and influenza A virus. Additionally, strategies to enhance the 
immunogenicity of the replicating-inefficient virus by changes in antigen availability, 
via alterations in the dose and route of administration were evaluated. Importantly, we 
have discussed the ability to prospectively predict the magnitude and potency of long-
lived neutralizing antibody induction using immunological biomarkers in blood, which 
would particularly aid the field of vaccine biology.  
 
Using replication-competent and replication-poor recombinant ECTV expressing 
mutant versions of hen egg lysozyme (HEL) in combination with SWHEL transgenic B 
cells, we extended our studies to antigen-specific B cell responses in poxvirus infection. 
To date, affinity maturation has been studied extensively using protein or protein-hapten 
immunization and the current study is the first, to our knowledge, to systematically 
examine antigen-specific B cell responses and affinity maturation to a virus-expressed 
antigen during infection of a natural host under physiological conditions. In mice 
transferred with SWHEL B cells and infected with recombinant ECTV encoding HEL, 
replicating virus induced massive proliferation of SWHEL B cells, somatic 
hypermutations (SHM) in the variable region exon of SWHEL Ig heavy chain, and 
affinity maturation. In contrast, poorly replicating viruses induced minimal proliferation 
of SWHEL B cells with little or no SHM events. Significantly, robust SWHEL B cell 
responses, associated with augmented proliferation, induction of SHM events and 
secretion of antibody, occurred when the dose and route of administration of poorly 
replicating ECTV encoding HEL was altered.  Collectively, the data presented in this 
thesis provide valuable insights into the rational design of poxviral vaccine vectors to 
achieve an efficacious induction of long-lasting immune memory. 
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1 Introduction 
 
1.1 Vaccination: Contribution of poxviruses 
Vaccination is considered the most important scientific accomplishment in medicine to 
date with significant contributions to public health. Since the first demonstration of 
vaccination by Edward Jenner in the 18th century, the field of vaccine biology has 
grown immensely and contributed to the control of several infectious diseases. The best 
vaccination success story to date is the eradication of smallpox in 1980. It is estimated 
that approximately 300 million people died from smallpox in the 20th century alone and 
decades of vaccination campaigns by the World Health Organization (WHO) 
culminated in the global eradication of the disease. This heralded the development of 
vaccines against a wide variety of infectious organisms and it is estimated that vaccines 
avert approximately 3 million deaths per year globally (WHO, Immunization coverage 
report, April 2015). A recent report released by Centers for Disease Control and 
Prevention (CDC) in April 2015 revealed significant decreases in morbidity as a direct 
impact of mass vaccination (Figure 1.1).  
Currently there are 14 licensed vaccines directed against viral pathogens and these are 
listed in Table 1.1 along with the corresponding correlates of vaccine-mediated 
immunity. It is evident from the review in Table 1.1, that most of the viral vaccines 
work through the production of antibodies to confer immunity. Despite their success, 
most of the currently used vaccines were developed empirically and the immunological 
mechanisms associated with their efficacy are poorly understood. Deconstructing the 
immune responses associated with successful vaccines will further our understanding of 
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vaccine-mediated protection and aid the shift from empiricism to rational design of 
vaccines. 
 
 
 
 
 
 
 
 
 
Figure 1.1. Impact of vaccines on morbidity due to infectious diseases. Comparison 
of 20th century and current morbidity as reported by the CDC, Epidemiology and 
prevention of vaccine-preventable disease, 13th edition, April 2015, Appendix E-7. 
Adapted from Pfizer: The value of vaccines in disease prevention 
(http://www.pfizer.com/files/health/VOMPaper_Vaccines_R7.pdf) 
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Table 1.1 Correlates of protection for licensed viral vaccines  
(Modified from Plotkin et al., 2010) 
 
Vaccine Correlate of protection Threshold of 
protection / Test 
References 
 
Smallpox 
 
Antibody (IgG) 
 
 
1:32 titer 
(Neutralization) 
 
 
(Mack et al., 1972) 
(Sarkar et al., 1975) 
Japanese 
encephalitis 
 
Antibody (IgG) 
 
1:10 titer 
(Neutralization) 
(Van Gessel et al., 2011) 
(Hombach et al., 2005) 
Polio 
 
Antibody ( IgG+ IgA) 1:8 titer 
(Neutralization) 
(Vidor and Plotkin, 2013) 
(Herremans et al., 1997) 
 
Rabies 
 
Antibody (IgG) 1:5 titer 
(Neutralization) 
 
(Gelosa and Borroni, 1990) 
  
Varicella Antibody (IgG) 1:64 titer 
(Neutralization) 
 
(Gershon et al., 2013) 
(White et al., 1992) 
(Li et al., 2002) 
 
Rubella Antibody (IgG) 10-15 mIU/ml 
(Immunoprecipitatio
n) 
 
(Skendzel, 1996) 
(Matter et al., 1997) 
Hepatitis A Antibody (IgG) 10 mIU/ml (ELISA) (Wiedermann et al., 1992) 
(Murphy et al., 2013) 
 
Hepatitis B Antibody (IgG) 10 mIU/ml (ELISA) 
 
(Jack et al., 1999) 
Rotavirus Antibody (IgA) Not defined 
 
(Franco et al., 2006) 
(Angel et al., 2012) 
 
Yellow fever Antibody (IgG) 1:5 titer 
(Neutralization) 
 
(Julander et al., 2011) 
(Monath et al., 2013) 
Human 
papillomavirus 
 
Antibody (IgG) Not defined (Schiller et al., 2013) 
Mumps Antibody (IgG) 1:2-1:34 
(Neutralization)  
No cut-off point 
defined 
 
(Weibel et al., 1975) 
(Cortese et al., 2011) 
Varicella zoster Antibody + cellular 
immunity (IgG + CD4) 
 
Not defined (Levin et al., 2008) 
(Weinberg et al., 2009) 
Influenza Antibody + cellular 
immunity (IgG + CD8) 
 
1:40 titer 
(Neutralization) 
(Reber and Katz, 2013) 
(Coudeville et al., 2010) 
Measles Antibody + cellular 
immunity (IgG + CD8) 
120 mIU/ml (Chen et al., 1990) 
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The exact immune correlates of protection for the most successful vaccine to date, the 
smallpox vaccine, remains unknown due to eradication of the disease 35 years ago. 
However, studies from vaccinated individuals and animal models point to a critical role 
for neutralizing antibodies in vaccine-mediated protection. Seminal work by Mack et 
al., found that a serum antibody neutralizing titer of >1:32 titer was associated with 
protection against smallpox (Mack et al., 1972). Longitudinal studies on smallpox 
vaccinees found that although the antiviral T cell responses gradually weakened over 
time with a half-life of 8-15 years, the antiviral antibody and humoral immune memory 
responses were maintained for life (Hammarlund et al., 2003; Crotty et al., 2003a). The 
long-term immunity in smallpox survivors and vaccinees associated with persisting 
antiviral antibody titers and immune memory is considered a valuable benchmark for 
understanding the functional attributes of an effective vaccine.  
Although Variola virus (VARV), the causative poxvirus of significant human morbidity 
and mortality has been eradicated, there still exists a renewed interest in understanding 
immunity to poxvirus infections. This interest stems from the re-emergence of zoonotic 
poxvirus infections over the last decade and the use of recombinant poxviral vectors as 
vaccine delivery systems. With the cessation of vaccination against smallpox, herd 
immunity to orthopoxvirus infections has been reduced and human outbreaks of 
zoonotic poxvirus infections such as monkeypox, cowpox and orf (contagious pustular 
dermatitis) have been on a steady increase (Shchelkunov, 2013; Lewis-Jones, 2004; 
Essbauer et al., 2010). The successful eradication of smallpox using the closely related 
Vaccinia virus (VACV) has provided impetus for trial of recombinant VACV vectors in 
many human and veterinary diseases and cancer. Poxviruses have a large genome, 
allowing insertion and high-level expression of exogenous genes, making them an ideal 
choice for use as recombinant vaccine vectors (Smith and Moss, 1983). The control of 
emerging zoonotic poxvirus infections and designs of efficacious recombinant poxvirus 
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vaccine vectors can be better facilitated by a deeper understanding of the antiviral 
immune responses generated following poxvirus infections. 
The immune response to poxvirus infection is mediated by a myriad of innate and 
adaptive immune mechanisms working in concert to eliminate infection and protect the 
host. Whilst the innate and cellular immune responses are critical for virus control, the 
engagement of humoral adaptive immune responses to generate high-affinity antibody 
secreting plasma cells and immune memory is absolutely essential for virus elimination 
and protection from re-infection. In the following sections, an overview of the immune 
response to poxvirus infection is complemented with a detailed description of the key 
cellular mediators of the germinal center (GC) reaction critical for durable and potent 
antiviral humoral immune response. 
1.2 Overview of immune response to poxvirus 
infections 
This section aims to provide a broad overview of the immune responses to 
orthopoxvirus infections, with a detailed description provided in section 1.4 of this 
chapter. The host response to poxvirus infection is multifaceted with all arms of the 
immune system: innate, cellular and humoral adaptive responses contributing to virus 
elimination and host protection. The innate adaptive responses that are initiated early in 
the infection are antigen-independent and play an important role in controlling the 
infection whilst the acquired immune response is mounted. The cells of the innate 
immune system [Natural killer (NK) cells, Dendritic cells (DC), macrophages] detect 
viral infection through germline encoded Pattern Recognition Receptors (PRR) either at 
the plasma membrane [via Toll-Like receptors (TLR) and C-type lectin receptors 
(CLR)] or within the cytosol [via Retinoic acid-inducible gene (RIG)-1 like receptors 
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(RLR) and Nucleotide-binding oligomerzation domain (NOD)-like receptors (NLR)]; 
reviewed in (Takeuchi and Akira, 2010). These PRR trigger downstream signal 
transduction pathways and influence the adaptive immune responses by the production 
of interferons and inflammatory cytokines; reviewed in (Brady and Bowie, 2014). 
Contrasting to the innate immune system, the adaptive immune responses take longer to 
develop and are antigen specific. Whilst the major histocompatibility complex (MHC) -
class I restricted, cytolytic T lymphocyte (CTL) effector function of CD8+ T cells in 
virus control is well acknowledged (Goulding et al., 2012; Karupiah et al., 1996), only 
few studies have highlighted the contribution of MHC-class II (MHC II)-restricted CTL 
effector activity of CD4 T cells in poxvirus infections (Karupiah et al., 1996; Fang et 
al., 2012). Several studies have demonstrated the importance of CD4 T helper cell 
activity in the generation of poxvirus-specific antiviral antibodies by B cells (Chaudhri 
et al., 2006; Xu et al., 2004). The antibodies produced confer protection by functioning 
either directly through virus neutralization or indirectly by activation of the complement 
cascade, antibody dependent phagocytosis or antibody dependent cellular cytotoxicity 
(Zinkernagel et al., 2001; Hirsch, 1982; Nimmerjahn and Ravetch, 2008; Cohen et al., 
2011). Importantly, it has been demonstrated that the poxvirus specific antiviral 
antibody responses, in both mice and humans, were maintained long-term and 
contribute to the protective immunity against secondary poxvirus infections 
(Panchanathan et al., 2006; Moss, 2011). Sustained levels of high-affinity antiviral 
antibodies are maintained by long-lived antibody secreting plasma cells and memory B 
cells; generated in specialized microenvironments referred to as GC that form the basis 
of T-cell dependent humoral immune response.  Within the GC, B cells undergo intense 
proliferation, cycles of positive / negative selection and somatic hypermutation (SHM), 
isotype-class switching and differentiation. Apart from B cells, specialized CD4+ T cell 
subsets within the GC, referred to as T-follicular helper (TFH) cells and T-follicular 
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regulatory (TFR) cells are required for the induction and regulation of GC responses 
(Breitfeld et al., 2000; Linterman et al., 2011). In poxvirus infections, very little is 
known about dynamics of the key cellular players that are critical for driving the GC 
response. The next section provides a detailed description of the primary cellular 
mediators of GC response: TFH cells, TFR cells and GC B cells. 
1.3 Cellular players in GC response 	  
1.3.1 T-follicular helper cells 	  
1.3.1.1 Introduction 
The field of CD4+ T helper (Th) helper cell has progressed immensely from the basic 
functional subset proposition by Mosmann and Coffman in 1986, when they described 
that IFN-γ secreting Th1 cells were distinct from IL-4 expressing Th2 cells (Mosmann 
et al., 1986). Since then in addition to the regulatory Th (TREG) cell subset, four 
auxillary subsets of Th cells: Th17, TFH, Th9 and Th22 have been described; reviewed 
in (Luckheeram et al., 2012). Master regulatory transcription factors and local cytokine 
milieu play an important role in determining the CD4 T cell fate and these key 
determinants are illustrated in Figure 1.2. Although our understanding of the various 
cytokines produced by the Th subset continues to evolve, dominant cytokine patterns 
are depicted in Figure 1.2. 
TFH cells are specialized providers of T cell help to B cells and are essential for GC 
formation and production of high-affinity antibodies in response to infection or 
vaccination. All the currently approved human vaccines work through the production of  
long-lasting antibody responses and TFH cells play an important role in protective
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Figure 1.2. T helper cell differentiation pathways. Following engagement of the T 
cell receptor (TCR) with cognate peptide-MHCII (pMHCII) presented by DC, naive 
CD4 T cells can differentiate into one of several effector Th cell lineages. Th cell 
lineages, their master transcription factor regulators, polarizing cytokines and effector 
cytokines are illustrated. 
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immunity as mediators of antibody output. To mediate this B cell help function, TFH 
cells express follicle homing chemokine (C-X-C motif) receptor 5 (CXCR5) to allow 
migration into the B cell follicular area along the chemokine C-X-C-ligand (CXCL)-13 
gradient. Although B-cell lymphoma 6 (Bcl6) has been established as the master 
regulatory transcription factor for TFH cells, other transcription factors such as Basic 
leucine zipper transcription factor (BATF), Interferon regulatory factor 4 (IRF4) and c-
maf make supporting contributions to TFH differentiation (Nurieva et al., 2009; Bollig et 
al., 2012; Ise et al., 2011; Bauquet et al., 2009). TFH cells have been typically identified 
by the high surface expression of CXCR5 and programmed cell death receptor-1 (PD-1) 
in conjunction with a variety of positive markers such as Bcl6, IL-21 and inducible co-
stimulator (ICOS) or a negative marker such as forkhead box P3 (Foxp3). An overview 
of the TFH cell biology including its differentiation, regulation and B cell help function 
is presented below. 
 
1.3.1.2 Stages of TFH differentiation 
TFH differentiation has been described as a multi-step process (illustrated in figure 1.3, 
page 16), starting with the priming of a naïve CD4 T cell by an antigen-presenting cell, 
usually a dendritic cell (DC). Following a foreign antigen encounter, DC take up, 
process and present antigen on MHC-II to the naïve T cells in the T cell zone of the 
secondary lymphoid organ. This first signal of T cell activation is complemented by 
additional co-stimulatory signaling between CD86 on the DC with CD28 on the T cells. 
CD28 ligation is an absolute requirement as evidenced by impaired TFH development, 
GC reaction and antibody responses in viral infections (Salek-Ardakani et al., 2011). 
TFH differentiation at this early stage is regulated by ICOS, IL-6, IL-2, and T cell 
receptor (TCR) signal strength. 
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 ICOS mediated Bcl6 induction is required for the downstream expression of CXCR5 
by the TFH cells (Choi et al., 2013a). In addition, ICOS:ICOSL mediated up-regulation 
of c-maf results in subsequent production of IL-21 by TFH cells (Bauquet et al., 2009), 
which in an autocrine manner promotes TFH development as well as influences GC 
formation and antibody responses. In the absence of ICOS, impaired development of 
TFH cells is observed in both mice and humans (Akiba et al., 2005; Bossaller et al., 
2006; Grimbacher et al., 2003).  
IL-6 signaling mediated through Signal Transducer And Activator Of Transcription 
(STAT) 1 and STAT3 have been identified as the earliest non-TCR signals in TFH 
differentiation. Addition of IL-6 and IL-21 to activated CD4 T cell cultures significantly 
increases the expression of Bcl6, the master transcription factor of TFH cells (Eto et al., 
2011). Bcl6 expression up-regulates CXCR5 and down-regulates CCR7, allowing TFH 
positioning at the T:B border. Apart from this migrational control of TFH cells, a recent 
study by Hatzi et al. identified Bcl6 as a primary repressor of alternate T cell fates 
(Hatzi et al., 2015). Early in the TFH differentiation pathway, IL-2 mediated STAT5 
signaling can inhibit TFH cell differentiation by down regulating CXCR5 and IL-21 
(Ballesteros-Tato et al., 2012). In addition to the cytokine mediated TFH differentiation, 
TCR signal strength has been identified as a regulator of fate preference. Tubo et al. 
demonstrate that variation in the TCR signaling imparted by the TCR: pMHCII dwell 
times can influence CD4 Th cell differentiation decision (Tubo et al., 2013). Therefore 
complex interactions between antigen, cytokine milieu, signaling molecules, TCR 
signal and transcription factors together orchestrate the early TFH cell differentiation. 
The second stage of differentiation occurs during cross talk between early TFH and B 
cells in the interfollicular area or the T:B border. In addition to the chemokine gradient 
described, two photon intra-vital imaging studies reveal an ICOS-mediated relocation of 
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the early TFH cells to the T: B border (Xu et al., 2013). CD40-CD40L interactions are 
critical for the exchange of signals between TFH and B cells; this is supported by 
impaired humoral responses against viral pathogens in CD40 or CD40L deficient mice 
(Borrow et al., 1996; Edelmann and Wilson, 2001; Sangster et al., 2003; Panchanathan 
et al., 2006). The third and final stage of TFH differentiation to form GC TFH cells that 
localize within the GC is governed by Signaling Lymphocyte Activation Molecule 
(SLAM)- associated protein (SAP) and this is discussed further in section 1.3.1.3.  TFH 
and GC TFH cells have similar expression profiles, with GC TFH cells representing a 
further polarized subset of TFH cells with higher expression of CXCR5, PD-1, Bcl6 and 
SAP (Yusuf et al., 2010). In addition to IL-21, GC TFH cells are potent producers of IL-
4, thereby playing a key role in GC maintenance and affinity maturated antibody 
responses. Importantly, loss of GC TFH cells results in impaired humoral responses 
underscoring the importance of the final differentiation step of TFH cells in antibody-
mediated protective immunity (Yusuf et al., 2010). 
1.3.1.3 SAP mediated TFH : B cell interaction 
The stability of T: B interaction appears to be a key determinant of TFH cell 
differentiation fate. SLAM family of receptors, differentially expressed on TFH and 
activated B cells, bind in a homophilic manner mediating TFH and B cell interactions. 
SAP, a Src-homology 2 (SH2)-domain adaptor protein encoded by the SH2D1A gene 
binds to the cytoplasmic tails of SLAM family of receptors and mediates positive 
signaling (Latour et al., 2003). Recent studies have highlighted that SAP not only 
mediates positive signaling to stabilize the T: B interaction, but can negate the dominant 
negative signal that would otherwise reduce the duration of contact (Kageyama et al., 
2012). It is worthwhile to note that T: DC interaction is not affected by SAP deficiency 
and the SAP deficient T cells acquire a surface TFH phenotype(Cannons et al., 2010). 
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However, subsequent contact-dependent interaction between the activated B cells and 
TFH cells in the inter-follicular area is affected in the absence of SAP. Elegant in-vivo 
two-photon microscopy studies have revealed that the SAP-deficient early TFH cells are 
unable to maintain prolonged, mobile conjugates with the antigen presenting cognate B 
cells leading to defective exchange of signals (Qi et al., 2008). As a result, the 
relocation of TFH cells to the GC and B cell proliferation is affected leading to impaired 
GC response. Decreased antibody titers have been demonstrated in SAP-deficient mice 
across several infection models including Lymphocytic choriomeningitis (LCMV), 
influenza, Leishmania major, Schistomosoma mansoni and Toxoplasma gondii (Crotty 
et al., 2003b; Kamperschroer et al., 2006; Cannons et al., 2006; Czar et al., 2001; Wu et 
al., 2001). These findings are consistent with hypogammaglobulinemia detected in 
SAP-deficient humans (XLP-1 patients) (Booth et al., 2011). In addition, SAP-deficient 
humans demonstrate increased susceptibility to several viral infections (Rezaei et al., 
2011). Veillette et al., using conditional SAP-deficient mice, demonstrated that the 
altered humoral immune responses were specifically due to SAP-deficiency in T cells 
(Veillette et al., 2008).  The critical contribution of SAP-mediated TFH: B cell 
interactions to long-term antibody responses suggest that regulation of SLAM-family 
receptor signaling as a strategy to mediate humoral responses post-vaccination.  The 
contribution of SAP to protective immune responses in poxvirus infections has not been 
investigated thus far and this is addressed in this thesis study. 
1.3.1.4 Circulatory TFH cells 
TFH cells have been primarily defined and discussed in relation to their follicular 
location in the secondary lymphoid organ. However, several recent studies have 
revealed the presence of circulating TFH cells in both mice and humans. Although He et 
al., demonstrated a strong correlation between the kinetics of circulatory and lymphoid 
	   14 
TFH cells post-immunization, circulatory blood TFH cells are not considered ‘bonafide 
TFH cells’ due to the lack of Bcl6 expression (He et al., 2013; Locci et al., 2013; Morita 
et al., 2011). Nevertheless, circulating TFH cells have been demonstrated to provide 
efficient B cell help both in-vitro and in-vivo (Sage et al., 2013; Morita et al., 2011; 
Schaerli et al., 2000). In Sanroque mice (Vinuesa and Goodnow, 2004), a model for 
systemic autoimmunity characterized by excessive TFH numbers in the absence of 
antigen, an increase in the circulating TFH numbers was also detected, further 
confirming a correlation between the magnitude of TFH cells in the secondary lymphoid 
organs and blood TFH cells (He et al., 2013). The circulating TFH cell population was 
maintained in the SAP-deficient mice in the absence of its GC counterpart, suggesting 
that the blood TFH cells were generated prior to the GC reaction. These results are 
consistent with the normal circulatory TFH numbers in XLP-1 patients (He et al., 2013). 
Despite an extensive variation in the markers used to identify circulatory TFH cells in 
published scientific literature, the ability to identify a blood correlate of lymphoid TFH 
cells is of immense significance to human studies encompassing autoimmune conditions 
and vaccination programs. Recent efforts have identified circulating TFH cell expansion 
following influenza vaccination in adults, underscoring the importance of these cells in 
the field of vaccine biology (Herati et al., 2014). Induction of circulating TFH cells and 
its correlation to long-term antiviral antibody response in poxvirus infections or 
recombinant poxvirus vector vaccinations have not been investigated thus far and will 
be one focus in this thesis. 
1.3.1.5 Memory TFH cells 
The memory TFH cell field is relatively new with several recent studies demonstrating 
the presence of TFH cell memory in both mice and humans. Although initial reports 
suggesting the presence of memory TFH cells were confounded by antigen persistence, 
	   15 
adoptive transfer experiments by Weber et al., and Hale et al., clearly demonstrated the 
presence of effector TFH memory cells that could be maintained in the absence of 
antigen (Weber et al., 2012; Hale et al., 2013). Importantly, these studies established 
that the TFH memory cells on recall, preferentially maintained a TFH phenotype. In 
addition, MacLeod et al., demonstrated that the CXCR5+ subset of memory CD4 T cells 
provide robust B cell helper activity during recall (MacLeod et al., 2011). Two 
pathways of memory TFH cell formation have been suggested: TFH cells devoid of ‘GC 
status’ can directly commit to a memory TFH cell phenotype or GC TFH cells upon 
exiting the GC can acquire a polarized TFH phenotype and develop into memory TFH 
cell (Choi et al., 2013b; Hale et al., 2013; Shulman et al., 2013). Transcriptional 
profiling of memory TFH cells revealed that the gene expression patterns were enriched 
for a TFH effector profile (Locci et al., 2013). As the field continues to evolve, 
identification of specific markers of memory TFH cells will allow for a better 
understanding of the role of TFH memory during recall responses during infections or 
vaccination boost. 
1.3.2 T follicular regulatory cells  
Production of high-affinity class-switched antibodies critical for viral clearance is 
dependent on interaction between TFH and B cells in the GC. A tight regulation of the 
GC  response  is   essential  to  ensure   optimal  levels  of   antibody  whilst  preventing 
autoimmunity. Although early studies reported the presence of TREG cells in the GC, it 
was only in 2011 that three independent groups described the existence of TFR cells, a 
specialized CD4 T cell subset with GC governing capabilities (Linterman et al., 2011; 
Wollenberg et al., 2011; Chung et al., 2011). TFR cells are phenotypically similar to TFH  
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Figure 1.3. Stages of TFH cell differentiation. Antigen presentation by pMHCII 
complexes on DC results in the activation of naïve CD4 T cells and differentiation to 
TFH cells in a SAP-independent manner (1st stage). Upregulation of CXCR5 allows TFH 
cells to migrate to the T:B border for interaction with activated B cells (2nd stage). This 
step is SAP-dependent and further migration and differentiation to GC TFH cells (3rd 
stage) is impaired in the absence of SAP. GC TFH cells provide help to cognate GC B 
cells, supporting the GC reaction and facilitating affinity maturation. Memory TFH cells 
can develop directly from GC TFH cells or TFH cells that have exited the GC reaction. 
Contrastingly, circulatory TFH cells are generated prior to the participation of the TFH in 
the GC response. 
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cells with expression of CXCR5, PD-1, ICOS and Bcl6. In addition, TFR cells also 
express Foxp3, glucocorticoid-induced TNFR family related gene (GITR) and cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4). Gene expression analysis of TFR cells by 
Linterman et al., revealed that TFR cells have a distinct transcriptional profile more 
similar to TREG cells than TFH cells. In the same study, using TCR transgenic CD4 T 
cells and adoptive transfer experiments it was demonstrated that the TFR cells are 
derived from TREG cells. Some of the cues for differentiation are shared between TFH 
and TFR cells such as ICOS, CD28, presence of B cells and SAP expression (Linterman 
et al., 2011).  
Despite the similar phenotype, certain distinct transcriptional differences exist between 
TFH and TFR cells. In contrast to TFH cells, in which Bcl6 cells suppress Foxp3 
expression, TFR cells co-express Bcl6 and Foxp3 (Chung et al., 2011). Moreover, 
CXCR5 up-regulation in TFR cells is Bcl6-independent. In a recent study by Vaeth et al., 
it was demonstrated that the transcription factor NFAT2 deficiency reduced CXCR5 
expression specifically on TFR cells resulting in enhanced GC response (Vaeth et al., 
2014). TNF-receptor associated factor 3 (TRAF3) and Inhibitor of DNA binding 3 
(ID3) have recently been identified as TFR specific developmental cues, further 
highlighting key molecular differences between TFH and TFR cells despite the similar 
phenotype (Chang et al., 2014; Miyazaki et al., 2014). Significantly, TFH and TFR cells 
are functionally distinct: whilst TFH cell promote humoral antibody responses, TFR cells 
have been shown to regulate the GC responses using differing experimental strategies. 
Linterman et al. used mixed bone marrow chimeras (irradiated Rag-/- mice reconstituted 
with cells from SAP-deficient mice and Foxp3 Diphtheria Toxin receptor (DTR) 
transgenic mice) to demonstrate an increase in TFH and GC B cells numbers following 
TFR cell depletion (Linterman et al., 2011). Adoptive transfer experiments by Chung et 
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al., (CXCR5-/- or Bcl-6-/- TREG transferred into Tcrβ-/- mice) and Wollenberg et al., 
(CXCR5-/- TREG transferred into Tcrα-/- mice) revealed a substantial increase in antibody 
levels without affecting TFH cells (Chung et al., 2011; Wollenberg et al., 2011). 
Collectively, these experiments demonstrate that the TFR cells control the magnitude of 
the GC response, however whether it is mediated through TFH cells, B cells or a 
combination of both is not clearly understood. Several mechanisms of suppression by 
TFR cells have been proposed such as cytokine production, mechanical disruption of 
TFH: B cell interaction and cytolysis. Further work is required to elucidate the 
mechanism of suppression specifically employed by TFR cells in comparison to non-TFR 
TREG cells. 
As seen with TFH cells, a circulatory counterpart of lymphoid TFR cells has recently been 
identified. In their studies, Sage et al., demonstrated that the circulatory TFR cells were 
capable of homing to the secondary lymphoid organs and migrating to the GC (Sage et 
al., 2014). Importantly, circulatory TFR cells can suppress TFH and B cells, albeit to a 
lesser extent compared to the lymphoid TFR cells. Work by the same group showed that 
the PD-1 pathway regulates TFR development and function, both in the lymphoid and 
blood compartment (Sage et al., 2013). PD-1 and PD-L1 deficient mice exhibited 
increased TFR cell numbers as well as enhanced suppressive activity. In this regard, 
understanding the role of TFR cells in induction of long-lived poxviral antibody 
responses will provide useful insights into modulation strategies required to augment 
humoral antibody responses to recombinant poxviral vaccine vectors. 
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1.3.3 Germinal center B cells 	  
1.3.3.1 Role of B cells in GC responses: an overview 
Engagement of the GC response to elicit antiviral antibody and immune memory 
response is a hallmark of adaptive immune responses. GC are specialized 
microenvironments that develop in B cell follicular areas of secondary lymphoid organs 
in response to T-dependent antigens (MacLennan, 1994) (illustrated in Figure 1.4, page 
23). B cell follicles are primarily located close to areas of antigen entry i.e., the 
marginal sinus in the spleen or sub-capsular sinus of the lymph node (Batista and 
Harwood, 2009). Naïve B cells scan the follicular area and are activated on encounter 
with foreign antigens, either on antigen presentation by sub-capsular sinus macrophages 
(Carrasco and Batista, 2007; Junt et al., 2007), antigen uptake from follicular dendritic 
cells (FDC) (Allen and Cyster, 2008; Phan et al., 2007) or by binding directly to soluble 
antigens (Pape et al., 2007). Subsequently, B cells internalize the antigen and up-
regulate Epstein-Barr virus induced gene 2 (EBI2) and C-C-Chemokine receptor 7 
(CCR7), facilitating a G-protein coupled receptor (GPCR) mediated and chemokine-
guided migration towards the interface of T and B cell follicular areas (Kelly et al., 
2011; Pereira et al., 2009; Okada et al., 2005; Okada et al., 2002). Here, B cells engage 
in cognate interactions with CD4+ T cells by presenting peptide antigen to cognate early 
TFH cells that have migrated to the T:B border following priming by DC. This initial 
interaction is followed by localization of B cells at the perimeter of the follicle, away 
from the T cell zone, mediated primarily by a combination of EBI2 and CCR7 down-
regulation. B cells proliferate and undergo proliferation to proceed down one of two 
independent routes: follicular or extra-follicular migration pathways 
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Upon adopting an extra-follicular fate, B cells migrate away from the perimeter of the 
follicle to the inter-follicular or bridging channel to form extra-follicular foci of 
antibody production. This migration of extra-follicular plasmablasts is mediated by a 
down-regulation of CXCR5 and up-regulation of CXCR4 resulting in translocation 
along the CXCL12 gradient (Wehrli et al., 2001; Hargreaves et al., 2001). Interaction 
with the CD11chi DC at the bridging channels is essential for survival and terminal 
differentiation into extra-follicular plasma cells that are responsible for early production 
of antibodies (Garcia De Vinuesa et al., 1999; Smith et al., 1996). This initial burst of 
antibodies is critical for the early control of infection whilst the GC reaction matures to 
produce high-affinity antibodies. 
B cells that adopt the alternative follicular fate migrate towards the center of the follicle 
mediated by down-regulation of EBI2 to seed the GC response (Gatto et al., 2009; 
Pereira et al., 2009). The clonal expansion of B cells results in the formation of two 
zones within the GC: dark zone and light zone. The dark zone, situated closer to the T 
cell zone is predominantly populated by rapidly dividing B cells referred to as 
centroblasts. During the phase of extensive division, centroblasts express high amounts 
of activation-induced deaminase (AID) essential for the process of SHM in which 
somatic mutations are introduced in the variable (V) region of the B cell receptor (BCR) 
(discussed in section 1.3.3.2.2) (Muramatsu et al., 2000; Berek et al., 1991). The 
stochastic nature of SHM can result in the generation of high, low or self-reactive BCR 
and the critical process of selection for cells with high-affinity BCR occurs in the light 
zone (Shlomchik et al., 1990; Ray et al., 1996; Liu et al., 1989).  GC B cells express 
high amounts of Fas (Apoptosis protein 1 (APO-1) or CD95) and Fas-dependent 
apoptosis has been implicated in the elimination of B cells with sub-optimal affinity or 
auto reactivity (Hao et al., 2008). 
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Prior to migration and selection in the light zone, the dark zone centroblasts exit the cell 
cycle and differentiate into non-dividing cells referred to as centrocytes (Victora et al., 
2010). The light zone is densely packed with centrocytes, interspersed with GC TFH 
cells and FDC. Centrocytes take up antigen from the FDC, internalize, process and 
present antigen in the form of peptide associated with MHCII to GC TFH cells (Allen et 
al., 2007). Several studies demonstrate that the high affinity clones outcompete the low 
affinity centrocytes for antigen-capture and cognate interaction with GC TFH cells that 
provide further proliferation and differentiation cues (Shih et al., 2002; Schwickert et 
al., 2011; Anderson et al., 2009). Positive exchange of signals between GC TFH and 
centrocytes can result in either re-entry into the dark zone to undergo further SHM or 
differentiation along one of two alternative fates: long-lived plasma cells or memory B 
cells (Victora et al., 2010; McHeyzer-Williams and Ahmed, 1999; Choi, 1997). Post-
GC, antibody-secreting plasma cells preferentially home to the bone marrow where they 
have been shown to persist for life in the absence of antigen and cell division (Manz et 
al., 1998; Slifka et al., 1995). Plasma cell formation is regulated by several factors 
including expression of transcription factors [such as B-lymphocyte-induced maturation 
protein-1 (BLIMP-1), X-box-binding protein 1(XBP1), Interferon regulator factor 4 
(IRF4)], the suppression of cytokines (IL-21 and IL-10) and PD-1 signaling pathway 
(Good-Jacobson et al., 2010; Turner et al., 1994; Reimold et al., 2001; Klein et al., 
2006). Memory B cells do not secrete antibody, but possess the intrinsic ability to 
rapidly differentiate into antibody secreting plasma cells during recall responses 
(Tangye et al., 2003). Similar to long-lived plasma cells, memory B cells can persist 
independent of antigen and several studies have suggested that B cell lymphoma-2 (Bcl-
2) family members that regulate the mitochondrion-dependent cell-death pathways play 
a role in the long-term survival of memory B cells (Maruyama et al., 2000; Clybouw et 
al., 2011; Smith et al., 2000). In addition, a recent study by Chen et al., demonstrate a 
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role for autophagy in memory B cell maintenance following influenza infection (Chen 
et al., 2014). Generation of immune memory and long-lived antibody responses are 
central to the protective immunity elicited by vaccines. The host and viral factors that 
contribute to the induction of long-lived humoral immune responses in poxvirus 
infections are discussed in this thesis. 
1.3.3.2 Affinity maturation 
The production of antigen-specific high affinity antibodies during the course of an 
immune response hinges on the process of affinity maturation, by which cells with high 
BCR antigen affinity are preferentially selected to survive and proliferate. Affinity 
maturation involves two inter-related events: SHM and class switch recombination 
(CSR) (Figure 1.5, page 28); a brief description of these events in the following sections 
provides an insight into the molecular complexities associated with the generation 
affinity matured antigen specific antibody responses. 
1.3.3.2.1 Class Switch recombination 
The heavy chain constant (CH) region of the immunoglobulin gene determines the 
antibody isotype and subsequent effector function. Immunoglobulin isotype switching is 
mediated by intrachromosomal deletion-recombination events via CSR. CSR occurs 
between the switch (S) regions containing short stretches of repetitive G-rich sequences 
located upstream of each of the CH region (Dunnick et al., 1993). CSR events in 
centroblasts are dependent on AID expression and are influenced by the number of 
mitotic cell cycles. Studies suggest that a minimum of two rounds of cell divisions is 
required for CSR to IgG and IgA isotype (Hodgkin et al., 1996; Rush et al., 2005; 
Deenick et al., 1999).  In  addition to  the mitotic cycles, studies  have shown  that  AID 
expression in centroblasts is regulated by several transcription factors such as paired 
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box protein 5 (Pax5), homeobox 4 (HOXC4) and forkhead box 01 (FOX01) (Tran et al., 
2010; Park et al., 2009; Dengler et al., 2008). Furthermore the local cytokine milieu has 
been shown to influence CSR to specific isotypes; for example, it has been 
demonstrated in mice that IFN-γ expression can promote switching of B cells to IgG2a 
subclass (Peng et al., 2002; Mohr et al., 2010). 
AID acts on the repetitive ‘hot spot’ targets in the S regions of the single stranded DNA 
resulting in the deamination of cytosine residues to uridine (Dickerson et al., 2003; 
Muramatsu et al., 2000). To introduce DNA breaks essential for CSR, enzymes of the 
base-excision repair (BER) pathway (specifically Uracil-DNA glycosylase [UNG]) 
excise the uridine residues resulting in an abasic site (Schrader et al., 2005; Rada et al., 
2002). The apurinic / apyrimidinic endonuclease 1 (APE1) introduces an incision at the 
abasic site leading to the production of a single-stranded break (SSB) (Kanno et al., 
2007; Guikema et al., 2007). Following conversion of SSB into double-strand break 
(DSB) by mismatch repair machinery, the gene segments of donor and acceptor S 
regions are rejoined by non-homologous end joining (NHEJ) resulting in the assembly 
of a functional immunoglobulin gene that encodes a different downstream isotype: γ 
(IgG), α (IgA) or ε (IgE) (Schrader et al., 2007; Rooney et al., 2004). 
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Figure 1.4. GC reaction. (1) Upon antigen encounter, activated B cells migrate 
towards the border of the T: B zone to seek cognate T cell help. (2) B cells then re-
localize to the outer follicular area away from the T cell zone, undergo rapid 
proliferation and differentiation along one of two alternate pathways: Extra follicular 
and Follicular pathway. (3) B cells differentiating into extra follicular plasma cells, 
migrate to the bridging channels of the inter-follicular area where they form foci of 
short-lived antibody production. (4) B cells that commit to the follicular pathway 
proliferate to form the dark zone where they undergo affinity maturation and selection 
in the light zone mediated by GC TFH cells and FDC. Ultimately, affinity matured B 
cells differentiate into either long-lived plasma cells or memory B cells.  
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1.3.3.2.2 Somatic Hypermutation 
Following exposure to foreign antigen, antibody diversity by the process of SHM 
results in the generation of antigen-specific high affinity antibodies. Similar to CSR, 
SHM occurs principally in the rapidly dividing centroblast cells situated in the dark 
zone that have a high level of expression of the AID enzyme. Preliminary studies by 
Rajewsky et al., indicate that SHM in the variable region of the immunoglobulin gene 
occurs at a rate of 10-3 mutations per base, per cell division; which is approximately a 
million-fold higher than the spontaneous mutation rates in other somatic genes 
(Rajewsky et al., 1987). The mutations introduced during the process of SHM are 
predominantly single base substitutions, although rare insertion and deletions have also 
been identified (Goossens et al., 1998). The process of SHM is influenced by the 
primary sequence and is principally targeted to the hot spot motifs in the variable 
region, beginning ~ 150-200 bp downstream of the promoter and terminating prior to 
the enhancer regions (Rada et al., 2002; Rogozin and Diaz, 2004). AID initiates the 
process of SHM by deamination of cytosine residues in the transcriptionally active 
variable region. Three alternative routes of repair have been proposed for the resulting 
mismatch introduced by the uridine residue. First if the mismatch is not repaired prior to 
the onset of DNA replication, DNA polymerases recruit an adenosine nucleotide 
leading to a transition mutation. Second, if the uridine residue is excised by UNG prior 
to DNA synthesis resulting in an abasic site, both transition and transversion mutations 
are possible. Third, recognition of the mismatch by the mismatch repair (MMR) 
pathway triggers an error prone mutagenic DNA repair synthesis than can create 
additional mutations at A-T base pairs near the initial mismatch. The random nature of 
SHM can result in either increase or decease in the affinity of the BCR to the antigen. 
Therefore cycles of SHM are followed by selection in the light zone to expand the high 
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affinity variants whilst causing apoptosis of low affinity or self-reactive clones 
(Takahashi et al., 1999).  
Much of our current understanding of affinity maturation comes from reports using 
model protein antigens (Jacob et al., 1993; Gearhart et al., 1981; Phan et al., 2003). One 
such model employing the use of transgenic SWHEL mice to study affinity to the protein 
antigen hen egg lysosome (HEL) is described in the following section.  
1.3.3.3 SWHEL transgenic system to study affinity maturation 
Anti-HEL MD4 mice, a classic immunoglobulin transgenic model has provided useful 
insights into the mechanism of B cell tolerance during development (Goodnow et al., 
1988; Goodnow et al., 1989; Goodnow, 1992). However, the inability of the MD4 
transgenic B cells to undergo CSR to downstream immunoglobulin isotypes (IgG, IgE 
and IgA)  and  SHM  limited  the use  of  this  model  in  T-dependent  antibody studies. 
Subsequently a heavy chain VDJ knock-in mice capable of affinity maturation, 
designated as SWHEL (switching anti-HEL) was developed (Phan et al., 2003). SWHEL 
mice carry two independently segregating loci; the rearranged VH10 region encoding 
HyHEL-10 [anti-HEL monoclonal antibody (mAb)] specificity targeted to the 
immunoglobulin heavy chain locus and the random integration of the VK10 light chain 
identical to that in the MD4 transgenic mice. Phan et al., demonstrated that mice 
heterozygous in both these alleles were capable of undergoing isotype switching (Phan 
et al., 2005). As a consequence of the variable gene recombination events in VDJ 
knock-in mice, 10-20% of the B cells in SWHEL mice bind HEL encoded by the 
HyHEL10 specificity (Brink et al., 2008; Chan et al., 2009). 
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Figure 1.5. Illustration of SHM process and CSR to IgE. (A) SHM: AID initiates the 
process of SHM by deamination of the cytosine residue (to uridine) in the 
transcriptionally active V region. Three error prone pathways of repair involved in the 
processing of the U:G mismatch resulting in transition or transversion mutations at the 
original C:G base-pair or downstream A:T base-pair are illustrated (described in section 
1.3.3.2.2). (B) CSR to IgE:  During CSR, AID mediated deamination of the 
transcriptionally active S region results in the generation of a SSB that is subsequently 
converted into a DSB by the MMR pathway. Isotype switched IgE is produced by 
NHEJ of the donor and acceptor S regions as illustrated in the figure. 
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HyHEL10 anti-HEL mAb binds to wild-type HEL with very high binding affinity 
(Padlan et al., 1989) and to study the process of affinity maturation, HEL variants with 
amino acid substitutions that reduce the affinity to HyHEL10, without altering the 
folding of the HEL protein were generated. These proteins designated as HEL1X, 
HEL2X, HEL3X (numbers reflecting the number of amino acid substitutions) have 
progressively lower affinity to HyHEL10 (Paus et al., 2006). To analyze T-dependent B 
cell responses, the model employs adoptive transfer of SWHEL B cells into congenic 
C57BL/6 mice followed by immunization with protein antigen HEL / HEL variants 
coupled with sheep red blood cells (SRBC) (Brink et al., 2008). Immunization with 
HEL alone fails to elicit a strong Th cell response, therefore SRBC’s were used to elicit 
a Th response such that the anti-SRBC Th response drive the anti-HEL SWHEL B cell 
response. The SWHEL model has been used extensively to study various aspects of B 
cell biology ranging from the contribution of antigen affinity and density to B cell fate, 
self-tolerance in the GC and the role of Fas in GC B cell control (Chan et al., 2009; 
Chan et al., 2012; Butt et al., 2015). 
Despite the undeniable importance of antibodies in protective immunity against 
poxvirus infections, the process of affinity maturation in these infections has never been 
studied.  The distinct antigen kinetics in protein immunization models and physiological 
viral infections necessitate that the process of affinity maturation leading to production 
of high affinity anti-viral antibodies in poxvirus infections is examined using an 
appropriate virus-host model system. In chapter 6 of this thesis we have established a 
model to study the process of affinity maturation in poxvirus infection, by using a 
combination of recombinant poxvirus expressing variants of HEL and the well-
characterized SWHEL BCR transgenic mouse model system. This system allows efficient 
tracking of antigen-specific B cells as they undergo SHM and CSR during poxvirus 
infection.  
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1.4 Virus models used in this study 	  
1.4.1 Poxviruses 
1.4.1.1 Overview of poxvirus infections 
Poxviruses belong to the family of Poxviridae and are large brick shaped DNA viruses 
that replicate in the cytoplasm of the host. Poxvirus have a linear double stranded DNA 
~130-300 kbp long, with the essential genes for replication and survival located in the 
central region of the genome with a hairpin loop at each end (Lefkowitz et al., 2005; 
Chen et al., 2003). The Poxviridae family is divided into two subfamilies: 
Enterpoxvirinae, which infects insects and Chordopoxvirinae that infects vertebrates. 
The Chordopoxvirinae subfamily is further subdivided into 8 genera comprising o 
Orthopoxviridae, Parapoxviridae, Avipoxviridae, Capripoxviridae, Leporipoxviridae, 
Suipoxviridae, Molluscipoxviridae and Yatopoxviridae. The genus Orthopoxviridae, of 
interest in this study, includes poxviruses of human significance such as VARV, VACV 
along with other viruses such as ectromelia (ECTV), cowpoxvirus, camel poxvirus and 
monkey poxvirus.  
The immunopathogenesis of human poxvirus infections has been studied using animal 
models, of which ECTV infection of mice is one of the best. ECTV was first described 
as an infection of rodents by Marchal in 1930. Seminal work by Frank Fenner in the 
1940’s has led to a detailed understanding of the pathogenesis of ECTV infection 
(Fenner, 1949; Fenner, 1947a). Infection of mice with ECTV results in mousepox, a 
disease that mimics smallpox in humans.  The mousepox model has been extensively 
used to study host immune response to poxvirus infections. The merits of the model, 
pathogenesis and immune responses elicited are discussed in detail in the following 
sections. 
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1.4.1.2 Ectromelia virus (ECTV) 
ECTV is a natural mouse pathogen with narrow host specificity, similar to VARV that 
only infects humans. Moreover, ECTV is infectious at very low doses and shares 
several aspects of immunopathology with VARV, including development of pox lesions 
and long-lived antiviral antibody responses. The narrow host range along with co-
evolution with its host makes it an ideal model to study virus immune evasion strategies 
as well as host immune responses (Seet et al., 2003; Smith and Alcami, 2000). ECTV 
infection in mice progresses to a systemic infection following a localized inoculation, 
making it an excellent model to also study generalized virus infections (Blanden and 
Gardner, 1976). In addition, ECTV infection in mice results in life-long humoral 
immunity, similar to that seen in smallpox vaccinees.  
1.4.1.2.1 Pathogenesis of ECTV infection 
Early studies by Frank Fenner revealed that the principal route of infection in mice is 
through abrasion in the skin of the footpad (Fenner, 1947b). Following inoculation, the 
virus replicates locally and reaches the draining lymph node. The spread via efferent 
lymphatics and blood stream leading to primary viraemia results in the seeding of the 
virus in various organs such as the spleen and liver where further replication occurs. 
Secondary viraemia from the release of virus at the secondary sites of replication results 
in further spread of virus to various other organs including the skin resulting in the 
development of pox lesions, which can lead to further transmission of the virus (Buller 
and Palumbo, 1991) (Figure 1.6, page 33). In the mousepox model, inbred strains of 
mice can be classified as resistant or susceptible based on their response and recovery 
from ECTV infection. Resistance to mousepox depends on several factors including 
virus dose, virus virulence and genotype of the mice. Resistance to ECTV infection in 
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mouse strains such as C57BL/6 that has been associated with four gene complexes 
(resistance to mousepox (RMP) loci 1-4) (Delano and Brownstein, 1995; Brownstein et 
al., 1992; Brownstein and Gras, 1995; Esteban and Buller, 2005) results in the 
production of good host immune response and recovery from mousepox without the 
development of pox lesions. Susceptible strains such as BALB/c, A/J and DBA/2 
exhibit uncontrolled virus replication and succumb to infection due to extensive 
necrosis of liver and spleen. A detailed understanding of the virologic and pathologic 
disease course has been extremely useful in evaluating the immune mechanism critical 
for the resolution of infection and establishment of long-term immune responses 
following poxvirus infection. 
1.4.1.2.2 Immune response to ECTV 
As alluded to previously in section 1.2, the immune response to poxvirus infections 
including ECTV involves co-ordinated innate and adaptive immune responses. 
Resistant C57BL/6 mice are able to efficiently control the virus by a plethora of effector 
mechanisms including activation of NK cells, macrophages, T cell, Th1 cytokines, 
soluble mediators as well as antibody responses. Loss of NK cells either by antibody 
mediated depletion or gene knockout leads to increased viral burden, morbidity and 
mortality in ECTV infection (Delano and Brownstein, 1995; Parker et al., 2007). 
Liposome mediated depletion studies demonstrated a crucial role for macrophages in 
recovery from ECTV infection (Karupiah et al., 1996). In addition to their phagocytic 
activity, macrophages have been shown to produce immune-stimulatory cytokines and 
play a role in antigen presentation for the induction of MHC-I restricted immune 
responses. The absolute requirement of CD8+ T cells in recovery from mousepox was 
confirmed by  studies using  antibody-mediated  depletion  of  CD8+  T cells in resistant 
C57BL/6 mice and β2M-/- mice, which lack MHC I surface molecules and CD8+ T cells 
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(Karupiah et al., 1996). In addition, effector molecules such as IFN-γ, IFN-α/β, 
granzyme A/B, perforin and NO are essential for host immune response to ECTV 
infection (Karupiah et al., 1998; Karupiah et al., 1993a; Mullbacher et al., 1996; 
Mullbacher et al., 1999; Ramshaw et al., 1997; Karupiah et al., 1993b; Panchanathan et 
al., 2006).  
Whilst CD8+ T cells play a key role in virus control between 6-12 days post-infection 
(p.i.), at later stages CD4+T cells and B cells are required for virus elimination and 
survival. In ECTV infection, CD4+ T cells have been shown to have both a B helper cell 
role as  well  a   cytotoxic  effector   activity  (Chaudhri et al., 2006; Fang et al., 2012). 
Studies by Chaudhri et al., and Szulc et al., have demonstrated that during ECTV 
infection, resistant mice elicited strong cellular immune responses associated  with Th1 
cytokines (Chaudhri et al., 2004; Szulc et al., 2012). In contrast, susceptible strains 
demonstrate low levels or absent Th1 cytokines resulting in a delayed, weaker cellular 
immune response associated with increased susceptibility. Recent studies have 
identified IL-17A producing CD4+ and CD8+ T cells during ECTV infection, however a 
role for them in recovery from ECTV infection is yet to be established (Szulc et al., 
2011). Studies using B cell deficient mice have highlighted a key role for B cells and 
their effector molecules, antibodies, in virus control (Chaudhri et al., 2006; Fang and 
Sigal, 2005). Previous work from our laboratory has demonstrated that transfer of 
ECTV immune serum or naïve B cells can protect B cell deficient mice from morbidity 
and that antibody generation by B cells is critical for survival particularly after the 
effector phase of CD8+ T cell responses (Chaudhri et al., 2006). In addition, production 
of  ECTV-specific antibodies  is  essential for  protective immunity  against  secondary  
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Figure 1.6. Pathogenesis of ECTV infection in susceptible mice.  Following infection 
through a break in skin, ECTV replicates locally in the regional lymph node and  
disseminates via the lymphatics and blood stream. Primary viremia allows the spread of 
virus to spleen, liver and other organs by day 3-4 p.i. Release of the virus from necrosis 
of the cells in these infected organs results in secondary viremia, leading to infection of 
distal sites such as the skin. In susceptible mice, virus rapidly multiplies in the 
epidermal cell layer of the skin giving rise to pale flat papules that progress to ulceration 
in a few days, similar to the pox lesions in smallpox. Resistant mice strains such as 
C57BL/6 are able to control the infection and recover without the development of any 
lesions. Principles of Virology, 3rd edition, Figure adapted from (Fenner, 1948) 
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poxvirus infections (Panchanathan et al., 2006; Panchanathan et al., 2010; Chaudhri et 
al., 2015).  
 Although recent reports have revealed the cellular players of GC-mediated antibody 
responses (reviewed in section 1.3), very little is known about the dynamics of these 
cellular players in long-lived antibody responses to poxvirus infections and this is 
addressed in the thesis using the ECTV model. This is an excellent model to study the 
key cell types and their responses in the induction of long-lived antiviral antibody 
responses for a number of reasons. ECTV, a natural mouse pathogen, replicates 
efficiently in mice and induces long-lived humoral immunity. In addition, antiviral 
antibodies are critical for recovery in both primary and secondary infections.  
Humoral immunity against smallpox, elicited by a live vaccine is stable and lasts for 
decades. Furthermore, individuals who recover from smallpox are protected for life 
against a second infection. Indeed, long-lived antibody responses have been 
demonstrated in humans following natural infection or live-virus vaccination. However, 
due to safety concerns, all the currently licensed viral vaccines are generated on an 
attenuated platform. For the empirical design of vaccines, it is imperative to understand 
the contribution of the replicating capacity of the virus to long-lasting humoral 
immunity. This is addressed in this thesis by the use of viruses that exhibit different 
ranges of replicative capacity. Whilst ECTV replicates efficiently in mice, the 
thymidine kinase (TK) mutant virus demonstrates reduced virulence associated with 
decreased replication capacity of the virus in-vivo (Kochneva et al., 1994). By 
employing replication-competent and replication-inefficient strains of virus, the 
contribution of viral replicative capacity to the induction of long-lived antiviral antibody 
response has been examined. Additionally, the roles of TFH, TFR and GC B cells in 
poxvirus induced long-lived protective neutralizing antibody responses have been 
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evaluated and this is of central importance in augmenting antibody responses to 
recombinant poxvirus vaccine vectors. 
1.4.1.3 Vaccinia virus 
Although, ECTV was employed as the primary poxvirus model in this thesis, translation 
of key research findings was confirmed in VACV, a prototypic member of 
orthopoxviridae with human significance. Although VACV virus is not a natural mouse 
pathogen, a high degree of homology exists between ECTV and VACV allowing cross 
protection. Several key differences in the pathogenesis and in-vivo replication have been 
identified between the two orthopoxviruses. Whilst ECTV is infectious at low doses 
(similar to VARV), VACV has to be administered at higher doses. In addition, ECTV 
causes a systemic infection following peripheral intradermal (i.d.) or subcutaneous (s.c.) 
infection, whereas VACV is relatively localized at the site of peripheral inoculation (Lin 
et al., 2013). Comparative studies of the two viruses have also identified differences in 
the activity of host response modifiers and functional heterogeneity of CD4+ T cells at a 
global and epitope level (Symons et al., 2002; Siciliano et al., 2014). These findings can 
be explained by the distinct differences in the host-pathogen relationship exhibited by 
the two viruses, further highlighting the usefulness of ECTV infection of mice in 
evaluating poxvirus infections in a natural host.  
However, with the successful utilization of VACV as a smallpox vaccine, the use of 
recombinant VACV as vaccine vectors expressing heterologous genes was first 
suggested over three decades ago (Mackett et al., 1982; Panicali and Paoletti, 1982). 
Trials involving VACV as vaccine delivery systems have been on a steady increase and 
therefore translation of our key research findings in the VACV model has immediate 
benefit to the field of vaccine biology. Although VACV is an excellent vaccine vector, 
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the adverse effects associated with the use of the original vaccine strains, ranging from 
mild to life threatening events such as eczema vaccinatum, post vaccinal encephalitis 
and progressive vaccinia in immuno-compromised individuals has restricted its use 
(Goldstein et al., 1975; Lane and Millar, 1971). With safety a priority, subsequent 
second and third generation vaccines were developed respectively by tissue adaptation 
and attenuation by passaging in an alternate host (Artenstein et al., 2005; Kenner et al., 
2006; Meyer et al., 1991). Modified Vaccinia Ankara virus (MVA), a third generation 
vaccine vector was generated by over 500 passages of its parent strain, Chorioallantois 
VACV Ankara (CVA) in chicken embryo fibroblast (CEF) cells resulting in a 
replication-defective virus with an excellent safety profile (McCurdy et al., 2004; 
Parrino et al., 2007). In the 1970s, MVA was used to vaccinate over 100,000 
individuals in Germany during the smallpox eradication campaign (Mayr et al., 1978). 
However, administration of MVA was followed by vaccination with the traditional 
smallpox vaccine and it is therefore not known whether MVA or the foreign antigens it 
is engineered to express induce long-lived humoral immunity. Long-term efficacy 
studies in animal model studies demonstrated that a single immunization regime with 
MVA did not offer complete protection during a lethal secondary challenge, in contrast 
to mice vaccinated with a first generation replicating VACV vaccine (Ferrier-Rembert 
et al., 2008). The impact of viral replication capacity on long-term humoral immunity 
and cellular GC dynamics was evaluated using the mouse-adapted Western Reserve 
strain of VACV (VACV-WR) with its TK deletion mutant and with CVA and the 
replication-incompetent MVA. 
1.4.2 Influenza A viruses 
Influenza viruses are single-stranded RNA viruses belonging to the orthomyxoviridae 
family, which are further classified into three types (A, B and C) based on the genetic 
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coding of the core proteins. Of the three, influenza A viruses have been a major source 
of morbidity and mortality across the globe.  Influenza A viruses have been further 
classified into subtypes based on the combination of the surface proteins 
haemagglutinin (HA) and neuraminidase (NA). The influenza vaccines currently in use 
induce a strain specific neutralizing antibody response against the variable HA protein 
(Reber and Katz, 2013). Due to the constant drift associated with HA (Hensley et al., 
2009; Glezen, 2008), the influenza vaccines are reformulated annually based on the 
reports provided by the WHO Global influenza Surveillance and Response system. 
Whilst two types of vaccines, inactivated and live attenuated have been approved, only 
the inactivated vaccines have been registered for use in Australia currently (Influenza 
vaccines for Australians, National Centre for Immunization Research and Surveillance 
(NCIRS), April 2005). 
The influenza A virus model was used in this thesis to confirm that the findings related 
to the cellular GC dynamics and contribution of virus replicative capacity to long-lived 
humoral immunity in poxvirus systems were translatable to other virus models. To 
evaluate the specific contribution of replication fitness to generation of 
haemagglutination inhibition (HAI) antibody levels, humoral immune responses were 
studied following infection with live replicating and formaldehyde inactivated non-
replicating virus infection. Since mice are not naturally infected by human influenza 
viruses, mouse adapted influenza A H1NI virus strains influenza A/Puerto Rico/8/1934 
H1N1 (influenza A/PR/8) and seasonal vaccine strain influenza A/Solomon 
Islands/3/2006 H1N1 (influenza A/SI/3/06) have been used in this thesis. 
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1.5 Purpose of the study 
Although the immune responses and correlates of protection in poxvirus infections have 
been well studied, there are several key knowledge gaps that have been addressed in this 
thesis. While the contribution of long-lived antibody responses to protective immunity 
against poxvirus infections has been established, very little is known about the 
dynamics of key humoral immune response mediators: TFH, TFR and GC B cells in this 
process and this is addressed in chapter 3 of the thesis. The influence of viral replicative 
capacity on the magnitude of the GC responses and modulation strategies to augment 
long-lived antiviral immune responses have been evaluated in chapter 4 and 5 of this 
thesis. Affinity maturation during the course of poxvirus infection and the impact of 
virus replicative fitness on the SHM patterns has been examined in Chapter 6 of the 
thesis. 
We hypothesize that: 
 
1. The escalating concentration of antigens in a replicating virus infection provides 
essential cues to key cellular mediators of GC responses in the induction and 
maintenance of potent and durable antiviral immune response. 
2. Long-lived antibody responses during replication-inefficient virus infection can 
be augmented by modulating antigen availability in lymphoid organs. 
3. Replication fitness of the virus influences the affinity maturation process, 
thereby impacting the quality of the antiviral antibody response. 
With an increasing number of recombinant attenuated poxvirus vectors in clinical trials 
for various infectious diseases and cancers, the findings of this study will be of 
immense value to the field of poxvirus vaccine biology. The specific aims of this 
research are as follows: 
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1. To evaluate the dynamics of TFH, TFR and GC B cells in ECTV-induced GC 
responses. 
2. To examine the effect of virus replicative capacity on the magnitude of TFH 
mediated GC responses and long-lived antiviral humoral immunity. 
3. To evaluate the contribution of antigen dose and route of administration in 
enhancing the immunogenicity of replication-inefficient virus. 
4. To establish a model to study affinity maturation in antigen-specific B cells in 
response to viral envelope-expressed antigen during ECTV infection 
5. To examine differences in the SHM patterns in antigen-specific B cells 
associated with replication fitness of virus and antigen availability. 
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2 Materials and methods  
	  
2.1 Materials 	  
2.1.1 Buffers and solutions 
Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich (St Louis, 
MO, USA). Common buffer recipes used in this thesis are listed in Table 2.1 
Table 2.1: Recipes for common buffers used in this thesis 
Common buffers Recipe 
50X Tris-Acetate-EDTA 
(TAE) buffer 
242 g/L Tris, 57.1 ml Glacial Acetic Acid, 100 ml 
0.5 M Ethylene	  diamine	  tetraacetic	  acid	  (EDTA) 
Ammonium-Chloride-
Potassium (ACK) lysis buffer 
150 mM NH4Cl2, 10 mM KHCO3, 0.1 mM 
Na2EDTA, pH 7.2 
Conjugation Buffer 0.35 M Mannitol, 0.1 M NaCl 
ELISA coating buffer 0.1 M sodium carbonate buffer, pH 9.6 
ELISA wash buffer PBS with 0.05% Tween-20 
Flourescence-activated cell 
sorting (FACS) buffer 
PBS with 2% Fetal calf serum (FCS) 
Influenza A virus plaque assay 
overlay medium 
2 µg/ml L-(tosylamido-2-phenyl) ethyl 
chloromethyl ketone (TPCK)	  treated trypsin in 1:1 
dilution of 2x Leibovitz L15 media and 1.8% low 
melting agarose 
Gel loading buffer 30% Glycerol, 0.25% (w/v) Bromophenol Blue, 
0.25% (w/v) Xylene Cyanol FF. 
HEL ELISA blocking buffer PBS with 1% bovine serum albumin (BSA) 
HEL ELISA dilution buffer PBS with 0.1% BSA 
IF blocking solution PBS with 3% BSA 
IF staining solution PBS with 0.5% BSA and 0.1% Tween-20 
EMEM-10 Eagle’s Minimum Essentail medium (MEM) 
supplemented with 10% FCS, 2 mM L-glutamine, 1 
mM 4-(2-hydroxyethyl)-1-piperazine 
ethanesulfonic acid (HEPES) and antibiotics 
(Pencillin 120 µg/ml, Streptomycin and Neomycin 
sulphate 20 µg/ml) 
EMEM-2.5 EMEM supplemented with 2.5% FCS, 2 mM L-
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Common buffers Recipe 
glutamine, 1 mM HEPES and antibiotics 
Methylcellulose overlay 
solution 
1% methylcellulose in MEM-2.5 
Nitrophenyl phosphate (NPP) 
buffer 
35 mM NaHCO3, 14 mM Na2CO3, 0.5 mM MgCl2, 
0.02% NaN3 
Phosphate buffered saline 
(PBS) 
13 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 
mM KH2PO4, 1 mM CaCl2 and 0.5 mM MgCl2 
RPMI-10 Roswell Park Memorial Institute 1640 (RPMI-
1640) medium supplemented with 10% FCS, 2 mM 
L-glutamine, 1 mM HEPES and antibiotics 
SHM PCR sorting mix 1X Taq PCR buffer, 0.5 mg/ml Proteinase K, 0.1 
mM EDTA, 0.1% EDTA 
Poxviral plaque assay dilution 
mix 
PBS with 1mM HEPES and 1% FCS 	  	  
2.1.2 Antibodies used in flow cytometry and Enzyme-linked 
immunosorbent assay (ELISA) 
Antibodies, clones, conjugates and sources are listed in table 2.2. Where required, 
proteins / antibodies were conjugated to Alexa 647 using the Alexa Fluor 647 labeling 
kit (InvitrogenTM Life Technologies) 
Table 2.2 List of antibodies used in flow cytometry and ELISA 
 
Antibody Clone Conjugate Source 
B220 RA3-6B2 APC-Cy7 BD Biosciences, 553786 
CD127 H1.2F3 APC eBioscience, 17-1271-82 
CD16/32 2.4G2 - BD Biosciences, 553141 
CD19 1D3 PE BD Biosciences, 553786 
CD4 RM4-5 PerCP BD Biosciences, 553052 
CD44 IM7 Pacific blue Biolegend, 103020 
CD45.1 A20 Pacific blue Biolegend, 110722 
CD62L MEL-14 PE BD Biosciences, 553151 
CD8 53-6.7 FITC Biolegend, 100706 
CD95 Jo2 PE BD Biosciences, 554258 
CD95 Jo2 PE-Cy7 BD Biosciences, 78452 
CXCR5 DG8 Biotin BD Biosciences, 551960 
Foxp3 FJK-16s FITC eBioscience, 11-5773-82 
GL7 GL7 FITC BD Biosciences, 553666 
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Antibody Clone Conjugate Source 
Granzyme B 16G6 PE eBioscience, 12-8822-80 
IFN-gamma XMG1.2 PE-Cy7 Biolegend, 505826 
IgG Pooled antisera Biotin  Southern Biotech, 1030-08 
IgG (H+L)  HRP Southern Biotech, 1031-05 
IgG1 Pooled antisera  Biotin Southern Biotech, 1070-08 
IgG1  HRP Southern Biotech, 1070-05 
IgG2b Pooled antisera Biotin Southern Biotech, 1090-08 
IgG2b  HRP Southern Biotech, 1090-05 
IgG2c Pooled antisera Biotin Southern Biotech, 1079-08 
IgG2c  HRP Southern Biotech, 1079-05 
IgG3 Pooled antisera Biotin Southern Biotech, 1100-08 
IgG3  HRP Southern Biotech, 1100-05 
KLRG1 2F1 PE-Cy7 eBioscience, 25-5893-82 
Streptavidin - AP Roche Diagnostics, 11089161001 
Streptavidin - PE-Cy7 eBioscience, 25-4317-82 
Streptavidin - PerCP-Cy5.5 BD Biosciences, 551419 
 
2.1.3 Cell lines 
All cell lines used in experiments presented in this thesis were obtained from American 
Type Culture Collection (ATCC), Manassas, Virginia, USA (Table 2.3). 
Table 2.3: List of cell lines 
Cell line ATCC 
number 
Species Cell type Culture 
medium 
BHK21 CCL-10 Hamster, Syrian  Kidney-fibroblast EMEM-10 
BS-C-1 CCL-26 Monkey, African  Kidney-epithelial EMEM-10 
MC57G CRL-2295 Mus musculus Fibrosarcoma EMEM-10 
MDCK CCL-34 Canis familiaris Kidney-epithelial RPMI-10 
YAC-1 TIB-I60 Mus musculus Lymphoblast EMEM-10 
 
2.1.4 Mouse strains 
All mice were bred and maintained in a specific-pathogen free environment at the 
Australian Phenomics Facility (APF), Australian National University (ANU) College of 
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Medicine, Biology and Environment, Canberra, Australia. All animal experiments were 
performed with mice aged six-to twelve weeks, in accordance to the guidelines provided 
by the ANU Animal Ethics and Experimentation Committee (Protocol number 
A2011/053). 
All mouse strains used in this thesis are detailed in Table 2.4. Genotyping of all the 
mouse strains maintained was carried out by the genotyping support staff at APF. 
Table 2.4: Inbred wildtype, targeted gene knockout or transgenic mouse strains 
used in this thesis 
 
Mouse strains Source / Reference 
C57BL/6J APF, Canberra, Australia 
SWHEL Ig Transgenic mouse Phan et al., 2003 
Blimp-1 GFP transgenic mouse Kallies et al., 2004 
SAP/ SH2D1A knockout mouse Czar et al., 2001 
IL-21 GFP transgenic mouse Luthje et al., 2012 
 
2.1.5 Viruses  	  
2.1.5.1 Ectromelia virus (ECTV) 
Moscow strain of ECTV was obtained from ATCC (VR-1734) and has been referred to 
in this thesis as ECTV-WT. TK deletion mutant of ECTV-WT, designated as ECTV-
TKΔ, was a kind gift from Dr. Ronald Jackson, ANU. Recombinant ECTV-WT and 
ECTV-TKΔ expressing hen egg lysozyme (HEL) protein of varying affinities are 
described in detail in section 2.2.3 
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2.1.5.2 Vaccinia virus (VACV) 
VACV-WR was obtained from ATCC (VR-1354) and designated as VACV-WT in this 
thesis. TK deletion mutant of VACV-WR, VACV-TKΔ, was generated by the insertion 
of lacZ gene into the TK region of the viral genome and was a kind gift of Dr. Bernard 
Moss, NIH. CVA virus was a kind gift from Dr.Jürgen Hausmann at the Bavarian 
Nordic GmbH, Germany. MVA virus was a kind gift of Dr. Bernard Moss, NIH. 
2.1.5.3 Influenza A virus strains 
Mouse-adapted influenza A/Peurto Rico/8/1934 (A/PR/8, H1N1) stocks were 
propagated in specific pathogen free embryonated chicken eggs under the guidance of 
Mr. Ron Thala, ANU. Mouse-adapted seasonal vaccine strain, Influenza A/Solomon 
Island/3/2006 (A/SI/3/06, H1N1) was a kind gift from Dr. Patrick Reading at the WHO 
Collaborating Centre for Reference and Research on Influenza, Victoria, Australia. 
2.2 Methods 	  
2.2.1 Preparation of virus stocks 	  
2.2.1.1 ECTV stocks 
All ECTV stocks were propagated in BS-C-1 cells. Confluent BS-C-1 cell monolayers 
in T175 cm2 flasks were infected with a multiplicity of infection (m.o.i.) of 0.05 in 
MEM-2.5 and incubated for 1 hour at 37°C in a 5% CO2 humidified incubator. After 
adsorption, the flasks were topped with 20 ml of MEM-2.5 and incubated for 48 hours 
at 37°C in a 5% CO2 humidified incubator. The monolayer was observed twice daily 
during the incubation period and virus was harvested when at least 80% of the 
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monolayer was infected, as evidenced by syncytial formation. To harvest the virus, cells 
were scraped into the medium and centrifuged at 1,560 x g for 10 minutes at 4°C. The 
cell pellet was washed twice with PBS, re-suspended in 300 µl of PBS and sonicated in 
a cup sonifier (S-450, Branson Sonic power company, Danbury, CT, USA) at 80 watts 
for 3 cycles of 10 seconds each. All mice infections were carried out using crude stocks 
of ECTV-WT. Single use aliquots were stored at -80°C until further use. Viral titer was 
determined by plaque assay as described in section in 2.2.2.1. 
2.2.1.2 Sucrose cushion purification of ECTV stocks 
Sucrose cushion purified ECTV-WT was used to coat plates in anti-ECTV ELISA. 
ECTV-WT stocks were generated as described above in section 2.2.1.1. Prior to 
sonication, the cell pellet was re-suspended in 10 ml of sterile 10 mM Tris-HCl, pH 9 
and lysed using a glass dounce homogenizer. The cell suspension was centrifuged at 
3,000 x g for 5 minutes at 4°C and the supernatant was layered onto 17 ml of sterile 
36% sucrose prepared in 10 mM Tris-HCl, pH 9 in a SW-28 centrifuge tube (Beckman 
and Coulter Inc., CA, USA). The samples were centrifuged for 80 minutes at 32,900 x g 
in a SW-28 rotor at 4°C. The cell pellet was re-suspended in 300 µl of PBS and stored at 
-80°C as single-use aliquots for future use. 
2.2.1.3 VACV stocks 
VACV-WR and VACV-TKΔ stocks were propagated in BS-C-1 cell lines at an m.o.i of 
0.01 as described in section 2.2.1.1. Virus stock titers were determined by plaque assay 
as described in section in 2.2.2.2. 
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2.2.1.4 Influenza A virus stocks 
Influenza A/PR/8 virus was propagated in specific-pathogen free, 9-11-day old 
embryonated chicken eggs. Briefly, 1,000 plaque forming units (PFU) of the virus stock 
in a 100 µl volume  was injected into the allantoic cavity of eggs and incubated for 2-3 
days in a 37°C humidified egg incubator. Allantoic fluid was harvested after cooling the 
eggs overnight at 4°C. Pooled samples were centrifuged at 500 x g for 10 minutes at 
4°C, aliquoted as single use-vials and stored at -80°C until further use. The viral titers 
were determined by plaque assay using MDCK cells as described below in section 
2.2.2.4. 
2.2.2 Virus titration 	  
2.2.2.1 Plaque assay for quantifying ECTV titers 
Organs harvested from infected animals were snap frozen in pre-weighed 2-ml tubes 
and the viral load was determined by plaque assay as described previously (Karupiah et 
al., 1996). One day prior to the assay, 1.5 x 105 BS-C-1 cells were plated per well in a 
12-well cluster plate (Nunc, Nalge Nunc International). On the day of the assay, the 
weight of the organ collected was determined and the organ was homogenized in 1 ml 
of ice-cold viral plaque assay dilution mix (Table 2.1) using a polytron homogenizer 
(Pro-scientific Inc., Monroe, CT, USA). The homogenate was sonicated (S-450 Cup 
sonicator, Branson sonic power company, Danbury, CT, USA) at 80 watts for 3 cycles 
of 10 seconds each. Samples were centrifuged at 2,000 x g for 1 min at 4°C to remove 
tissue debris and serial dilutions of the supernatant were prepared in viral plaque assay 
dilution mix. A 100 µl volume of the serial dilutions were plated onto the BS-C-1 
monolayers and the plates were incubated for 1.5 hours at 37°C in a 5% CO2 humidified 
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incubator to allow for virus adsorption. One ml of the methylcellulose overlay medium 
was added to the monolayers and the plates were incubated at 34°C for 3-4 days in a 5% 
CO2 humidified incubator. At the end of the incubation period, the plaques were 
visualized by staining the monolayer with 0.1% crystal violet.  For the quantification of 
viral stocks, serial dilutions were plated onto the BS-C-1 monolayer and processed as 
described as above. The virus titer was calculated based on the number of plaques 
counted at an optimal dilution and expressed as PFU/ml. 
2.2.2.2 Plaque assay for quantifying VACV titers 
Titers of VACV stocks or VACV-infected organs were determined by plaque assay as 
outlined in section 2.2.2.1. Following serial dilutions and adsorption onto BS-C-1 
monolayers in 6 well cluster plates (Nunc, Nalge Nunc International), 2 ml of EMEM-
2.5 was added to the wells as overlay medium. The plates were incubated for 48 hours 
at 37°C in a 5% CO2 humidified incubator and the plaques were visualized by staining 
the monolayer with 0.1% crystal violet.  
2.2.2.3 Titration of MVA stocks by immunostaining 
Titration of MVA stocks was carried out on BHK21 cell monolayers by 
immunostaining. One day prior to the assay, 6 x 105 BHK21 cells were plated per well 
in a 6-well cluster plate. On the day of the assay, a 10-fold serial dilution of the virus 
was prepared in EMEM-2.5 and 1 ml of the dilution mix was plated in duplicate on 
confluent BHK21 cell monolayers. The plates were incubated for 4 hours at 37°C in a 
5% CO2 humidified incubator to allow for virus adsorption. The inoculum was then 
replaced with 2 ml of MEM-2.5 and the plates were further incubated for 48 hours. To 
determine the titer by immunostaining, the cells were fixed with a 1:1 (v/v) mixture of 
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acetone/methanol for 5 minutes at room temperature followed by blocking with PBS 
containing 3% FCS for 30 minutes to prevent non-specific staining.  The virus was 
immunostained using a polyclonal rabbit anti-vaccinia antibody (generated in-house) in 
a pre-determined optimal concentration for 1 hour at room temperature. The monolayer 
was washed twice with PBS containing 3% FCS and incubated with secondary antibody 
(HRP conjugated donkey anti-rabbit antibody, Cat # 711-035-152, Jackson 
ImmunoResearch Laboratories, USA) for 15 minutes at room temperature. The foci of 
infected cells were stained by incubating for 10-15 minutes with HRP substrate (3,3’ 
Diaminobenzidine; DAB, Sigma Aldrich). Following incubation, the number of 
reddish-brown foci of infected cells were counted and multiplied by the dilution factor 
to express the titer as PFU/ml.  
2.2.2.4 Plaque assay for quantifying Influenza A viral titers 
MDCK cell monolayers (1.2 x 106 cells / well) in a 6-well cluster plate were washed 
and infected with 100 µl of serially diluted virus suspension prepared in RPMI-1640. 
After adsorption for 45 minutes at 37°C in a 5% CO2 humidified incubator, cells were 
overlayed with 3 ml of influenza virus assay overlay medium (Table 2.1). Following 
incubation for 4 days at 37°C in a 5% CO2 humidified incubator, the infected 
monolayer was fixed with 2 ml of 5% formalin for 30 minutes at room temperature. 
After fixation, the overlay was removed and the plaques were visualized by staining 
with 0.1% crystal violet. The virus titer was expressed as PFU/ml. 
2.2.3 Recombinant ECTV-WT / ECTV-TKΔ viruses expressing 
HEL 	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2.2.3.1 Generation of recombinant viruses 
Dr. Tim Newsome at the University of Sydney generated the recombinant ECTV-WT 
and ECTV-TKΔ expressing HEL2X or HEL3X used in this study. The choice of the HEL 
epitope used (HEL2X or HEL3X) and its role in affinity maturation has been described in 
detail in Chapter 6. The HEL epitope was introduced into the ECTV155 gene that 
encodes a homologue of VACV envelope protein B5R. The ECTV155 gene encodes a 
N-terminal signal peptide followed by 4 short consensus repeat (SCR) regions and a 
trans-membrane domain. The HEL epitope (HEL2X / HEL3X) was inserted in the SCR 
regions 1-3 of ECVT155 gene. A schematic representation of the ECTV155 gene in WT 
and recombinant virus is shown in Figure 2.1. Mixed virus stocks, containing both 
recombinant and non-recombinant (WT) viruses were generated by transient dominant 
selection and the stocks had to be further purified as a part of this thesis. 
2.2.3.2 Purification of recombinant viruses 
To purify recombinant virus from mixed virus stocks, single plaque picks were analyzed 
by PCR screening. Briefly, a monolayer of BS-C-1 cells in a 6-well cluster plate were 
infected with dilutions of the mixed stocks and post adsorption, the monolayer was 
overlaid with 2 ml of MEM-F15 containing 2.5% FCS and 0.9% Ultrapure agarose 
(Invitrogen). At 48 hours p.i., single plaques were isolated by plaque picks and further 
amplified on a BS-C-1 monolayer in a 24-well cluster plate. The infected monolayer 
was harvested in PBS 48-72 hours later and the stock from one amplified plaque pick 
was split into two portions. DNA was extracted from one portion using the QIAmp 
DNA blood mini kit (Cat # 51106, Qiagen), whilst the second portion was stored at -
80°C for future amplification. Pure recombinant virus isolates were identified by PCR 
screening as described in 2.2.3.3. 
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Figure 2.1 B5R proteins produced by WT and recombinant ECTV viruses. (A) 
Schematic representation of B5R protein produced by WT virus containing a N-terminal 
signal peptide (black dot), four SCR domains (shaded orange circles numbered 1-4) and 
a transmembrane domain (black bar). (B) Recombinant viruses were generated by 
replacing the SCR 1-3 domains by mutant HEL epitopes (green shaded region). 
 
2.2.3.3 PCR screening for identification of pure recombinant virus isolates 
For PCR screening, primers were designed flanking the site of the HEL epitope 
insertion. The primer sequences, PCR reaction mix and conditions are listed in Table 
2.5, 2.6 and 2.7 respectively. In our study, an average of 80-100 individual plaque picks 
were screened per recombinant virus to yield about 3-4 pure recombinant virus isolates. 
Pure recombinant virus plaque picks were differentiated from mixed or non-
recombinant viral plaque picks based on the size of PCR products as shown in a 
representative gel picture in Figure 2.2. PCR products were separated on a 2% agarose 
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gel containing GelRedTM  (Cat # 41003, Biotium Inc, USA). Homemade gel loading 
buffer was added to the samples and run alongside a 100 bp DNA ladder (MBI 
Fermentas, USA) to determine the product size. The agarose gels were run in a standard 
electrophoresis setup (BioRad) at 100V and imaged under UV light by a Gel-Doc 
imaging system (Syngene, Cambridge).  
The presence of the insert was further confirmed by sequencing at the Australian Cancer 
Research Foundation (ACRF) Biomolecular Resource Facility (BRF) at JCSMR, ANU. 
 
Table 2.5 Primers used in for recombinant virus screen 	  
Primer name Primer sequence 
Forward primer ATG AAA ACG ATT TCC GTT GTT ACG TT 
Reverse primer CCA CCG ATA GAA AAT GTA GAT CCG G 	  	  
Table 2.6 PCR conditions for recombinant virus screen 	  	  	  	  	  	  	  	  	  	  	  
Table 2.7 PCR reaction mix for recombinant virus screen 
Component Volume 
10X MgCl2 free buffer 2.5 µl 
50mM MgCl2 0.75 µl 
dNTP mix (2.5 mM each: dATP, dCTP, dGTP, dTTP) l 
5 µM primary Forward primer  1 µl 
5 µM primary Reverse primer 1 µl 
5U/µl Taq polymerase 0.25 µl 
DNA (20 ng/ µl) 5 ul 
ddH2O To 20 µl total volume 
	  
Temperature Time Number of cycles 
94°C 5 minutes   1 cycle 
94°C 30 seconds 
  35 cycles 60°C 30 seconds 
72°C 30 seconds 
72°C 5 minute  1 cycle 
	  	   54 
 	  
 
	  
 
Figure 2.2 PCR screening to identify pure recombinant virus isolates. Genomic 
DNA from individual viral plaques was used as a template for PCR screening. Primers 
designed to flank the regions of the insert (Table 2.5) were used to amplify the insert 
gene and the size of the amplicons was used to determine the purity. The expected band 
sizes for pure recombinant and WT virus isolates are 527 and 614 bp respectively. 	  
2.2.4 Flow cytometric analysis 	  
2.2.4.1 Cell surface protein stain 
Spleens were aseptically harvested from euthanized mice and single cell suspensions 
were prepared by mechanical disruption through a 70 µm cell strainer (BD falcon) into 
Hanks balanced salt solution (HBSS). Cells were pelleted by centrifugation at 300 x g 
for 5 minutes at 4°C. Red blood cells (RBC) were lysed by addition of 1 ml per spleen 
of ACK lysis buffer (Table 2.1) for 3 minutes at room temperature. Cells were washed 
and re-suspended in FACS buffer at a final concentration of 2 x 107 cells /ml. Prior to 
FACS staining, when required, non-specific binding to Fc receptors was blocked by 
incubation with anti-CD16/32 (mouse BD Fc block, Cat # 553141) for 15 minutes at 
1. 100 bp ladder	  2. Pure Recombinant virus 
isolate	  3. WT virus isolate	  4. Mixed virus isolate      	  
1 2 3 4 
500 - 
1000 - 
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4°C. Approximately 106 cells were stained in 50µl FACS buffer containing relevant 
antibodies in pre-determined optimal concentrations for 30-40 minutes at 4°C in the 
dark. If a second step of staining with secondary antibody was required, the cells were 
then washed twice with FACS buffer and re-suspended in 50µl of FACS buffer 
containing relevant secondary antibody at a pre-determined optimal concentration for 
20 minutes at 4°C. Cells were washed twice with FACS buffer and samples acquired on 
BD LSRII or BD LSR Fortessa cell analyzers (Becton Dickson, San Jose, CA).  
2.2.4.2 Intracellular cytokine stain 
Single cell suspension of splenocytes was prepared as described above in section 
2.2.5.1. Approximately 106 splenocytes were stimulated with 0.1 µg/ml of Phorbol 12-
Myristate 13-Acetate (PMA) and 1 µg/ml Ionomycin for 2 hours at 37°C, followed by 
continued stimulation in the presence of 1 µg Brefeldin A (BFA) for 3 hours at 37°C in 
a 5% CO2 humidified incubator. Cells were washed twice with FACS buffer and then 
stained for cell surface proteins. Post-wash, cells were fixed with 4% PFA for 10 
minutes at room temperature in the dark and permeabilized by incubation with 0.1% 
Saponin in FACS buffer for 30 minutes at 4°C. All subsequent washes and incubation 
steps were carried out in FACS buffer containing 0.1% Saponin. The cells were washed 
twice and stained for the required cytokines overnight at 4°C. Cells were then washed 
twice to remove any unbound antibody and samples were acquired on BD LSRII or BD 
LSR Fortessa cell analyzer. 
2.2.4.3 Staining protocol for TFH and TFR cells 
Single cell suspensions were prepared as described in section 2.2.5.1. 2 x 106 cells were 
surface stained for B220, CD4, CD44, CXCR5 and PD-1 using antibodies mentioned in 
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Table 2.2. After washing the cells to remove unbound antibodies, they were fixed and 
permeabilized as per the manufacturer’s instruction in the Foxp3 transcription factor 
buffer kit (e-Bioscience, Cat# 00-5523-00). Cells were washed twice with 
permeabilization buffer and incubated with anti-mouse Foxp3 mAb (Table 2.2) at a pre-
determined concentration in permeabilization buffer for 1 hour at 4°C. Cells were 
washed twice with permeabilization buffer and re-suspended in FACS buffer just prior 
to sample acquisition on BD LSRII or BD LSR Fortessa cell analyzer. 
2.2.4.4 Data acquisition 
Data from stained samples were acquired on BD LSRII or BD LSR Fortessa cell 
analyzers using BD FACS Diva software. Subsequently the samples were analyzed 
using FlowJo software (TreeStar Inc.). Light scatter gating (forward scatter; FSC and 
side scatter; SSC) was used to excluded dead cells and debris and to further gate on 
lymphocytes. Doublet exclusion gate was used in the next step and where appropriate, 
autofluorescent dump channels were included to exclude autofluorescent cells from 
further analysis. Fluorescent minus one (FMO) controls were used to set the gating 
boundaries. Specific gating strategies for individual cell populations have been 
described in the respective chapters. 
2.2.4.5 Cell isolation by FACS 
Cell populations for adoptive transfer experiments (Chapter 4) and VH10 variable gene 
analysis (Chapter 6) were purified by Dr. Harpreet Vohra and Michael Devoy at the 
Imaging and Cytometry facility, JCSMR, ANU. Sorting of individual cell populations 
was carried out on BD FACS Aria II cell sorter instrument using BD FACS Diva 
software. 
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2.2.5 Chromium (51Cr) release assays 	  
2.2.5.1 Natural Killer Assay 
Ex-vivo NK cell cytotoxic activity was determined by 51Cr release assay using YAC-1 
target cells as described previously (Karupiah et al., 1990). Target cells were labeled 
with 100 µCi of 51Cr in 200 µl of EMEM-2.5 for 1 hour at 37°C. The cells were washed 
twice and re-suspended at a concentration of 2 x 105 cells/ml. Single cell suspensions of 
effector splenocytes were prepared as described in section 2.2.5.1 and re-suspended at a 
final concentration of 2 x 107 cells/ml. Three-fold serial dilutions of the effector 
splenocytes were incubated with 2 x 104 51Cr-labeled target cells for 4 hours at 37°C in 
a 5% CO2 humidified incubator, such that the assay was carried out at effector: target 
cell ratios of 100:1, 33:1, 11:1 and 3.3:1. Following incubation, the plate was 
centrifuged and 25 µl of the supernatant was transferred to a 96-well Luma plate 
(Perkin-Elmer, Boston, USA) and allowed to dry overnight at room temperature. The 
following day, radioactive counts per minute (cpm) were measured using a TopCount-
NXTTM microplate scinitillation and luminescence counter (Packard Bioscience 
company, Meriden, CT, USA) and percent specific lysis was calculated using the 
equation mentioned below 
% specific lysis  = 100 x  Sample 51Cr release (cpm) – Spontaneous release (cpm) 
          Maximum release (cpm) – Spontaneous release (cpm)  
51Cr release from target cells in the absence of effector cells was used to determine the 
spontaneous release, whereas maximum release was determined by target cell lysis with 
Triton-X-100. 
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2.2.5.2 Cytotoxic T lymphocyte (CTL) assay 
Virus specific CTL activity was assayed ex-vivo using MC57G target cells to determine 
antigen specific MHC class I restricted killing. Prior to 51Cr labeling, target cells were 
infected with ECTV-WT at an m.o.i of 20 PFU/well for 1 hour at 37°C. Following 
effector: target cell incubation, percent specific lysis was calculated as described in 
section 2.2.5.1. Percent specific lysis of uninfected target cells was subtracted from 
infected target cells to calculate the virus specific CTL activity. 
2.2.6 Real-time Quantitative Polymerase Chain Reaction (RT-
qPCR) to quantify blood viral titers 
DNA was isolated from blood using QIAmp DNA blood mini kit as per manufacturer’s 
instructions. Viral genome copy numbers was determined by RT-qPCR using a plasmid 
containing ECTV156.  ECTV156  encodes viral haemagglutinin, a late gene that is only 
expressed after viral DNA replication. The virus copy numbers in the sample were 
derived from a standard curve generated by 10-fold serial dilutions of the linearized 
plasmid. RT-qPCR was performed on Bio-Rad iQ5 iCycler (96 well format) using iQ 
SYBR green super mix (Cat # 1708882, Bio-Rad Laboratories Inc). The RT-qPCR 
conditions, reaction mix components and primers are listed in Table 2.8, 2.9 and 2.10 
respectively. 
Table 2.8 RT-qPCR cycling conditions 
Temperature Time Number of cycles 
95°C 3 minutes        1 cycle 
95°C 10 seconds 
      40 cycles 
55°C 30 seconds 
95°C 1 minute         1 cycle 
Melt curve analysis 
60°C to 95°C 10 seconds 0.5°C ramp / second 
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Table 2.9 RT-qPCR reaction mix (Total volume 20 µl) 
Component Volume 
iQ SYBR green supermix 10 µl 
5µM Forward primer 1 µl 
5µM Reverse primer 1 µl 
Sample DNA (10ng/ µl) 2 µl 
ddH20 6 µl 
 
Table 2.10 Primers used in RT-qPCR assay 
Primer name Primer sequence 
ECTV156 Forward primer CGC TAC ACC TTA TCC TCA GAC AC 
ECTV156 Reverse primer GGA ATT GGG CTC CTT ATA CCA 
Viral genome copy numbers depicted throughout the thesis were calculated from 20ng 
of DNA. It is of interest to determine the number of viral copy numbers present in one 
PFU. 100µl of viral stocks (in triplicates) were used in RT-PCR and viral plaque assay 
to determine the viral copy numbers and PFU respectively. Comparative analysis of the 
PFU and viral copy numbers from equal volumes of virus stocks indicate that 1PFU 
equals approximately 274 ± 31 viral copy numbers. 
2.2.7 ELISA protocols 	  
2.2.7.1 Anti-ECTV antibody ELISA 
ECTV-specific IgM and IgG subclass levels were analyzed by ELISA. Briefly, 96-well 
round-bottomed Immunolon II plates (Thermofisher scientific Australia, Victoria) were 
coated with sucrose cushion purified ECTV-WT virus in ELISA coating buffer (Table 
2.1) and incubated overnight at 4°C. On the day of the assay, the plates were washed six 
times with ELISA wash/dilution buffer using an ELISA microplate washer (ELx405HT 
microplate washer, Biotek, Winooski, VT). Unless otherwise indicated, serum samples 
were diluted 1 in 200 using ELISA wash buffer. A 50 µl volume of the dilution was 
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added to the appropriate well and incubated for 1 hour at 37°C. The plates were washed 
as described earlier and 50 µl of Horse-radish Peroxidase (HRP) conjugated anti-mouse 
IgM or IgG subclass antibodies were added at a pre-determined optimal dilution. After 
1-hour incubation, plates were washed and 50 µl of HRP substrate, Tetramethyl 
benzidine (TMB; InvitrogenTM LifeTechnologies, Cat # 00-2023) was added to the 
plates and incubated for 20 minutes in the dark at room temperature. The reaction 
absorbance was read at 650 nm using Infinite 200 Pro microplate reader with Tecan-i-
control software (TECAN, Mannedorf, Switzerland). 
2.2.7.2 Anti-HEL antibody ELISA 
HEL-specific antibody levels of all IgG subclasses were measured by ELISA. 96-well 
polystyrene Maxisorp plates (Nunc) were coated with 10 µg/ml HEL in 60 µL NPP 
buffer (Table 2.1) and incubated overnight at 4°C. Plates were washed 3 times with 200 
µL of ELISA wash buffer in a microplate washer and blocked with 100 µl of HEL 
ELISA blocking buffer for 1 hour at 37°C.  Post-wash, serial 2-fold dilutions of serum 
samples in 50 µl of HEL ELISA dilution buffer were added in duplicate to the wells and 
incubated at 37°C for 1 hour. The plates were washed and biotin conjugated anti-mouse 
IgG subclass specific secondary antibody in 50 µl of HEL ELISA dilution buffer was 
added to the wells. Antibody levels were quantitated against recombinant HyHEL10 
standards. Streptavidin conjugated to alkaline phosphatase was diluted to an optimal 
concentration in HEL ELISA dilution buffer and 50 µl was added per well. The reaction 
was visualized by the addition of 1 mg/ml of p-nitrophenyl phosphate (ICN biochemical 
Inc) substrate in 100 µl of NPP buffer. The reaction absorbance was read at 405 nm on a 
Multiscan NCC/340 microplate reader (Fisher Scientific Thermo Labsystems). Anti-
HEL antibody levels were determined from the standard curve using the absorbance of 
dilutions that were within the dynamic range of the curve. 
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2.2.8 Plaque Reduction Neutralization Test (PRNT) assay 
Virus neutralizing capacity of antibodies was determined using the PRNT assay. One 
day prior to the assay, 3 x 105 BS-C-1 cells were plated per well in a 6-well tissue 
culture plate. On the day of the assay, the test serum samples were heat inactivated at 
56°C for 45 minutes and six 2-fold serial dilutions of the heat inactivated samples were 
prepared in PBS. The sample dilutions were transferred to glass tubes and incubated 
with 100 µl of PBS containing 100 PFU of ECTV-WT for 1 hour at 37°C. After 
incubation, 300 µl of MEM was added to the samples and transferred onto confluent 
BS-C-1 monolayers for 1 hour at 37°C in a 5% CO2 humidified incubator to allow for 
virus adsorption. Following adsorption, 2 ml of methylcellulose overlay medium was 
added to the monolayers and incubated for 4 days at 34°C in a 5% CO2 humidified 
incubator. At the end of the incubation period, viral plaques were visualized by addition 
of 0.1% crystal violet solution. PRNT50 titer was calculated as the reciprocal of plasma 
dilution at which 50% of the input virus is neutralized and determined by non-linear 
four-parameter curve-fit of data using Prism 6 (Graphpad software, La Jolla California, 
USA).  
2.2.9 Detection and elimination of mycoplasma contamination 	  
2.2.9.1 Detection of mycoplasma contamination:  
All cell-lines and virus stocks used in this thesis were demonstrated to be mycoplasma 
free by PCR screening (Uphoff and Drexler, 2002). Briefly, DNA was extracted from 
the samples using QIAmp blood mini kit as manufacturer’s instructions and standard 
PCR reaction was performed using BioTaq polymerase enzyme (Cat # BIO-21040, 
Bioline pty Ltd). The PCR conditions, reaction mix components and primer sequences 
are listed in table 2.11, 2.12 and 2.13 respectively. The PCR products were separated on 
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a 2% agarose gel and imaged under UV light. A representative gel picture is shown in 
Figure 2.3 
Table 2.11 PCR conditions to detect mycoplasma contamination 
Temperature Time Number of cycles 
95°C 3 minutes   1 cycle 
95°C 10 seconds 
  35 cycles 55°C 30 seconds 
72°C 50 seconds 
72°C 1 minute  1 cycle 
 
 
Table 2.12 PCR reaction mix for mycoplasma detection  
Component Volume 
10X MgCl2 free buffer 2.5 µl 
50mM MgCl2 0.75 µl 
dNTP mix (2.5mM each: dATP, dCTP, dGTP, dTTP) 2 µl 
10µM primer (each) 0.5 µl 
5U/µl Taq polymerase 0.5 µl 
DNA template (100ng) 20-100 ng 
ddH20 To 25 µl total volume 
 
 
Table 2.13 Primers used in PCR for detection of mycoplasma contamination 
Primer Name Primer sequence 
Mycoplasma Primer 1F CGC CTG AGT AGT ACG TTC GC 
Mycoplasma Primer 2F CGC CTG AGT AGT ACG TAC CG 
Mycoplasma Primer 3F TGC CTG AGT AGT ACA TTC GC 
Mycoplasma Primer 4F TCG CTG GGT AGT ACA TTC GC 
Mycoplasma Primer 5F CGC CTG GGT AGT ACA TTC GC 
Mycoplasma Primer 6F CGC CTG AGT AGT ATG CTC GC 
Mycoplasma Primer 1R GCG GTG TGT ACA AGA CCC GA 
Mycoplasma Primer 2R GCG GTG TGT ACA AAA CCC GA 
Mycoplasma Primer 3R GCG GTG TGT ACA AAC CCC GA 	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2.2.9.2 Elimination of mycoplasma contamination 
The stocks generated of recombinant ECTV viruses expressing HEL were mycoplasma 
contaminated. Mycoplasma was eliminated from these viral stocks preparations by 
solvent extraction as described previously (La Linn et al., 1995). Briefly, 250 µl of ether 
was added to 750 µl of the virus stock suspension and vortexed for 1 minute at 4°C. The 
samples were centrifuged at 10,000 x g for 5 minutes at 4°C, 100 µl of the water phase 
was diluted in EMEM-2.5 and the virus was propagated in BS-C-1 monolayers as 
described in section 2.2.1.1. The virus stocks propagated over two passages were tested 
for mycoplasma contamination by PCR as described in section 2.2.9.1. 
Figure 2.3 Detection of mycoplasma contamination by PCR screening. DNA 
extracts from virus samples, with or with out ether treatment was screened for 
mycoplasma contamination using the PCR primers mentioned in Table 2.13. A 500 bp 
positive band confirmed mycoplasma contamination.	  	  
2.2.10 Immunofluorescent (IF) staining protocol 
Spleen sections embedded in cryoprotective Tissue-tek optimal cutting temperature 
(O.C.T) compound were snap frozen on dry ice/ ethanol slurry and stored at -80°C until 
further processing. Cryo-sections of 10 µm thickness were air-dried for 1 hour at room 
temperature and subsequently fixed in ice-cold acetone for 10 minutes at 4°C. Sections 
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were air dried to get rid of acetone and then washed 3 times with PBS. Non-specific 
binding was prevented by blocking the sections with 200 µl of IF blocking solution for 
20 minutes prior to staining with biotin conjugated PNA (# L135, Sigma Aldrich), PE- 
conjugated rat anti-mouse IgD (clone 11.26C, Cat # 1120-09, Southern Biotech) and 
FITC conjugated rat anti-mouse CD4 (clone GK1.5, Cat # 100406, Biolegend) for 90 
minutes. All staining steps were performed in IF staining buffer at room temperature in 
a humidified chamber. After three wash steps in PBS, sections were incubated with 
Streptavidin conjugated to Brilliant violet 421 (Biolegend, Cat # 405226) for 30 
minutes. Sections were washed, mounted with Vectashield mounting medium (Cat # H-
1000, Vector laboratories) and imaged using a Leica-SP5 confocal laser scanning 
microscope. 
2.2.11 Formalin inactivation of influenza A virus stocks 
Inactivation of influenza A virus stocks was carried out using formalin as described 
previously (Jonges et al., 2010). Influenza A virus stocks were incubated with formalin 
(0.02% final concentration) for 18 hours at 37°C. Following inactivation, the sample 
was dialyzed against four changes of PBS over 24 hours at 4°C using a Slide-A-Lyzer 
dialysis cassette (7K molecular weight cut-off (MWCO), Cat # 66372, Thermo 
Scientific). Virus inactivation was confirmed by influenza viral plaque assay as 
described in section 2.2.2.3. 
2.2.12 Determination of influenza haemagglutination units (HAU)  
Two-fold serial dilutions of influenza virus stocks in PBS were incubated in triplicate 
with 1% chicken red blood cell (CRBC) solution for 1 hour at room temperature. The 
	  	   65 
HA titer was calculated as the reciprocal of highest dilution showing complete 
haemagglutination. 
2.2.13 Determination of influenza haemagglutination inhibition 
(HAI) titers  
Anti-viral antibodies generated following infection with influenza A virus were 
quantified by the HAI assay. Test serum samples were incubated at 56°C for 45 minutes 
to remove complement activity. This was followed by adsorption against 1% CRBC 
suspension for 30 minutes at room temperature to remove non-specific 
haemagglutination activity. After adsorption, CRBC were pelleted by centrifugation at 
14,000 g for a few seconds. Two-fold serial dilution of the serum samples were 
incubated with 4 HAU of influenza A virus for 30 minutes at room temperature. 
Subsequently, 1% CRBC in PBS was added to the wells and the haemagglutination 
patterns were read after incubation for 30 minutes at room temperature. HAI titers were 
expressed as the reciprocal of the highest serum dilution that completely inhibited 
haemagglutination of CRBC. 
2.2.14 CD4 T cell depletion 
Anti-mouse CD4 mAb, clone GK1.5 (Isotype Rat IgG2b; Cat # BE0003) and 
appropriate isotype control, clone LTF-2  (Cat # BE0090) were obtained from BioXcell 
(West Lebanon, NH). One day prior to the infection, 500 µg of anti-CD4 mAb was 
administered per mouse intraperitoneally (i.p.). Continual T-cell depletion was 
maintained by administration of 250 µg mAb every third day until the time of sacrifice. 
LTF-2 isotype antibody was administered accordingly to the control group. 
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2.2.15 T-cell enrichment by immunomagnetic beads 
For TFR adoptive transfer experiments, prior to FACS staining, the samples were 
enriched for T-cells by immunomagnetic depletion of B cells and monocytes. Single 
cell suspensions of splenocytes were incubated with rat anti-mouse CD45R/B220 
(Clone RA3-6B2) and rat anti-mouse CD11b (Clone M1/70) at an optimal dilution for 
45 minutes at 4°C. BioMag goat anti-rat IgG beads (Cat# 310147, Qiagen) were  
washed and prepared as per the manufacturer’s instruction. Splenocytes were washed to 
remove any unbound antibody and incubated with BioMag beads at a bead: cell ratio of 
5:1. The cells and beads were mixed gently by inversion and incubated for 30 minutes 
at 4°C on a rotating platform. Cell populations bound to BioMag beads were removed 
by placing the cell/bead suspension onto a Dynal magnetic particle concentrator (Dynal 
Biotech) for 5 minutes. The supernatant collected showed a three-fold enrichment for T 
cells as determined by FACS analysis (Figure 2.4). 
Figure 2.4. Flow cytometric analysis of T cell enrichment. Splenocyte suspensions 
were enriched for T cells (~ 3-fold) by immunomagnetic bead depletion of B220+ and 
CD11b+ cells as described in section 2.2.15.  
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2.2.16 Conjugation of HEL with sheep red blood cells (SRBC) 
Fresh SRBCs were purchased from Applied Biological Products Management 
(Adelaide, South Australia) and conjugated to HEL as described previously (Kipp and 
Muller 1980). About 2 ml of sterile SRBC in Alsevers was washed in 50 ml of PBS and 
centrifuged at 1,111 x g for 5 minutes at 4C. This was repeated twice and the pellet was 
washed in 20 ml of conjugation buffer (Table 2.1). After centrifugation, SRBC pellet 
was re-suspended in conjugation buffer containing HEL at a final concentration of 20 
µg HEL/ml. The cell suspension was allowed to mix on ice on a platform rocker for 10 
minutes. A volume of 200 µl of 100 mg/ml 1-ethyl-3-(3-diethylaminopropyl) 
carboiimide hydrochloride (EDCI) in conjugation buffer was added to crosslink HEL 
with SRBC and allowed to incubate for a further 30 minutes. Subsequently, the SRBC 
was washed three times with 50 ml PBS or until no further cell lysis was noted. Cells 
were counted and re-suspended at 109 cells / ml of PBS. 
2.2.17 SWHEL splenocyte preparation and adoptive cell transfer 
SWHEL donor mice were ethically sacrificed by cervical dislocation and the spleens 
were harvested in HBSS solution. Single cell suspensions were prepared and RBC lysed 
as described in section 2.2.4.1. The HEL-binding B cells were stained with anti-B220 
APC-Cy7 and HEL-Alexa 647 and detected by acquisition on BDLSRII. The donor 
cells were re-suspended at a final concentration of 3 x 104 HEL binding B cells in 100 
µl PBS and adoptively transferred into congenic recipient mice. 
2.2.18 SHM analysis 
The gating strategy used for sorting donor derived single GC B cell is illustrated in 
Figure 6.4, Chapter 6. For SHM analysis single cells were sorted into 96-well semi-
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skirted PCR plates (Axygen Scientific) containing 10 µl of SHM PCR sorting mix 
(Table 2.1). After single cell sorting, the plates were sealed and centrifuged at 500 x g 
for 5 minutes. The plates were heated at 56°C for 40 minutes to allow for proteinase K 
mediated cell digestion followed by incubation at 95°C for 8 minutes to inactivate 
proteinase K. Following this, primary PCR was set up, usually on the same day as the 
sort for maximum efficiency. The primary PCR conditions and reaction mix 
components are detailed below in Table 2.14 and 2.15. 
Table 2.14 PCR conditions for primary PCR in SHM analysis 
Temperature Time Number of cycles 
94°C 3 minutes   1 cycle 
95°C 15 seconds 
  35 cycles 62°C 1 minute 
72°C 1 minute 
 
Table 2.15 Primary PCR reaction mix for SHM analysis  
Component Volume 
10X MgCl2 free buffer 1.5 µl 
50mM MgCl2 1 µl 
dNTP mix (10 mM each: dATP, dCTP, dGTP, dTTP) 0.5 µl 
10µM primary Forward primer  0.1 µl 
10µM primary Reverse primer 0.1 µl 
5U/µl Taq polymerase 0.15 µl 
DNA template in SHM PCR sorting mix 10 ul 
ddH2O To 25 µl total volume 
 
After primary PCR, the plates can be stored up to 3 days at -20°C prior to setting up the 
secondary PCR. About 2.5 µl of the primary PCR mix was transferred to a 96-well plate 
and secondary PCR was set up using same similar cycling conditions as primary PCR 
(Table 2.15). The PCR reaction mix for the secondary PCR is outlined in Table 2.16. 
Primers used in both primary and secondary PCR are listed in Table 2.17.  
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Table 2.16 Secondary PCR reaction mix for SHM analysis  
Component Volume 
10X MgCl2 free buffer 2.25 µl 
50mM MgCl2 1 µl 
dNTP mix (10 mM each: dATP, dCTP, dGTP, dTTP) 0.5 µl 
10µM secondary Forward primer  1 µl 
10µM secondary Reverse primer 1 µl 
5U/µl Taq polymerase 0.1 µl 
DNA template in primary PCR mix 2.5 ul 
ddH2O To 25 µl total volume 	  	  
Table 2.17 Primers used in SHM analysis 
Primer Name Primer sequence 
Primary Forward primer GTT GTA GCC TAA AAG ATG ATG GTG 
Primary Reverse primer GAT AAT CTG TCC TAA AGG CTC TGA G 
Secondary Forward primer TTG TAG CCT AAA AGA TGA TGG TGT TAA GTC 
Secondary Reverse primer CAA CTT CTC TCA GCC GGC TC 
SHM sequencing primer GTT GTA GCC TAA AAG ATG ATG GTG 	  	  
PCR products were screened by gel electrophoresis as described in section 2.2.3 and a 
representative gel picture is shown in Figure 2.5. A PCR product of 600 bp represents 
positive amplification of the Ig VH10 exon region. PCR products were cleaned up 
(inactivation of nucleotides and removal of primers) using Illustra ExoProstar 1-Step 
(GE Healthcare) as per manufacturer’s instructions. Cleaned up PCR products were 
diluted 1 in 10 and submitted for sequencing at the Australian Cancer Research 
Foundation (ACRF) Biomolecular Resource Facility (BRF) at JCSMR, ANU. The 
sequences obtained were aligned and mutations in the translated protein sequence were 
detected by alignment with the HyHEL-10 sequence using MacVectorTM (Oxford 
Molecular Group, Campbell CA). 
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Figure 2.5. Screening of secondary PCR products in SHM analysis. To analyze 
SHM, the VH10 gene was PCR amplified from single donor-derived antigen specific 
GC and plasma cells as described in section 2.18. PCR amplicons were sequenced for 
further SHM analysis. 	  
2.2.19 Animal infections and clinical assessment 
Mice were anesthetized by i.p. administration of Avertin (2,2,2- tribromoethanol, 
(Sigma Aldrich No. T48402) dissolved in 2-methyl 2-butanol), at 160- 240 mg/kg body 
weight. All subcutaneous (s.c.) injections (50 µl volume) were performed in the left of 
the left hind leg using BD insulin syringe. Mice were monitored daily and scored 
according to the clinical scoring matrix detailed in Table 2.18. 
2.2.20 Statistics 
Where indicated, single comparisons were analyzed using unpaired student two-tailed t-
test with Welch correction. Multiple comparisons were analyzed using One-way or two-
way Analysis of Variance (ANOVA) followed by Holm-Sidak multiple comparison 
test. All statistical analysis was carried out using Prism 6 statistical software. 
	  
 
 
 
 
1 2 3 4 5 6 7 8 
1       100 bp ladder 
2       Primary PCR control 
3-7    PCR products 
8       Secondary PCR control 
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Table 2.18 Scoring matrix used for clinical assessment of mice 
 
I.	  Hair coat 
0. Groomed and shiny 
1. Groomed but not shiny 
2. Rough 
3. Unkempt ('scruffy') 
II. Posture 
0. Back is straight 
1. Hunched but with spontaneous straightening of the back 
2. Hunched but straightens only upon stimulation 
3. Hunched even on stimulation 
III. Breathing 
0. Normal 
1. Intermittent rapid breathing 
2. Rapid, shallow breathing 
3. Labored breathing along with abdominal retractions 
IV. Activity/ movement/ behavior 
0. Active; spontaneous movement 
1. Inactive; movement upon stimulation;  
2. Huddled; inactive; reluctant to move 
3. Moribund; does not go back to prone position when placed on a supine position 
VI. Condition 
0. Normal 
1. Thin 
2. Loss of fat, no growth 
3. Loss of muscle 
VI. Dehydration 
0. Nil 
1. Skin less elastic 
2. Skin tents 
3. Skin tents, eyes sunken 
VII. Body Weight 
0. Normal 
1. Reduced growth 
2. Weight loss >15% 
3. Weight loss >10% over short period or >25% over time 
VIII. Foot swelling 
0. Mild 
1. Intermediate 
2. Oedma / rounded foot 
3. Any sign of appendage necrosis 
IX. Lacrimation and nasal discharge 
0. None 
1. Lacrimation without nasal discharge; or nasal discharge without lacrimation 
2. Moderate lacrimation and nasal discharge 
3. Excessive lacrimation/cattarh; blockade of either nares 	  
Mice with clinical score of  ≥ 3 and/or weight loss of  ≥ 25% of original weight were 
ethically sacrificed. 
 
	  	   72 
 
 
 
 
Chapter 3 	  
TFH, TFR and GC responses in primary ECTV 
infection 
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3. TFH, TFR and GC responses in primary 
ECTV infection 
 
3.1 Introduction 
ECTV, a natural mouse pathogen that has co-evolved with its host, is an excellent 
small-animal viral model to study generalized viral infections. Excellent 
characterization of this virus model that was started in the 1940’s by Frank Fenner 
(Fenner, 1947a; Fenner, 1947b; Fenner, 1949) has led to the subsequent identification 
of key immune parameters required for resolution of infection. 
The immune response to ECTV infection that confers life-long protection, similar to 
that seen in smallpox survivors or vaccinees, is mediated by well-orchestrated innate 
and adaptive immune responses. Previous studies from our laboratory amongst other 
studies have demonstrated a critical role for CD4 T cells and B cells in viral elimination 
and host survival, specifically after the effector phase of CD8 T cells (Chaudhri et al., 
2006; Fang and Sigal, 2005). Whilst the general role of CD4 T cells in providing help to 
B cells in protective antibody responses in ECTV infection has been well appreciated, 
very little is known about the contribution of a specialized subset of CD4 T helper cells, 
TFH cells in this process.  
Recent studies have highlighted complex interactions between TFH and B cells which 
impact the magnitude and quality of protective antibody responses that are fundamental 
to vaccine-mediated protection [reviewed in (King et al., 2008)]. Any mutations that 
reduce the TFH numbers (Akiba et al., 2005; Nurieva et al., 2009; Ma et al., 2012; 
Bossaller et al., 2006) or disrupt the TFH: B cell interaction (Cannons et al., 2006; Qi et 
al., 2008) have detrimental effects on GC reactions and subsequent antibody responses. 
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These findings suggest modulating the magnitude of TFH responses and / or SAP 
mediated TFH: B cell interactions as strategies to augment protective antibody responses 
following vaccination. In addition, localized within the GC, recently identified 
regulatory TFR cells have been shown to curtail the GC response (Linterman et al., 
2011; Wollenberg et al., 2011; Chung et al., 2011) and it appears that crosstalk between 
TFH, TFR and GC B cells dictates the outcome of the GC reaction. Understanding these 
interactions is of particular interest in viral infections and vaccines that depend on 
robust T cell dependent antibody responses to confer protective immunity.   
With the eradication of smallpox, ECTV is one of the best available small animal 
models for evaluating the long lasting protective antibody responses to poxvirus 
infections. However, very little is known about the dynamics of key mediators of 
antibody responses: TFH cells, GC B cells and TFR responses in ECTV-induced long-
lived humoral immune responses. In this chapter, we aimed to address this gap in 
scientific literature by comprehensive kinetic analyses of ECTV-induced GC B cell and 
TFH cell responses. In addition, we have investigated the contribution of SAP-dependent 
and SAP-independent TFH responses to ECTV-specific neutralizing antibody responses.  
3.2 Results 	  
3.2.1 Kinetics of viral load and antibody responses during 
primary ECTV infection 
To investigate the viral titers following ECTV infection, C57BL/6 mice were infected 
subcutaneously (s.c.) with ECTV-WT. The natural route of infection in mice is through 
abrasions in the skin of the footpad. Following replication at the site of infection, there 
is a stepwise dissemination of the virus to the lymph nodes, blood and other organs 
(Fenner, 1948). Infection in the footpad, leads to occasional foot loss and to prevent 
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such adverse effects, infection was performed via subcutaneous ECTV injection in the 
flank of the left hind leg, as described previously in various publications from our 
laboratory (Panchanathan et al., 2010; Chaudhri et al., 2015). Mice were bled prior to 
infection to establish the baseline level of virus detection and weekly thereafter 
following infection. DNA was extracted from blood to determine the viral load by RT 
qPCR as described in Chapter 2 (section 2.2.6). Viral load by RT qPCR was determined 
by referencing against the plasmid copy numbers of ECTV156, which encodes viral 
haemagglutinin, a late gene that is only expressed after viral DNA replication. 
Comparative analysis to determine the ratio of ECTV-WT PFU to genome copy number 
indicated that one PFU of ECTV-WT equates to approximately 275 viral genome copy 
numbers. Upon analyses of the viral titers in the blood between 0-35 days p.i., 
maximum levels were detected  at day 7 p.i. and these progressively declined to below 
the level of detection by day 35 p.i. (Figure 3.1).  
Next, antiviral antibody responses were evaluated post ECTV-WT infection at days 0, 
7, 10, 14, 18, 21 and 28 p.i. using ELISA. ECTV-specific IgM levels peaked early by 
day 10 p.i. and then gradually declined thereafter (Figure 3.2A). In contrast, ECTV-
specific IgG levels progressively increased during the period of this study, until day 28 
p.i. (Figure 3.2B). In an extension of this study, we confirmed maintenance of 
circulating ECTV-specific IgG levels up to day120 p.i. (Appendix Figure 3.1). 
Virus neutralization is an important aspect of antibody-mediated protection. The plaque 
reduction neutralization test  (PRNT) is the most commonly accepted method to 
measure in-vitro virus neutralization and thus determine the protective capacity of 
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Figure 3.1: Blood viral titers following primary ECTV infection in resistant 
C57BL/6 mice: C57BL/6 mice infected with 1000 PFU of ECTV-WT via the s.c. route  
were bled at times indicated. DNA isolated from blood was used to quantitate the viral 
load by RT	  qPCR. Dotted line indicates the basal level of detection (10 viral genome 
copy numbers). Data shown is from one of two independent experiments with similar 
results represented as means of log10 viral genome copy numbers ± SEM (n=6 mice). 
Data was log transformed and statistical significance determined using Holm-Sidak’s 
One-Way ANOVA test. **P<0.005; ***P<0.0005; ****P<0.0001. 	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Figure 3.2: ECTV-specific antibody levels following primary ECTV infection in 
C57BL/6 mice: C57BL/6 mice infected with 1000 PFU of ECTV-WT via the s.c. route 
were bled at times indicated. ECTV-specific (A) IgM and (B) IgG levels were measured 
at a serum dilution of 1:200 using ELISA. Data shown are from one of two independent 
experiments with similar results represented as means of absorbance values ± SEM 
(n=3 mice per group). Data was log transformed and statistical significance determined 
using Holm-Sidak’s One-Way ANOVA test. ECTV-specific IgG levels at all days p.i. 
indicated  were  statistically different from the D0 levels (indicated by **** above the 
D0 column).***P<0.0005; ****P<0.0001.  	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antibodies. C57BL/6 mice infected with ECTV-WT were bled at times indicated in 
Figure 3.3, starting from day 7 to day 35 p.i.  and the neutralizing titers were evaluated 
using PRNT assay. Briefly, the plaques generated at varying plasma dilutions were 
compared to the control virus input and the percentage neutralization was calculated by 
the reduction in plaque counts. PRNT50 titer was calculated as the reciprocal of plasma 
dilution at which 50% of the virus was neutralized. Following infection, the plasma 
dilutions at which 50% neutralization was achieved increased progressively until day 35 
p.i. (Figure 3.3A). As expected, a gradual significant increase in the PRNT50 titers was 
observed in the initial stages of infection until about 5 weeks p.i. (Figure 3.3B).  In the 
repeat of this experiment, we extended the course of the study, to evaluate any further 
changes in the neutralization capacity of the antibodies. After day 35 p.i., no further 
increase in virus neutralization (Appendix Figure 3.2A) and PRNT50 titers were 
observed for the period of the study (until day 90pi; Appendix Figure 3.2B).  
In summary, the fall in blood viral titers observed in this study was associated with an 
increase in neutralizing antibody titers. Importantly, virus-specific neutralizing 
antibodies were maintained long-term following ECTV-WT infection. 
3.2.2 GC response kinetics in primary ECTV infection 
The role of B cells and CD4 T cells in the establishment of humoral immunity is very 
well studied. As reviewed in Chapter 1, antigen-experienced B and T cell proliferation 
within specialized microenvironments referred to as GC are critical for generation of 
antibodies with good neutralizing capacity (Gatto and Brink, 2010; MacLennan, 1994). 
To evaluate the GC B cell response kinetics during primary ECTV infection, groups of 
C57BL/6 were infected with a sub-lethal dose of virus at various times and all mice 
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Figure 3.3. Virus-Neutralizing antibody titers in primary ECTV infection: 
C57BL/6 mice infected with 1000 PFU of ECTV-WT s.c., were bled at times indicated. 
ECTV-specific neutralizing activity was determined by PRNT. (A) Curve-fitting of the 
data was done using four-parameter non-linear regression analysis (Dotted line indicates 
50% neutralization). (B) PRNT50 titer was calculated as the reciprocal of plasma 
dilution at which 50% of the virus is neutralized. Data shown are from one of two 
independent experiments with similar results and represented as means ± SEM (n=3 
mice per group).  
 
Table 3.1. Statistical comparison of PRNT50 titers 
 
Data shown in figure 3B was log transformed and statistical significance determined 
using Holm-Sidak’s One-Way ANOVA test. *P<0.05; **P<0.005; ***P<0.0005; 
****P<0.0001; ns=not significant. 
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Table 3.1 	   D0	   D7	   D10	   D14	   D18	   D21	   D28	   D35	  
D0	   	   ****	   ****	   ****	   ****	   ****	   ****	   ****	  
D7	  	   ****	   	   ns	   ns	   **	   ****	   ****	   ****	  
D10	  	   ****	   ns	   	   ns	   *	   ****	   ****	   ****	  
D14	   ****	   ns	   ns	   	   ns	   ****	   ****	   ****	  
D18	  	   ****	   **	   *	   ns	   	   *	   ****	   ****	  
D21	  	   ****	   ****	   ****	   ****	   *	   	   *	   ****	  
D28	  	   ****	   ****	   ****	   ****	   ****	   *	   	   ****	  
D35	  	   ****	   ****	   ****	   ****	   ****	   ****	   ****	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sacrificed on the same day such that each group had been infected for the indicated 
period of time as shown in Figure 3.4. All flow cytometric processing was carried out 
on the same day to ensure consistency in staining amongst the experimental groups. GC 
B cells were identified by flow cytometry as B220+, Fas+ (CD95, apoptosis protein 1) 
and GL7+ (Ly77) positive cells.  
Upon infection, robust GC B cell responses were induced in the spleen and Figure 3.4 
provides a flow cytometric representation of the GC B cell populations at the indicated 
time points. GC B cell percentages as well total cell numbers were calculated. As the 
mice were maintained in specific pathogen free environments, less than 0.1% of B cells 
were Fas+ GL7+ in the control naïve mice. On examining the kinetics post ECTV-WT 
infection, GC B cells appeared at day 7 p.i., peaked at day 14 p.i. and diminished 
thereafter. However, a small level of GC activity could still be identified at day 35p.i. 
The GC B cell kinetics was similar in terms of percentage and total numbers in the 
spleen (Figure 3.5). 
In order to confirm the flow cytometric finding, sections of spleens were analyzed by 
immuno-fluorescent staining for GC formation. PNA, anti-CD3 and anti-IgD staining 
were used to delineate the GC, splenic T and B cell areas respectively. GC formation 
was not observed in the naïve spleen sections in contrast to clearly recognizable PNA+ 
GC in the spleen sections of ECTV-WT infected mice (Figure 3.6). Compared to all 
other time-points studied, day 14 p.i. mice exhibited significantly larger and more GC 
per spleen section  (Figure 3.6C) which was consistent with the flow cytometric GC 
analysis at this time-point. 
Taken together, these results indicate that although GC’s were apparent by day 7 p.i., 
the response peaked at day 14 p.i. This time-point was therefore used to study 
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Figure 3.4: Flow cytometric representation of GC B cell population kinetics in primary ECTV infection. Groups of 3 C57BL/6 mice were 
infected at various times with 1000 PFU of ECTV-WT via the s.c.  route and all sacrificed on the same day such that each group had been infected for 
the period indicated. GC B cells were identified by flow cytometry as B220+, Fas+ and GL7+ cells. Numbers indicate the % of GC B cells gated on 
B220+ cells. Data shown are concatenated events from all samples at the indicated time-points.  	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Figure 3.5: GC B cell kinetics in primary ECTV infection. Groups of 3 C57BL/6 
mice were infected at various times with 1000 PFU of ECTV-WT via the s.c. route and 
all sacrificed on the same day such that each group had been infected for the period 
indicated. GC B cells were identified as described in figure 4 and expressed as (A) % of 
B220+ve cells and (B) Total cells per spleen. Data from one experiment represented as 
means ± SEM. Data was log transformed and statistical significance determined using 
Holm-Sidak’s One-Way ANOVA test. *P<0.05; **P<0.005; ***P<0.0005; 
****P<0.0001. 	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Figure 3.6: Immunoflourescent staining for GC during the course of primary 
ECTV infection. C57BL/6 mice infected with 1000 PFU ECTV-WT via the s.c. route 
were sacrificed at times indicated and spleen samples were snap frozen as described in 
section 2.2.10. Spleen sections (10µm) were stained using anti-CD4 mAb (clone: 
GK1.5; represented in green), anti-IgD mAb (clone: 11-26c; represented in red) and 
PNA (represented in blue). Sections were imaged using Leica SP5 confocal Laser 
scanning microscope. The panels shown are representative of (A) Naïve spleen section, 
(B) Day 10 p.i., (C) Day 14 p.i.,  (D) Day 18 p.i., (D) Day 21 p.i. and (E) Day 28 p.i. 
Images are representative of multiple fields per section from 3 mice per group; 
Magnification 10X. 	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differences in the magnitude of GC responses between experimental groups in 
subsequent experiments of this thesis. 
3.2.3 TFH and TFR kinetics in primary ECTV infection 
Recent reports have demonstrated TFH cells to be critical in providing help to cognate B 
cells in the formation and maintenance of GC. To better understand the TFH cell 
dynamics following ECTV infection, groups of C57BL/6 mice were infected with a 
sub-lethal dose of ECTV-WT and the TFH cell kinetics were evaluated by flow 
cytometry. As described in Chapter 1, TFH cells express high surface levels of CXCR5 
and PD-1 and were identified by flow cytometry as CD4+, CD44hi, CXCR5hi, PD-1hi, 
Foxp3-ve cells as illustrated in Figure 3.7. All flow cytometric processing was carried 
out at the same time to ensure consistency in staining among all infected experimental 
groups. 
Concatenations of flow cytometer files from individual mice at each time-point 
analyzed are shown in Figure 3.8. The percentage of TFH cells within the CD4+ T cell 
gate as well as the total splenic numbers were determined during the course of infection. 
Upon examining the percentage of TFH cells within the CD4+ gate, highest levels were 
detected at day 10 p.i. compared to all other time-points examined (Figure 3.9A). 
However, the highest numbers of TFH cells were found at day 14 p.i. (Figure 3.9B). This 
difference can be largely accounted for by an increase in the number of activated i.e., 
CD4+ CD44hi cells at day 14 p.i. Following this proliferative phase, there was a steady 
decrease in the numbers of TFH cells. By day 28 p.i., the TFH cell numbers were similar 
to that seen at day 7 p.i., prior to the peak proliferative response, suggesting a 
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Figure 3.7: Gating strategy for identification of TFH population:  C57BL/6 mice infected with 1000 PFU of ECTV-WT via the s.c. route were 
sacrificed at day 14 p.i., and splenocytes used to identify TFH populations by flow cytometry as described below. Numbers within the gates indicate the 
percentage of parent population. 
TFH cell stain: B220-ve, CD4+ve, CD44hi, CXCR5hi, PD-1hi, Foxp3-ve.  
TFR cell stain: B220-ve, CD4+ve, CD44+ve, CXCR5hi, PD-1hi, Foxp3+ve. 	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Figure 3.8: Flow cytometric representation of TFH and TFR cell populations in 
primary ECTV infection. Groups of 3 C57BL/6 mice were infected subcutaneously 
with 1000 PFU of ECTV-WT at various times and all sacrificed on the same day such 
that each group had been infected for the period indicated. TFH and TFR cells were 
identified by flow cytometry as described in figure 3.7. The first column shows 
CXCR5hi, PDhi cells (gated on B220-ve, CD4+ve, CD44hi cells); second column shows the 
TFH and TFR cells gated on the CXCR5hi, PD-1hi cells in column 1. Numbers within the 
gate indicate the percentage of the indicated parent population. Data shown are 
concatenated events from all samples at the indicated time-points. 	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contraction in the TFH response. This contraction mirrors what was seen with the GC B 
cell population (Figure 3.4). 
Next, the kinetics of regulatory TFR cell subset in ECTV-induced GC reaction was 
examined. TFR cells, a subset of Foxp3+ TREG cells, shares features with both TFH and 
TREG cells and can be identified by flow cytometry as CD4+, CD44hi, CXCR5hi, PD-1hi, 
Foxp3+ cells (illustrated in Figure 3.7). The frequency of TFR cells within the CD4 gate 
as well as the total splenic numbers was calculated during the course of ECTV-induced 
GC response. Interestingly, on evaluating the TFR cell dynamics, an initial significant 3-
fold drop in the percentage as well as total TFR cell numbers was detected at day 7 p.i. 
(Figure 3.9C and 3.9D respectively). TFR and TFH cells are known to play opposing roles 
in regulating the host humoral response; TFH cells stimulate, whereas TFR cells suppress 
the humoral immune response (Linterman et al., 2011). The initial drop in TFR cell 
numbers observed in this study may therefore be a requirement to allow for TFH cell 
expansion. Subsequently, TFR cell numbers increased 12 to 16-fold between days 14 and 
21 p.i., which coincides with the decline of TFH cell numbers. The differences in the 
kinetics of TFH and TFR cells are noteworthy; maximal TFH cell numbers were detected 
at day 14 p.i., prior to the TFR cell number peak at 21 p.i. The double Y-axis graph in 
Figure 3.10 better illustrates the relationship between the TFH and TFR cell numbers in 
the establishment and resolution of GC responses. 
Based on this dynamic interplay between TFH and TFR cell numbers in GC maturation, 
we hypothesized that the TFH:TFR ratio changes as the GC evolves and this data can be 
useful in discerning an ‘optimal’ GC reaction. In the experiment described above, we 
calculated the TFH:TFR ratio at each time-point studied during the course of the 
infection. The data shows that there is an initial significant increase in the TFH:TFR ratio, 
with the highest ratio noted at days 7 and 10 p.i. (Figure 3.11A). This reflects both the 
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Figure 3.9: TFH and TFR population kinetics in primary ECTV infection. Groups of 
3 C57BL/6 mice were infected s.c with 1000 PFU of ECTV-WT at various times and all 
sacrificed on the same day such that each group had been infected for the period 
indicated. TFH and TFR cells were identified by flow cytometry as shown in figure 3.7 
and presented as (A) TFH population expressed as % of CD4 T cells, (B) TFH cell 
numbers per spleen, (C) TFR population expressed as % of CD4 T cells and (D) TFR cell 
numbers per spleen. Data from one experiment presented as means ± SEM. Data was 
log transformed and statistical significance determined using Holm-Sidak One-Way 
ANOVA test. *P<0.05; **P<0.005; ***P<0.0005; ****P<0.0001. 	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Figure 3.10: Double axes graphical representation of TFH and TFR cell numbers in 
primary ECTV infection. Data from figure 8 is re-represented as a double Y-axis 
graph for better illustration of the population kinetics. Left and right Y-axis show the 
TFH and TFR populations respectively expressed as cells/spleen. Data shown are from 
one experiment; means ± SEM. 	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increase in numbers of TFH cells and a corresponding decrease in TFR cell numbers seen 
at these time-points. Subsequently there is a drop in the TFH:TFR ratio, signaling a 
contraction of the GC reaction. At day 28 p.i., the TFH:TFR ratio was still significantly 
higher than that of the naïve mice. This data is consistent with the data in the previous 
sections of this chapter that shows an ongoing GC reaction, as demonstrated by TFH and 
GC B cell numbers. As expected, the TFR:TFH ratio follows the reverse kinetics, with a 
significant drop at days 7 and 10 p.i., followed by a gradual increase thereafter (Figure 
3.11B). 
Although the role of TFR cells in the control of GC response has been established, the 
exact mechanism of action is yet to be defined. If our hypothesis that TFR cell numbers 
play a direct role in the regulation of TFH-mediated GC response is correct, we would 
expect that exogenous transfer of TFR cells to negate the initial observed drop in TFR 
numbers would increase the TFR:TFH ratio and as a consequence result in decreased GC 
response, compared to mice not receiving the transfer. Foxp3 GFP transgenic mice 
express green fluorescent protein (GFP) under the control of Foxp3 promoter (Fontenot 
et al., 2005). GFP expression within the CD4+, CD44hi, CXCR5hi, PD-1hi population 
was used to effectively identify and sort splenic TFR cells. Prior to sorting, the samples 
were enriched for T cells by magnetic bead depletion of B cells and monocytes as 
described in section 2.2.15. Following adoptive transfer of TFR cells at day 6 post-
infection, we observed reduced TFH (Appendix Figure 3.3A-C) and GC B cells 
(Appendix Figure 3.4A-C) at day 14 p.i., which was identified earlier as a time-point at 
which the GC response reaches its peak. However, it should be noted that the reductions 
in TFH and GC B cell numbers or percentages were not statistically significant, 
presumably due to the small numbers of animals used. Due to inadvertent introduction 
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Figure 3.11: TFH:TFR and TFR:TFH ratio kinetics in primary ECTV infection. TFH and 
TFR cells cell numbers shown in Figure 3.9 were used to calculate (A) TFH:TFR ratio and 
(B) TFR:TFH ratio. Data shown is from one experiment and represented as means ± 
SEM; Data was log transformed and statistical significance determined using Holm 
Sidak’s One-Way ANOVA test. *P<0.05; **P<0.005; ****P<0.0001. 	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of RAG knockout genotype into the Foxp3 GFP breeding colony in the Animal Facility, 
we could not repeat this experiment before the thesis was submitted. However, based on 
the above preliminary data, we can conclude it is likely that the reduction in the 
magnitude of GC response is due to an early increase in TFR cell numbers. 
 Intriguingly, the proportion of TFR cells that express the cell surface receptor CD25 (IL-
2Rα) progressively increased during the course of infection (Appendix Figure 3.5A-G). 
This is further corroborated by a steady increase in the CD25 median fluorescent 
intensity (MFI) within the TFR populations (Appendix Figure 3.5H). It would be of 
particular interest to examine if the CD25 expression on TFR cells contributed to the 
suppressive activity. 
Traditionally TFH cells are identified by the combined expression of CXCR5, PD1 
and/or ICOS and IL-21. Recent studies have shown that GC localization and higher 
cytokine expression by TFH cells is associated with GL7 expression (Yusuf et al., 2010). 
These cells, referred to as GC TFH cells, in addition to IL-21 have a hallmark expression 
of IL-4. Both IL-21 and IL-4 are required for GC formation and mice deficient in both 
cytokines have impaired GC formation and immunoglobulin production (Ozaki et al., 
2002). We therefore next investigated the dynamics of GC TFH cells during the course 
of ECTV infection. GC TFH cells are identified as CD4+, CD44hi, CXCR5hi, PD1hi, 
GL7+ cells and the gating strategy is illustrated in Figure 3.12. Concatenated flow 
cytometric files from individual mice at each time-point analyzed are shown in Figure 
3.13. At all time-points studied p.i., a significantly higher GL7 MFI was detected in 
comparison to naïve control mice. In the time-course examined, there was a steady 
increase in GL7 MFI within the TFH cells till day 18 p.i. (Figure 3.14A). After this time, 
no further increases in the GL7 MFI were detected during the course of infection. The  
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Figure 3.12: Gating strategy for identification of GC TFH population: C57BL/6 mice infected with 1000 PFU of ECTV-WT via the s.c. route were 
sacrificed at day 14 p.i., and splenocytes used to identify GC TFH populations by flow cytometry as B220-ve, CD4+, CD44hi, CXCR5hi, PD-1hi, GL7+ 
single lymphocytes. Numbers within the gates indicate the percentage of parent populations. 	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Figure 3.13: Flow cytometric representation of GC TFH population kinetics during 
primary ECTV infection.	  Groups of 3 C57BL/6 mice were infected at various times 
with 1000 PFU of ECTV-WT via the s.c. route and all sacrificed on the same day such 
that each group had been infected for the period indicated. GC TFH cells were identified 
as described in Figure 3.12. Numbers within the gates indicate the percentage of the 
parent population (CXCR5hi, PD-1hi). Data shown are concatenated events from all 
samples at the indicated time-points. 	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Figure 3.14: GC TFH population kinetics in primary ECTV infection. Groups of 3 
C57BL/6 mice were infected with 1000 PFU of ECTV-WT via the s.c. route at various 
times and all sacrificed on the same day such that each group had been infected for the 
period indicated. GC TFH cells were identified by flow cytometry as described in Figure 
3.12 and expressed as (A) GL7 median fluorescence intensity in B220-ve, CD4+ve, 
CD44hi, CXCR5hi, PD1hi population, (B) GC TFH population expressed as % of CD4 T 
cells and (C) GC TFH cell numbers per spleen. Data shown from one experiment 
represented as means ± SEM. Data was log transformed and statistical significance 
determined using Holm-Sidak’s One-Way ANOVA test. *P<0.05; **P<0.005; 
***P<0.0005; ****P<0.0001. 	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percentage and numbers of GC TFH cells within the CD4 T cell gate were calculated and 
both these kinetics were comparable (Figure 3.14B and 3.14C). The highest GC TFH cell 
numbers were detected at day 14 p.i (Figure 3.14C). At this stage, about 50% of the TFH 
cells expressed GL7, a proportion that was maintained during the contraction phase 
from day 18 p.i. (Figure 3.15). 
Collectively, the above results indicate that the GC response follows the TFH cell 
kinetics during ECTV infection. In contrast, TFR cells are reduced in numbers initially 
but increase in the later stages to curtail the GC response.  The TFH:TFR ratio changes as 
the GC response evolves and in subsequent chapters of this thesis, this ratio will be 
shown to be an effective predictor of the magnitude of GC and antibody responses. 
3.2.4 TFH mediated GC responses in SAP-deficient mice following 
ECTV infection 
SAP, an intracellular adaptor molecule that binds to the members of SLAM family of 
receptors is essential for GC reaction and subsequent antibody responses (reviewed in 
Chapter 1, section 1.3.1.3). Although it has been established that SAP-deficient humans 
and mice display impaired serum antibody responses due to a selective defect in stable 
interactions between TFH and B cells (Qi et al., 2008), the requirement for SAP in TFH 
differentiation remains controversial. Whilst TFH numbers were significantly reduced in 
SAP-deficient mice infected with LCMV, no loss was detected in influenza infection 
and other protein immunization models, suggesting that the role of SAP in TFH 
differentiation is not universal (Yusuf et al., 2010; Kamperschroer et al., 2008). 
Consequently we examined the requirement of SAP in TFH differentiation and 
subsequent neutralizing antibody responses following ECTV infection. 
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Figure 3.15: Comparative analysis of GC and non-GC TFH population kinetics in 
primary ECTV infection. C57BL/6 mice were infected as described in figure 3.14 and 
GC TFH cells were identified by flow cytometry as described previously. By day 14 p.i., 
approximately 50% of the CXCR5hi PD-1hi population expressed GL7. Data from one 
experiment represented as means ± SEM.  
 
 
 
 
0 7 10 14 18 21 28
0
1×105
2×105
3×105
4×105
5×105
Days post-infection
# 
T F
H
 c
el
ls
/s
pl
ee
n Non-GC TFH
GC TFH
	  	   100 
Given that the immune response of SAP knockout mice to ECTV infection is not 
known, we first investigated the influence of SAP deficiency on key immune subsets 
that express SAP, i.e. NK cells, CD8+ T cells and CD4+ TFH cells (Nagy et al., 2002; 
Dupre et al., 2005; Yusuf et al., 2010). Following ECTV infection, an approximate 
three-fold reduction in ex-vivo splenic NK cell cytolytic activity was detected in SAP-
deficient mice by 51Cr release assay (Figure 3.16A). This reduction can be accounted for 
by a significantly lower number of NK cells detected in SAP knockout mice after 
infection (Figure 3.16B). This is further reflected in the reduced numbers of granzyme 
B (GzmB) or IFN-γ expressing NK cells (Figure 3.16C and Figure 3.16D). The 
proportions of NK cells expressing the effector molecules were comparable between 
SAP-deficient and WT mice (data not shown). In contrast, SAP deficiency did not 
significantly affect the cytolytic activity (Figure 3.17A), numbers (Figure 3.17B), 
granzyme B and IFN-γ expression (Figure 3.17C and 3.17D) by virus-specific CD8 T 
cells.  
To examine the effects of SAP-deficiency on TFH and GC B cell responses, WT and 
SAPKO mice were infected s.c. with a sublethal dose of ECTV-WT. Mice were 
sacrificed at the peak of the GC reaction, i.e., at day 14 p.i., and the frequency and total 
number of TFH cells were investigated. Concatenated flow cytometric files representing 
TFH responses in WT and SAP-deficient mice are shown in Figure 3.18A. Compared to 
WT mice, SAP-deficient mice exhibited a significant 3-4-fold reduction in the 
frequency (Figure 3.18B) as well as total number of TFH cells (Figure 3.18C). 
Subsequently, the magnitude of GC B cell response was examined by flow cytometry 
(Figure 3.18D). Consistent with the reduced TFH cell response, SAP-deficient mice 
demonstrated significant reduction in the frequency (Figure 3.18E) and absolute number 
of GC B cell responses (Figure 3.18F).  
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Figure 3.16: NK cell activity in WT and SAP-deficient mice during primary ECTV 
infection. WT and SAP-deficient mice infected with 1000 PFU of ECTV-WT via the 
s.c.  route were sacrificed at day 5 p.i. Splenic NK cell cytolytic activity was measured 
ex-vivo using 51Cr release assay in (A) Naïve and (B) ECTV-WT infected mice. Total 
splenic cell numbers of (C) NK cells, (D) GzmB expressing NK cells and (D) IFN-γ 
producing NK cells were enumerated by flow cytometry. Data shown is from one of 
two independent experiments with similar results and represented as means ± SEM (n=5 
mice per group). Data was log transformed and statistical significance was determined 
by Mann-Whitney t-test. **P<0.005.  	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Figure 3.17: CTL activity WT and SAP-deficient mice during primary ECTV 
infection.  WT and SAP-deficient mice infected with 1000 PFU of ECTV-WT via the 
s.c. route were sacrificed at day 8 p.i. (A) Splenic CTL activity was measured ex-vivo 
using 51Cr release assays, (B) CD8+ T cell numbers per spleen, (C) numbers of GzmB 
expressing CD8+ T cells and (D) IFN-γ producing CD8+ cells were enumerated by 
intracellular staining. Data from one experiment represented as means ± SEM (n=4-5 
mice per group). Data was log transformed and statistical significance was determined 
by Mann-Whitney t-test.  
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Figure 3.18: TFH and GC responses in WT and SAP-deficient mice during primary 
ECTV infection: WT and SAP-deficient mice infected with 1000 PFU of ECTV-WT 
s.c. were sacrificed at  day 14 p.i., and TFH and GC populations were examined by flow 
cytometry. (A) Concatenated flow cytometric contour plots of TFH cells in WT and 
SAP-deficient mice  (B) TFH cells as % of CD4 T cells, (C) TFH cell numbers per spleen, 
(D) Concatenated flow cytometric contour plots of TFH cells in WT and SAP-deficient 
mice  (E) GC B cells as % of B220+ cells and (F) GC B cell numbers per spleen. . Data 
shown is from one of two independent exepriments with similar results represented as 
means ± SEM (n=3-4 mice per group). Data was log transformed and statistical 
significance was determined using Holm Sidak’s One-Way ANOVA test. **P<0.005; 
***P<0.0005; ****P<0.0001.	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Next, virus-specific antibody levels in WT and SAP-deficient mice were evaluated. WT 
and SAP-deficient mice infected with a sublethal dose of ECTV were bled weekly until 
day 35p.i. and anti-ECTV IgM and IgG levels were analyzed by ELISA. At day 7 p.i., 
ECTV-specific IgM levels were comparable between WT and SAP-deficient mice. 
After this time-point, further increase in the anti-ECTV IgM levels were detected in WT 
mice at day 14 p.i., following which a gradual decline was observed. In contrast, SAP-
deficient mice did not exhibit any further increases after day 7p.i. A statistically 
significant difference in the ECTV-specific IgM levels between WT and SAP-deficient 
mice was observed at day 14 p.i. (Figure 3.19A).  
Upon analyzing the ECTV-specific IgG responses, no statistically significant 
differences could be detected between WT and SAP-deficient mice at day 7 p.i. 
However, at all other time-points analyzed during the course of infection, SAP-deficient 
mice demonstrated significantly reduced anti-ECTV IgG titers compared to WT mice 
(Figure 3.19B). Subsequently, the functional neutralizing capacity of the antibody was 
determined by PRNT assay. At all time-points analyzed, sera from WT mice exhibited 
significantly higher neutralizing capacity and PRNT50 titers compared to SAP-deficient 
mice (Figure 3.20).  
In summary, SAP-deficient mice exhibited impaired TFH differentiation and GC B cell 
responses resulting in lower antiviral antibody titers with reduced neutralizing capacity. 
These findings suggest that in the absence of SAP, SAP-independent CD4 T cell help 
might contribute to the production of functional, virus-specific antibody in ECTV 
infection. 
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Figure 3.19: Virus-specific antibody responses in WT and SAP-deficient mice 
during primary ECTV infection. WT and SAP-deficient mice infected with 1000 PFU 
of ECTV-WT via the s.c. route were bled at times indicated. ECTV-specific (A) IgM 
and (B) IgG levels were measured at a plasma dilution of 1:200 using ELISA. Data 
from one experiment represented as as means of absorbance values ± SEM (n=5 mice 
per group).. Data was log transformed and statistical significance determined using t-
test; **P<0.005; ***P<0.0005. 	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Figure 3.20: Virus-neutralizing antibody titers in WT and SAP-deficient mice 
during primary ECTV infection. WT and SAP-deficient mice were infected as in 
Figure 3.19 and ECTV specific neutralizing activity was determined by PRNT. Curve-
fitting of the data was done using four-parameter non-linear regression analysis to 
evaluate the neutralizing capacity in (A) WT and (B) SAP-deficient mice. (Dotted line 
indicates 50% neutralization):  PRNT50 was calculated as the reciprocal of plasma 
dilution at which 50% of the virus is neutralized: (C) Comparison of PRNT50 values 
between the two groups. Data shown is from one of two independent experiments with 
similar results and represented as means ± SEM (n=3-4 mice per group). Data was long 
transformed and statistical significance was determined using Two-way ANOVA test. 
**P<0.005; ****P<0.0001. 
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3.2.5 Contribution of SAP-independent CD4 T cell help pathway 
to protective immune responses in poxvirus infection 
Data presented in the preceding section indicate that both SAP-dependent and SAP-
independent CD4 T cell help to B cells contributes towards anti-ECTV neutralizing 
antibody responses. Previous studies have demonstrated CD4 T-dependent antibody 
responses are critical for recovery of mice from ECTV infection (Chaudhri et al., 2006; 
Fang and Sigal, 2005). In the current experiments, all SAP-deficient mice survived the 
infection (data not shown), suggesting a critical role of SAP-independent T cell help 
pathway in host survival. To ascertain the importance of this pathway to antibody 
response generation, virus control and host survival, SAP-independent T cell help 
pathway was abrogated in SAP-deficient mice by CD4 T cell depletion. The rationale 
for the experimental design in this section was to evaluate virus control and neutralizing 
antibody responses during ECTV infection, in conditions of ‘graded’ T cell help. The 
experimental setup included: WT mice (both SAP-dependent and SAP-independent 
pathways of CD4 T cell help active), SAP-deficient mice (only SAP-independent CD4 
T cell help pathway active), SAP-deficient mice with CD4 T cell depletion (both 
pathways inactive) and WT mice with CD4 T cell depletion (both pathways inactive; as 
control for SAP-deficient mice with CD4 T cell depletion). 
CD4 T cells were depleted by i.p. administration of anti-CD4 mAb (clone GK1.5) as 
described in section 2.2.14. Isotype matched rat IgG was administered accordingly to 
control groups. CD4 T cell depletion was confirmed by flow cytometry using a different 
clone of anti-CD4 mAb (RM4.4) that binds to an anatomically distinct region of CD4. 
The efficacy of CD4 T cell depletion in the spleen was greater than 99% (Figure 3.21). 
After infection, the mice were bled weekly to study the virus load and ECTV-specific 
antibody response. The mice were monitored daily and their clinical
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Figure 3.21: Flow cytometric confirmation of CD4 T cell depletion. Groups of WT and SAP-deficient infected subcutaneously with 1000 PFU of 
ECTV-WT were treated with either isotype control or anti-CD4 mAb as described in section 2.2.14. CD4 T cell depletion was confirmed by flow 
cytometry.  	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scores noted. In comparison to the control groups, by day 18 p.i., CD4 T depleted mice 
developed ruffled fur, hunched posture, moderate to severe inactivity and pox lesions on 
the tails and ears (Figure 3.22). By day 21 p.i., the mice in the CD4 T cell depleted 
groups were severely moribund and the experiment had to be terminated for ethical 
reasons. All mice were sacrificed; lungs and liver were collected for determination of 
viral load and spleen for flow cytometric analysis.  
Foremost, the magnitude of GC B cell responses was evaluated by flow cytometry. 
Concatenated flow cytometric files of GC B cell responses from individual mice in each 
experimental group are shown in Figure 3.23A. Maximal GC B cell responses were 
detected in WT mice treated with isotype control mAb. As expected, impaired GC B 
cell responses were observed in SAP-deficient mice treated with the control mAb. No 
GC B cell population was observed in any of the CD4 T cell depleted group. Next, the 
TFH responses were examined and concatenated flow cytomteric files of the TFH 
responses in WT and SAP-deficient mice (isotype control treated groups) are shown in 
Figure 3.23B. Due to the complete depletion of CD4 T cells in the WT and SAP-
deficient group treated with anti-CD4 mAb, flow cytometric plots for TFH responses in 
these groups are not included in the figure. Within the isotype control mAb treated 
group, the magnitude of the TFH responses in SAP-deficient mice were reduced 
compared to the WT mice; correlating with the GC B cell responses. Upon evaluating 
the blood viral load by RT qPCR, high viral titers were detected in CD4 T cell depleted 
groups (both WT and SAP-deficient) at all times examined during the course of 
infection. Within the isotype control treated groups, the SAP-deficient mice exhibited 
higher blood viral titers at days 7 and 14 p.i., but nonetheless were able to control virus 
by day 21 p.i., similar to the WT mice (Figure 3.24). Consistent with this finding, at the 
time of sacrifice, i.e. at day 21 p.i., no virus could be detected in  the liver and lungs of
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Figure 3.22: Pox lesions in CD4 T cell depleted groups. Groups of WT and SAP-
deficient mice were infected and treated with isotype-control or anti-CD4 mAb as 
described in Figure 3.21. By day 18 p.i., pox lesions were detected in the CD4 T cell 
depleted groups. Images of SAP-deficient mice depleted treated with anti-CD4 mAb, 
with pox lesions on (A) Tail, (B) Magnified image of tail pox lesion boxed in panel A 
and (C) pox lesions on the ear. Similar lesions were detected on WT mice treated with 
ant-CD4 mAb. No lesions were detected in the control groups (data not shown). 
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Figure 3.23: TFH and GC B cell responses in WT and SAP-deficient mice with / 
without CD4 T cell depletion. Groups of WT and SAP-deficient mice were infected 
and treated with isotype-control or anti-CD4 mAb as described in Figure 3.21. At day 
21 p.i, the mice were sacrificed and GC B cells and TFH cells were identified by flow 
cytometry. (A) GC B cell responses in WT and SAP-deficient mice with or without 
CD4 depletion as indicated in the panel. (B) TFH populations in WT and SAP-deficient 
mice treated with isotype control mAb.  Due to the complete depletion of CD4 T cells in 
anti-CD4 mAb treated groups, no plots for TFH populations have been shown for these 
groups.  	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Figure 3.24:  Blood viral load in WT and SAP-deficient mice with / without CD4 
depletion in primary ECTV infection: Groups of WT and SAP-deficient mice were 
infected and treated with isotype-control or anti-CD4 mAb as described in Figure 3.21. 
Mice were bled at times indicated and DNA isolated was used to quantitate the viral 
load by RT	   qPCR. Data from one experiment represented as means of log10 viral 
genome copy numbers ± SEM (n=3-4 mice per group). Dotted line indicates the level of 
detection. Data was log transformed and statistical significance determined using Two-
way ANOVA. *P<0.05; ***P<0.0005; ****P<0.0001. 	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isotype control mAb treated WT and SAP-deficient mice. In contrast, significant viral 
load was detected in the organs of moribund CD4 T cell depleted WT and SAP-
deficient mice (Figure 3.25).  
To examine the antiviral antibody response, ECTV-specific IgG subclass responses 
were determined by ELISA at day 21 p.i. Within the isotype control mAb treated group. 
SAP-deficient mice exhibited significantly lower ECTV-specific IgG1, IgG2b, IgG2c 
and IgG3 titers compared to WT mice. Upon treating the WT and SAP-deficient mice 
with anti-CD4 mAb, these responses were completely abrogated and none of the IgG 
subclasses were detected in the CD4 T cell depleted groups (Figure 3.26). Subsequently, 
the functional virus-neutralizing capacity of the antibody was determined by PRNT 
assay. Consistent with the results in the previous section, control mAb treated SAP-
deficient mice exhibited significantly reduced neutralizing capacity (Figure 3.27A) and 
PRNT50 (Figure 3.27B) compared to control mAb treated WT mice. In accordance to 
the antibody responses, no virus neutralizing activity could be detected in the CD4 T 
cell depleted group. 
Finally, we investigated the degree of immune protection conferred by a primary ECTV 
infection in WT and SAP-deficient mice to a lethal secondary challenge. SAP-deficient 
mice generate significantly reduced antibody responses during a primary ECTV 
infection but nonetheless recover with no evidence of virus persistence. It was of 
therefore of interest to determine whether SAP-deficiency impacted protective 
immunity in secondary challenge. WT and SAP-deficient mice were primed with 
ECTV-WT and challenged 8 weeks later with a lethal dose of 106 PFU ECTV-WT i.v. 
At day 5 post-challenge, the mice were sacrificed and viral load in the organs was 
determined by viral plaque assay. At the time of sacrifice, viral load in the organs of 
naïve WT and SAP-deficient mice were comparable. Interestingly, despite the
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Figure 3.25: Viral load in WT and SAP-deficient mice with / without CD4 
depletion in primary ECTV infection: Groups of WT and SAP-deficient mice were 
infected and treated with isotype-control or anti-CD4 mAb as described in Figure 3.21. 
At day 21 p.i., mice were sacrificed and viral load in liver and lungs was determined by 
plaque assay. Data from one experiment represented as means of log10  PFU / gram of ± 
SEM (n=3-4 mice per group). Data was log transformed and statistical significance 
determined using Holm-Sidak’s One-Way ANOVA test. **P<0.005; ***P<0.0005; 
****P<0.0001. 	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Figure 3.26: Virus-specific IgG subclass antibody levels in WT and SAP-deficient 
mice with / without CD4 depletion in primary ECTV infection: Groups of WT and 
SAP-deficient mice were infected and treated with isotype-control or anti-CD4 mAb as 
described in Figure 3.21. At Day 21 p.i., ECTV-specific IgG subclass levels were 
measured at a serum dilution of 1:200 using ELISA. Data from one experiment 
represented as means of absorbance units ± SEM (n=3-4 mice per group). Data was log 
transformed and Statistical significance was determined using Holm Sidak’s One-way 
ANOVA test. *P<0.05; **P<0.005; ****P<0.0001. 	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Figure 3.27: Virus neutralizing antibody titers in WT and SAP-deficient mice with 
/ without CD4 depletion in primary ECTV infection: Groups of WT and SAP-
deficient mice were infected and treated with isotype-control or anti-CD4 mAb as 
described in Figure 3.21. ECTV specific neutralizing activity was determined by PRNT 
assay at day 21 p.i. (A) Curve-fitting of the data was done using four-parameter non-
linear regression analysis to evaluate the neutralizing capacity (Dotted line indicates 
50% neutralization). (B) PRNT50 titer was calculated as the reciprocal of plasma 
dilution at which 50% of the virus is neutralized. Data from one experiment represented 
as means of absorbance units ± SEM (n=3-4 mice per group). Data was log transformed 
and statistical significance determined using Holm Sidak’s One-Way ANOVA test. 
**P<0.005; ***P<0.0005.  
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significantly reduced virus neutralizing capacity, the SAP-deficient mice were able to 
control the virus similar to WT mice (Figure 3.28). In this experiment, it is assumed that 
the recall antiviral CD8 T cell responses in both strains of mice will be similar as the 
primary responses were comparable. This finding highlights the importance of SAP-
independent pathways in protective immune responses to poxvirus infection.  
Collectively, these results indicate that both SAP-dependent and SAP-independent 
pathways contribute to the neutralizing antibody responses during primary and 
secondary ECTV infection. Depletion of the SAP-independent CD4 T cell help pathway 
in SAP-deficient mice was associated with loss of antiviral neutralizing antibody 
response and impaired virus clearance. 
3.3 Discussion 
 
Smallpox eradication through vaccination is one of the most successful public health 
endeavors of modern medicine. Studies analyzing the immunity generated following 
smallpox vaccination reveal that T cell memory declined slowly over time, whereas the 
antiviral antibody responses are retained for life, with little or no discernable decline 
(Hammarlund et al., 2003). This long-term antiviral immunity generated is considered 
as a valuable benchmark for the functional attributes of an effective vaccine.  
Like VARV, the causative agent of smallpox, ECTV has a narrow host range, is 
infectious at low doses, shares several aspects of immunopathology, including the 
development of pox lesions and induces long-lived antiviral antibody responses. ECTV 
is therefore one of the best available small animal models to elucidate the various 
immune parameters that are cardinal for the induction of long-lasting antiviral immune
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Figure 3.28: Viral control in primed WT and SAP-deficient mice following challenge with a lethal dose of ECTV-WT. WT and SAP-deficient 
mice were primed subcutaneously with 1000 PFU of ECTV-WT or left uninfected. At 8 weeks post-priming, mice were challenged with a lethal dose 
of ECTV-WT (106 PFU i.v.). Mice were sacrificed at day 5 post-challenge; viral load in (A) Liver (B) Spleen and (C) Lungs was determined by viral 
plaque assay and expressed as means of log10  PFU / gram of tissue ± SEM (n=4 mice per group). (D) DNA isolated from blood was used to quantitate 
the viral load by qRT-PCR and expressed as means of log10 viral genome copy ± SEM. Dashed lines indicate the limit of detection. No statistical 
significance could be detected between WT and SAP-deficient mice.	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responses to poxvirus infections.  A number of studies, including some from our own 
laboratory have identified key immune requirements for resolution of ECTV infection 
in mice. While NK cells, pDCs, macrophages and cytotoxic effector T cells are critical 
for the control of virus replication early during the course of infection, the humoral arm 
of the adaptive immune response is critical to effectively clear virus (Delano and 
Brownstein, 1995; Parker et al., 2007; Karupiah et al., 1996; Fang and Sigal, 2005; 
Chaudhri et al., 2006). 
 
Whilst the importance of antibodies in recovery from primary ECTV has been well 
supported by studies using mice lacking B cells, CD40 or MHC II, there remains a 
specific knowledge gap concerning ECTV-induced GC responses (Panchanathan et al., 
2006; Fang and Sigal, 2005). In the recent literature there has been an intense focus on 
key facilitators of GC formation and subsequent humoral immune responses, TFH and 
GC B cells. TFH cells promote GC responses by providing proliferation and 
differentiation cues to GC B cells in the generation of high affinity antibodies. Despite 
previous reports concluding antibody as the primary correlate of protection against 
secondary poxvirus infections, very little is known about the TFH and GC B cell 
responses in ECTV infection, a valuable model for human orthopoxvirus and 
generalized viral infections.  Our main aim in this chapter was to further our 
understanding of the TFH responses and its association to GC responses during ECTV 
infection. 
Towards this aim, C57BL/6 mice were infected with ECTV and the viral load kinetics 
were examined in blood. Analysis of the viraemia patterns revealed that peak viral titers 
were reached at day 7 p.i., with subsequent viral elimination between days 28-35 p.i. 
(Figure 3.1). The fall in blood viral titers with a concomitant appearance of ECTV-
specific antibodies at day 14 p.i., is consistent with the importance of antiviral 
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antibodies in mopping up any residual virus and eventual viral elimination (Figure 3.2). 
The generation of effective virus specific antibodies requires the induction of a GC 
response and this was studied over the course of infection. Using flow cytometry and 
immunoflourescent staining, ECTV-induced GCs were first detected at day 7 p.i. GCs 
were absent in the control naïve animals confirming that the responses detected were 
indeed ECTV-induced. Based on the percentage and total number of GC B cell 
numbers, GC responses can be delineated into an expansion phase until as late as day 14 
p.i., followed by a contraction phase thereafter (Figure 3.5). At day 35 p.i., a residual 
amount of GC response could still be detected. Recent studies have revealed long-lived 
GC-like structures following immunization with protein antigens (SRBC and NP-CGG) 
and virus infections (influenza A/PR/8) (Dogan et al., 2009; Aiba et al., 2010; Boyden 
et al., 2014). The duration of the GC responses can influence long-lived humoral 
immune responses by allowing continual refinement of antigen-specific B cell by the 
process of affinity maturation. Future experiments designed with an extended time-
course of study will provide valuable information regarding the longevity of the GC 
response and their role in the potency and duration of humoral immune response in 
poxvirus infections. 
Within the GC, a stepwise increase in the affinity of B cells towards the foreign antigen 
occurs through the process of SHM of the immunoglobulin variable gene regions. This 
process can be indirectly studied in the periphery by determining the neutralizing 
capacity of the circulating antibodies. Using the PRNT assay, we have demonstrated a 
gradual increase in the neutralization capacity of the antibodies (Figure 3.3) akin to the 
affinity maturation process in the GC. A more direct approach to understanding of the 
induction of SHM events and affinity maturation in antigen-specific B cells would 
require the use of BCR transgenic B cells that recognize a virally expressed antigen.  
Such an approach will be expected to result in significant advances in the field of 
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humoral immunity to poxvirus infections. To this end, in collaboration with Dr. 
Timothy Newsome at the University of Sydney, we have generated recombinant ECTV 
expressing HEL. Using the SWHEL BCR transgenic system (Phan et al., 2005) in 
combination with recombinant ECTV expressing HEL, we have been able to study the 
induction of SHM antibody and affinity maturation in antigen-specific B cells following 
virus infection and this work is presented in Chapter 6. 
 
Whilst the role of CD4 T cells in providing help to B cells for protective antibody 
responses during ECTV infection is well known, the contribution of TFH cells to this 
process has not been examined. To address this, TFH cells dynamics were examined in 
the spleen following exposure to ECTV. Consistent with GC B cell kinetics, marked 
TFH cell expansion was observed through to day 14 p.i., followed by contraction (Figure 
3.9B). Recent studies by Yusuf et al., revealed a phenotypically discrete subset of TFH 
cells with enhanced B cell help capabilities residing within the GC, referred to as GC 
TFH cells. GL7 expressing GC TFH cells represent the final stage of TFH differentiation 
and the kinetics of GC TFH cell formation post-ECTV infection was investigated. GC 
TFH cells followed similar kinetic patterns as the total TFH response (Figure 3.14). 
Importantly, at the peak of the response, i.e., at day 14 p.i., GC TFH cells represent 
approximately 50% of the total TFH response and this proportion was maintained 
throughout the contraction phase. Apart from providing co-stimulatory signals, TFH and 
GC TFH cells secrete cytokines that are critical for GC B cell differentiation and affinity 
maturation. Although IL-21 has been identified as the primary cytokine associated with 
TFH cells, there has been recent reports of additional cytokines secreted by TFH cells 
such as IFN-­‐γ	   that can influence class switching and the magnitude of antibody 
responses (Reinhardt et al., 2009). Cytokine profiling of ECTV-induced TFH cells will 
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further our understanding of the GC cytokine milieu associated with the long-lived 
antiviral humoral immune responses seen in poxviral infections. 
 
Dysregulation of TFH responses can trigger autoimmunity and therefore stringent 
regulation of the GC mediated TFH responses is crucial. TFR cells have been recently 
identified to play an important role in the control of the GC response (Linterman et al., 
2011; Chung et al., 2011; Wollenberg et al., 2011). On examining the TFR population in 
ECTV-infected mice, an initial drop in the cell numbers was detected in the early stages 
of GC response (Figure 3.9D). Further, upon adoptive transfer of only 5,000 exogenous 
TFR cells into mice infected with ECTV, a trend towards reduced TFH and GC B cell 
numbers and proportions was observed. This finding suggests that the initial drop in the 
TFR cell numbers likely influences the magnitude of TFH cell expansion. The 
mechanism(s) that control TFR cell numbers during ECTV infection is not known and 
will require further investigation. In further repeat of this experiment, it would be of 
interest also to determine the effect of larger numbers of TFR transfer and its 
consequences on antiviral antibody titers. The use of mouse models that selectively lack 
TFR cells will be expected to inform on the consequences of TFR deficiency on antiviral 
antibody response generation. As an example, bone-marrow chimeric mice could be 
used [similar to that used in (Linterman et al., 2011)], in which TFR cells can be 
selectively ablated during the early stages of infection. However, in this experiment, it 
is important to optimize the recovery of TFR cells post diphtheria toxin administration, 
such that post short-term ablation, there is a quick recovery of TFR cells to simulate 
levels seen post ECTV infection.  
 
Whilst the role of TFR cells in governing the GC responses has been established, the 
exact mechanism is still unclear. A study by Linterman et al., proposed that TFR cells 
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suppress TFH cell differentiation whereas another study by Chung et al. suggested a B 
cell mediated role of TFR suppression. In our studies, an increase in the proportion of 
CD25 (IL-2Rα) expressing TFR cells was observed during the course of infection 
suggesting an IL-2 mediated mechanism in the suppressive activity of TFR cells 
(Appendix 3.5). CD25 deficient mice and humans develop autoimmune disorders and 
CD25 expression has been shown to be required for the production of the 
immunosuppressive cytokine, IL-10 (Willerford et al., 1995; Caudy et al., 2007). TFR 
cells have been shown to express IL-10 (Linterman et al., 2011) and it is likely that the 
CD25 expression-mediated IL-10 production could contribute to the suppressive 
activity of TFR cells. In support of this hypothesis, a recent study by Cai et al., 
highlighted the role of IL-10 in limiting the size of CXCR5+ T cell population in 
secondary lymphoid organs (Cai et al., 2012). The suppressive effects of TFR cells may 
be further complemented by at least two other immune regulatory cell types specialized 
for GC responses; these include Qa-1 CD8+ T regulatory cells (CD8 TREG) (Kim and 
Cantor, 2011) and IL-10 producing B regulatory cells (BREG) (Mauri et al., 2003; 
Bouaziz et al., 2008). Future work will further elucidate the orchestrated contributions 
of these regulatory subsets in constraining the GC response. 
 
In addition to the several layers of regulation, the outcome of the GC responses is 
primarily influenced by the crosstalk between TFH and GC B cells. Elegant in-vivo two-
photon microscopy studies have revealed that sustained contact between TFH and B cells 
for efficient transmission of help signals is mediated by SAP (Qi et al., 2008). In the 
absence of SAP, Yusuf et al., demonstrated that the terminal differentiation of TFH cells 
to GC TFH is severely affected (Yusuf et al., 2010). In our studies with SAP-deficient 
mice, despite the significantly reduced TFH and GC B cells responses following ECTV 
infection, sufficient ECTV-specific antibody responses were generated to control the 
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primary infection as well as protect against secondary challenge. These results are in 
sharp contrast to the reported susceptibility of primed SAP-deficient mice to lethal 
secondary influenza challenge (Kamperschroer et al., 2006). These results underscore 
the importance of SAP-independent pathways in protective immunity to poxvirus 
infections. The question then arises as to what are the SAP-independent pathways 
capable of generating protective antiviral antibody responses. The antibody responses 
were completely abrogated in following CD4 T cell depletion and therefore the 
contribution of T cell-independent B cell activation pathways to this process is likely to 
be minimal. Deenick et al., demonstrated that in the presence of persistent antigen 
stimulation, TFH cell numbers could be upregulated in SAP-deficient mice along with 
GC localization (Deenick et al., 2010). B cells are the most prevalent antigen-presenting 
cells that the T cells are likely to encounter within the follicle and the GC. In our study 
involving live replicating orthopoxvirus infection, it is likely that signals for class 
switching and affinity maturation (as evidenced by increasing neutralization capacity) 
can be exchanged between TFH and GC B cells in the absence of SAP, possibly by 
abundant B cell antigen presentation along with CD40 signaling. Several diverse lines 
of evidence support this hypothesis. Firstly, impaired B cell responses in SAP-deficient 
mice can be partly restored by anti-CD40 treatment (Detre et al., 2013). Secondly, SAP 
deficiency does not influence the expression of CD40L on CD4 T cells following 
activation (Cannons et al., 2006). Thirdly, post-ECTV infection, CD40-deficient mice 
demonstrate stunted antiviral antibody responses similar to that seen in B cell deficient 
mice (Fang and Sigal, 2005; Panchanathan et al., 2006). Whilst recent studies in 
improving vaccine efficacy have focused on modulation of SAP-dependent TFH: B cells 
interactions, our findings suggest that in poxviral vaccine vectors, SAP-independent 
pathways provide a further avenue for augmenting vaccine efficacy. However, the role 
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of SAP-independent help in long-term humoral immune memory remains to be 
elucidated. 
 
In conclusion, the results presented in this chapter further our understanding of the 
dynamic interplay between TFH, TFR and GC B cells in long-lived antiviral antibody 
responses. Our findings suggest that TFH mediated GC responses, both SAP-dependent 
and SAP-independent contribute to the antiviral neutralizing antibody responses in 
poxvirus infection. Future studies need to be undertaken to delineate the mechanistic 
contributions of SAP-independent pathways in the success of smallpox vaccination. 
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4 Viral replicative capacity drives induction 
of long-term antiviral humoral immunity 	  	  
4.1 Introduction 
The ultimate goal of any vaccination is to induce long-term protective immunity. 
Studies on the most successful vaccine to date, the smallpox vaccine, have reported 
potent circulating antiviral antibody levels 7-8 decades after vaccination (Hammarlund 
et al., 2003). In addition, studies by Crotty et al., have demonstrated an effective long-
lived memory B cell response following smallpox vaccination (Crotty et al., 2003a). 
However, the live VACV vaccine used during the smallpox eradication campaign was 
associated with a number of adverse reactions ranging from mild to severe (Zaludko and 
Vrbova, 1976; Eggers, 1974; Farkas et al., 1969; Levy, 1969). This led to the 
development of subsequent generations of smallpox vaccines focused on achieving an 
improved safety profile. Currently, attenuated strains of VACV such as MVA are being 
trialed as safer smallpox vaccine substitutes and recombinant vaccine vectors against 
other infectious diseases.  
Despite the extensive use of attenuated VACV strains in numerous studies, specifically 
in prime-challenge / vaccination regimes, very little is known about their ability to 
induce long-lived humoral immunity in animal models. In addition, the attenuated 
strains have been administered in varying routes and doses, thereby making it difficult 
to draw any conclusions into the vital role of key basic input parameters such as 
replication capacity, dose and route of administration in long-term antiviral immunity. 
In this chapter, we have addressed this gap in the literature by studying differences in 
the magnitude and quality of antiviral immunity generated with strains of ECTV and 
VACV exhibiting varied replication capacities. We hypothesize that the escalating 
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concentration of antigens generated by a replicating virus provides important cues to 
key immune subsets in the GC response and these are critical for induction as well as 
maintenance of robust long-lived antiviral immunity. 
As discussed in Chapter 1, ECTV is an excellent small animal model for studying 
immunity to smallpox. ECTV-WT is replication-competent and replicates very 
efficiently in its natural host, the mouse. Previous studies, as well data shown in the 
preceding chapter highlight that it induces long-term antiviral protective immunity 
similar to that seen in VARV infection. The availability of ECTV strains of varying 
replicating efficiencies presented an excellent opportunity to dissect the effect of viral 
replicative capacity on induction of long-lived humoral immunity. We have therefore 
used WT and TKΔ strains of ECTV to test our hypothesis that virus replicative capacity 
impacts on the magnitude of TFH and GC B cell responses, long-lived antiviral antibody 
response and memory B cell responses. In addition, we have investigated if TFH:TFR 
ratios in the spleen and blood can be used as a predictor for induction and maintenance 
of long-lived immunity to viruses. Furthermore, we have extended these studies to 
include VACV, the vaccine vector strain MVA and Influenza A viruses to provide 
additional translational value. 
4.2 Results 	  
4.2.1 Viral replicative capacity impacts on splenic and blood TFH 
responses  
In order to test our hypothesis that viral replicative capacity impacts TFH response and 
subsequent GC reaction, C57BL/6 mice were infected subcutaneously with either 
replication-competent ECTV-WT or replication-inefficient ECTV-TKΔ at the same 
dose. Differences in the induction phase of humoral immunity were studied by 
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evaluating the magnitude of TFH and GC B cell responses at the peak of the GC 
reaction. From data presented in the previous chapter, the peak of GC reaction was 
observed at day 14 post ECTV-WT infection, when maximal TFH and GC B cell 
numbers were detected (Figure 3.5 and 3.9). Prior to cross-sectional comparison 
between the two viruses at this time-point, it is critical to establish that the TFH and GC 
responses induced by ECTV-TKΔ followed similar kinetics as in ECTV-WT infection. 
GC B cell and TFH cell numbers in the spleen were evaluated in mice following ECTV-
TKΔ infection at 0, 14, 21 and 35 days p.i. Maximum cell numbers were detected at day 
14 p.i., following which the numbers declined slowly to almost base-line naïve levels by 
day 35 p.i (Figure 4.1A and 4.1B). TFH and GC B cell numbers at day 14 p.i. were 
statistically higher compared to all other time-points in this study. In summary, the GC 
response kinetics was similar between ECTV-TKΔ and ECTV-WT, with peak responses 
for both viruses observed at day 14 p.i. Therefore, this time-point was chosen to carry 
out cross-sectional comparative analysis between the two viruses. 
To investigate the differences in TFH responses elicited by ECTV-WT and ECTV-TKΔ, 
TFH cell percentages as well as total splenic numbers were calculated. Replication-
competent ECTV-WT induced significantly higher TFH cell numbers compared to its 
replication-inefficient counterpart, ECTV-TKΔ (Figure 4.2A and 4.2B). In addition, 
significantly higher GC TFH cells were induced following infection with ECTV-WT 
(Figure 4.2C and 4.2D). As reviewed in Chapter 1, IL-21 is a hallmark cytokine of TFH 
cells and loss of IL-21 is associated with premature resolution of GC reaction and lower 
antibody levels (Zotos et al., 2010; Linterman et al., 2010; Lee et al., 2011). Therefore, 
following infection with ECTV-WT and ECTV-TKΔ, IL-21+ TFH cell population was 
evaluated using IL-21 GFP transgenic mice (Luthje et al., 2012). Significantly higher 
numbers of IL-21+ TFH cells were detected following infection with ECTV-WT (Figure 
4.3) in comparison to naïve and ECTV-TKΔ infected mice. The MFI for IL-21 was
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Figure 4.1: Kinetics of TFH and GC B cell responses during ECTV-TKΔ infection. 
C57BL/6 mice were infected subcutaneously with 1000 PFU of ECTV-TKΔ at various 
times and all sacrificed on the same day such that each group had been infected for the 
period indicated. GC B cell and TFH cell numbers were calculated and expressed as (A) 
Total GC B cell numbers per spleen and (B) Total TFH cell numbers per spleen. Data 
from one experiment is represented as means ± SEM (n=3 mice per group). Data was 
log transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak’s multiple comparison test; *P<0.05; **P<0.005; ***P<0.0005; 
****P<0.0001	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Figure 4.2: Effect of viral replicative capacity on TFH cell responses in primary 
ECTV infection. C57BL/6 mice were infected subcutaneously with 1000 PFU of 
ECTV-WT or ECTV-TKΔ or left uninfected. At day 14 p.i., the mice were sacrificed 
and TFH  and GC TFH cells were quantitated by flow cytometry as described previously. 
(A) TFH as % of CD4 T cells, (B) TFH cell numbers per spleen, (C) GC TFH as % of CD4 
T cells and (D) GC TFH cell numbers per spleen. Data shown is from one of three 
independent experiments with similar results; means ± SEM  (n=6 mice per group, 
except naïve n=2). Data was log transformed and statistical significance determined 
using One-Way ANOVA with Holm Sidak multiple comparison test; ***P<0.0005; 
****P<0.0001.  	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Figure 4.3: Splenic IL-21+ TFH cells in ECTV-WT or ECTV-TKΔ infected mice. IL-21 GFP transgenic mice were infected subcutaneously with 
1000 PFU of ECTV-WT or ECTV-TKΔ. At day 14 p.i., the mice were sacrificed and TFH cells expressing IL-21-GFP were identified by flow 
cytometry. Plots shown are concatenation of cytometer files from three samples in each group (A) ECTV-WT infection (B) ECTV-TKΔ infection and 
(C) IL-21 GFP histogram comparison plots. Numbers on the plots represent percent of the parent CXCR5hi, PD-1hi population. 
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calculated to determine whether production of IL-21 by individual TFH cells was altered 
between the two viral infections. However, no significant differences were observed 
between ECTV-WT (MFI: 3830±50) and ECTV-TKΔ infections (MFI: 3378±908), 
indicating that the replication capacity of the virus does not affect IL-21 production by 
TFH cells, but it does promote an increase in the number of IL-21+ TFH cells. 
Proportions of TFH and TFR cells within the parent CXCR5hi, PD-1hi population varied 
distinctly between the two viral infections as shown in concatenated flow cytometry 
files in Figure 4.4. In naïve mice, an almost equal proportion of TFH and TFR cells was 
observed (Figure 4.4A). In ECTV-WT infected mice we noticed significant changes in 
the cell proportions with a bias towards TFH cell population (Figure 4.4B). In contrast, 
following infection with poorly replicating ECTV-TKΔ, TFR cell proportions remained 
high with a small increase in TFH cell proportions (Figure 4.4C). Graphical 
representations of these findings are provided in Figure 4.4D. 
Consequently, differences in the ratio of TFH cell to TFR cells following the viral 
infections were compared in this study. Our data indicates that a ratio of 1:1 exists 
between TFH and TFR cells in naïve mice. An increase in TFH:TFR ratio was detected in 
both ECTV-WT and ECTV-TKΔ infected mice at day 14 p.i. Importantly, a greater than 
10-fold significant increase in the TFH:TFR ratio  was detected in ECTV-WT infected 
mice compared to ECTV-TKΔ infected animals (Figure 4.5A). Conversely, a higher 
TFR:TFH ratio was detected in the ECTV-TKΔ infected mice compared to ECTV-WT 
infected mice (Figure 4.5B). 
Over the past decade, TFH cells have been extensively studied in secondary lymphoid 
organs with recent studies highlighting the presence of circulating TFH cells in both 
humans and mice (He et al., 2013). Consequently, blood TFH cell responses following
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Figure 4.4: Effect of viral replicative capacity on TFH and TFR cell proportions. C57BL/6 mice were infected as described in Figure 4.1,  sacrificed 
at day 14 p.i. and splenocytes were stained for TFH and TFR cells as described previously. Plots shown are concatenation of cytometer files from all 
samples in the respective group (A) Naïve, (B) Infection with ECTV-WT and (C) Infection with ECTV-TKΔ. Numbers on the plots represent percent 
of the parent CXCR5hi, PD-1hi population. (D) Graphical representation of the proportions of TFH and TFR cells within the follicular parent CXCR5hi 
PD-1hi cell population; means ± SEM. 	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Figure 4.5: Effect of viral replicative capacity on TFH and TFR ratios in spleen. 
C57BL/6 mice infected as described in figure 4.1, sacrificed on day 14 p.i. and TFH and 
TFR cells were identified by flow cytometry. TFH and TFR cell numbers were quantified 
and (A) TFH:TFR and (B) TFR:TFH ratios are shown. Data shown is from one of three 
independent experiments with similar results; means ± SEM  (n=6 mice per group, 
except naïve n=2). Data was log transformed and statistical significance determined 
using One-Way ANOVA with Holm Sidak multiple comparison test;  **P<0.005; 
****P<0.0001.  	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infection with ECTV-WT and ECTV-TKΔ were evaluated. Replication-competent 
ECTV-WT induced significantly higher blood TFH cell numbers compared to mice 
infected with replication-inefficient ECTV-TKΔ (Figure 4.6A and 4.6B). This response 
was similar to the TFH cell response detected in the spleen. These results indicate that 
the blood TFH cells induced post ECTV infection is indeed representative of the ongoing 
TFH response in secondary lymphoid organs.  
In a recent study by Sage et al., TFR cells were identified in the blood compartment and 
subsequent work published by the same group demonstrated that circulating TFR cells 
can home to the secondary lymphoid organs and inhibit antigen specific antibody 
production (Sage et al., 2014; Sage et al., 2013). These results allude to the important 
role of circulating TFR cells and blood TFH:TFR ratios in antiviral humoral immunity. In 
response to ECTV-WT or ECTV-TKΔ infection, a significant increase in blood TFH: TFR 
ratio was detected in both groups. ECTV-TKΔ infected mice demonstrated a 2.5-fold 
increase in the blood TFH: TFR ratio over naïve mice. In comparison, ECTV-WT infected 
mice demonstrated an approximate 11-fold increase in blood TFH:TFR ratio (Figure 
4.6C) over naïve mice. These results indicate that infection with a replication-competent 
virus induces a significantly higher blood TFH: TFR ratio and conversely, a higher TFR: 
TFH ratio was detected during infection with a replication-inefficient virus (Figure 
4.6D). Next, the question arises whether the ratios detected in the blood are similar to 
those detected in the spleen. Hence, splenic and blood ratios were compared in this 
study and the data clearly demonstrates that the TFH:TFR  and TFR:TFH ratios were 
indistinguishable in spleen and blood (Figure 4.7A and 4.7B). 
Collectively, the results indicate that the replication capacity of the virus determines the 
magnitude of TFH response both in the blood as well as secondary lymphoid organs.
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Figure 4.6: Effect of viral replicative capacity on blood TFH populations in primary 
ECTV infection. C57BL/6 mice were infected subcutaneously with 1000 PFU of 
ECTV-WT or ECTV-TKΔ or left uninfected. At day 14 p.i., the mice were sacrificed; 
blood TFH populations were identified by flow cytometry and represented as (A) % of 
CD4 T cells,  (B) Cell numbers per 106 CD4 T cells, (C) TFH: TFR ratio, and (D) TFR: 
TFH ratio. Data shown is from one of two independent experiments with similar results 
and represented as means ± SEM (n=3-4 per group). Data was log transformed and 
statistical significance determined using One-Way ANOVA with Holm-Sidak multiple 
comparison test. **P<0.005; ****P<0.0001.	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Figure 4.7: Comparison of TFH:TFR and TFR:TFH ratios in spleen and blood. 
C57BL/6 mice were infected subcutaneously with 1000 PFU of ECTV-WT or ECTV-
TKΔ or left uninfected. Spleen and blood TFH and TFR populations were identified by 
flow cytometry and represented as (A) TFH:TFR ratio and  (B) TFR: TFH ratio. Within 
each experimental group, the TFH: TFR or TFR: TFH ratios in spleen and blood were 
comparable. Combined data from all experiments represented as means ± SEM (n= 7-9 
mice in each group). 
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Importantly, we have established that TFH and TFR cell balance is dictated by the viral 
replicative capacity and this can be efficiently tracked in blood. 
4.2.2 Viral replicative capacity dictates GC responses and long-
term neutralizing antibody levels 
Next, to evaluate the effect of viral replicative capacity on GC B cell responses, 
C57BL/6 mice were infected with either ECTV-WT or ECTV-TKΔ at the same dose. 
Mice were ethically sacrificed at day 14 p.i. and GC B cell percentages as well as total 
splenic numbers were calculated. Mice infected with replication-competent ECTV-WT 
demonstrated a significantly higher GC B cell response in comparison to mice infected 
with replication-inefficient ECTV-TKΔ (Figure 4.8A and 4.8B). At the same dose, a 10-
12-fold lower GC B cell response was detected in mice infected with ECTV-TKΔ. In 
order to confirm these findings, spleen sections were analyzed for GC formation by 
immunofluorescent staining as described in the previous chapter (section 3.2.2). As 
expected, no GC was detected in naïve spleen sections (Figure 4.9A). In contrast, GC’s 
were detected in the spleen sections of both ECTV-WT and ECTV-TKΔ infected mice  
(Figure 4.9B and 4.9C). Importantly, ECTV-WT infected mice exhibited substantially 
higher numbers of GC, that were also larger in size compared with those induced in 
spleens of ECTV-TKΔ infected mice (Figure 4.9B).  
Studies in the preceding chapter, established that the generation of ECTV-specific 
isotype switched antibody levels was dependent on TFH mediated GC responses. 
Consequently, it was hypothesized that the reduced TFH cell and GC B cell responses 
observed upon infection with ECTV-TKΔ would lead to lower virus-specific antibody 
levels.  In the experiment described above, ECTV-specific IgM and IgG levels were 
determined at day 14 p.i. using ELISA. As postulated, significantly lower ECTV-
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Figure 4.8: Effect of viral replicative capacity on GC B cell responses in primary 
ECTV infection. C57BL/6 mice infected as in Figure 4.2 were sacrificed at day 14 p.i. 
GC B cells were quantitated by flow cytometry as described previously and represented 
as (A)  % of B220 cells and (B) Cell numbers per spleen. Data shown is from one of 
two independent experiments with similar results and represented as means ± SEM 
(n=3-4 per group). Data was log transformed and statistical significance determined 
using One-Way ANOVA with Holm Sidak’s multiple comparison test. **P<0.005; 
***P<0.0005; ****P<0.0001. 
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Figure 4.9: Differences in immunofluorescent staining of GC based on viral replicative capacity. C57BL/6 mice were infected subcutaneously 
with 1000 PFU of ECTV-WT or ECTV-TKΔ or left uninfected. At day 14 p.i., the mice were sacrificed, spleens snap-frozen and 10µm spleen sections 
were stained using anti-CD4 mAb (clone: GK1.5; represented in green), anti-IgD mAb (clone: 11-26c; represented in red) and PNA (represented in 
blue). Sections were imaged using Leica SP5 confocal Laser scanning microscope. The panels shown are representative of (A) Naïve spleen section, 
(B) ECTV-WT infection and (C) ECTV-TKΔ infection. Images are representative of multiple fields per section from 3 mice per group; Magnification 
10X.  
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specific IgM as well as isotype switched IgG levels were detected in ECTV-TKΔ 
infected mice (Figure 4.10).  
Further, the frequencies of circulating antibody-secreting cells (ASC) were evaluated 
using B Lymphocyte-induced maturation protein 1 (Blimp-1) GFP transgenic mice 
(Kallies et al., 2004). At the peak of the GC reaction (i.e. at day 14 p.i.), significantly 
higher frequencies of circulating ASC’s were detected in mice infected with ECTV-WT 
compared to ECTV-TKΔ infected mice (Figure 4.11A and 4.11B). Due to limited 
availability of Blimp-1 GFP transgenic mice, the antibody secreting plasma cell 
population was further studied in C57BL/6 mice using CD138 (Syndecan-1) expression 
as a marker. Whilst plasma cells are generated in the secondary lymphoid organs in 
response to an antigen, most of the long-lived plasma cells eventually reside in the bone 
marrow (Slifka and Ahmed, 1998; Slifka et al., 1998; Manz and Radbruch, 2002). 
Therefore, differences in the induction of plasma cells were evaluated in the spleen at 
day 14 p.i. and long-term maintenance was studied in the bone marrow at 10 weeks p.i. 
Following infection with ECTV-WT, at day 14 p.i., significantly higher plasma cell 
numbers were detected in the spleen compared to ECTV-TKΔ infection (Figure 4.11C, 
left y-axis) and these differences were maintained in the bone marrow at 10 weeks p.i. 
(Figure 4.11C, right y-axis). These findings indicate that the plasma cell induction as 
well as long-term survival niches are affected by the replicative capacity of the virus. 
To further evaluate if the long-term circulating virus specific antibody levels were 
consistent with the plasma cell data, C57BL/6 infected with ECTV-WT or ECTV-TKΔ 
were bled at time-points indicated in Figure 4.12. Infection with ECTV-TKΔ elicited 
significantly lower ECTV-specific IgG levels at all time-points studied up to day 70 p.i 
(Figure 4.12). In addition, functional neutralizing capacity of the antibody was 
determined by the PRNT assay. At all time-points studied, mice infected with ECTV-
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Figure 4.10: Effect of viral replicative capacity on ELISA antibody levels in 
primary ECTV infection. C57BL/6 mice were infected subcutaneously with 1000 
PFU of ECTV-WT or ECTV-TKΔ. Mice were bled at day 14 p.i. and  ECTV-specific 
IgM and IgG levels were measured at a plasma dilution of 1:200 using ELISA. Data 
shown is from one of two independent experiments with similar results and represented 
as means of absorbance values ± SEM (n=4 mice per group). Data was log transformed 
and statistical significance determined using Two-Way ANOVA. ***P<0.0005. 
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Figure 4.11: Effect of viral replicative capacity on ASC populations. Blimp-1 GFP 
transgenic mice infected subcutaneously with 1000 PFU of ECTV-WT or ECTV-TKΔ 
were sacrificed at day 14 p.i. Frequency of circulating ASC’s (Blimp-1 GFP+ve cells) 
represented as (A) % of single lymphocytes and (B) Histogram plots. Data from one 
experiment represented as means ± SEM (n=4 mice per group, except naïve n=2). Data 
was log transformed and statistical significance determined using One-way ANOVA; 
**P<0.005. (C) Splenic and bone marrow plasma cells (B220-ve, CD138+ve) in C57BL/6 
mice infected with ECTV-WT or ECTV-TKΔ were identified by flow cytometry at 
times indicated. Data from one experiment represented as means ± SEM (Day 14 p.i., 
n=9 mice per group; Day70 p.i., n=5 mice per group). Data was log transformed and 
statistical significance determined using t-test. ***P<0.0005; ****P<0.0001. 	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Figure 4.12: Effect of viral replicative capacity on long-term antibody levels 
following primary ECTV infection. Groups of 4 C57BL/6 mice were infected 
subcutaneously with 1000 PFU of ECTV-WT or ECTV-TKΔ. Mice were bled at times 
indicated and ECTV-specific IgG levels were measured at a plasma dilution of 1:200 
using ELISA. Data was log transformed and statistical significance determined using 
Two-Way ANOVA and represented as means of absorbance values ± SEM. Data shown 
is from one of two independent experiments with similar results. **P<0.005; 
***P<0.0005; ****P<0.0001.  	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WT exhibited significantly higher PRNT50 titers than mice infected with ECTV-TKΔ 
(Figure 4.13). By day 70 p.i., infection with ECTV-WT elicited PRNT50 titers between 
1200-1800. In comparison, infection with ECTV-TKΔ elicited PRNT50 titers between 
20-50. 
Collectively, these results indicate that the replicative fitness of the virus determines the 
magnitude of the GC B cell response, long-term antibody levels and serum neutralizing 
PRNT50 titers.  
4.2.3 Antibodies generated following a replicating virus infection 
offer better in-vivo protection during secondary challenge  
In the previous section, we demonstrated ex-vivo that antibodies generated following 
infection with a replication-competent virus has significantly higher neutralizing 
PRNT50 titers. To examine the capacity of antibodies to protect against ECTV challenge 
in-vivo, a passive transfer-challenge approach was used. Groups of C57BL/6 mice were 
infected with ECTV-WT or ECTV-TKΔ at the same dose and at 8 weeks p.i., mice were 
exsanguinated and polyclonal serum was extracted from the blood of mice individually. 
Serum thus collected was transferred i.p. into naïve mice such that each mouse received 
polyclonal serum from one primed mouse (~200µl). One day later, the mice were 
challenged with a sub-lethal dose of ECTV-WT and ethically sacrificed at day 5 post-
challenge. Mice receiving sera from ECTV-WT primed mice exhibited a 3 log10 PFU 
reduction of viral titers in liver (Figure 4.14A) and spleen (Figure 4.14B) compared to 
naïve or mice receiving sera from ECTV-TKΔ primed mice. In addition, a 1-2 log10 
reduction in viral titers was also detected in the lungs (Figure 4.14C) and blood (Figure 
4.14D) of mice receiving sera from ECTV-WT primed mice. The viral load in the 
organs were comparable between the naïve and mice receiving sera from
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Figure 4.13: Virus-neutralizing (PRNT50) antibody titers in primary ECTV 
infection. C57BL/6 mice were infected subcutaneously with 1000 PFU of ECTV-WT 
or ECTV-TKΔ. Mice were bled at times indicated and plasma extracted. ECTV specific 
virus neutralizing activity was determined by PRNT. Curve-fitting of the data was done 
using four-parameter non-linear regression analysis and represented as (A) % 
Neutralization following infection with ECTV-WT, (B) % Neutralization following 
infection with ECTV- TKΔ and  (C) Comparison of PRNT50 titers between the two 
groups. Data shown is from one of two independent experiments with similar results 
and represented as means ± SEM (n=4 mice per group). Data was log transformed and 
statistical significance determined using Two-Way ANOVA; ****P<0.0001. 	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Figure 4.14: Protective capacity of ECTV-specific antibody generated based on 
viral replicative capacity. C57BL/6 mice were primed subcutaneously with 1000 PFU 
of ECTV-WT or ECTV-TKΔ or left uninfected (n=4 mice per group). Primed and 
uninfected mice were sacrificed at day 50, serum was extracted and approximately 
200µl from each animal was transferred i.p. into one naïve mouse.  One day later, 
animals passively transferred with serum were challenged with a sub-lethal dose of 
1000 PFU ECTV-WT 24 hrs later. Following sacrifice at day 5 post-challenge, viral 
load in (A) Liver, (B) Spleen and (C) Lungs was determined by plaque assay and 
expressed as means of log10  PFU / gram of tissue ± SEM. (D) DNA isolated from blood 
was used to quantitate viral load by qRT-PCR and expressed as means of log10 viral 
genome copy ± SEM. Dashed lines indicate the limit of detection. Data shown is from 
one of two independent experiments. Data was log transformed and statistical 
significance determined using One-Way ANOVA test. *P<0.05; ***P<0.0005.  	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 ECTV-TKΔ primed mice. Taking into account that all recipient mice were age-matched 
and no endogenous ECTV-specific IgG antibodies were observed by day 5 post-
challenge in the naïve control group (data not shown), the differences in viral titers 
observed between the groups, can be attributed to the passively transferred anti-ECTV 
antibodies. 
Ex-vivo neutralizing titer of serum samples collected from recipient mice transferred 
with immune serum, pre- and post-challenge was determined by PRNT assay. The pre- 
and post-challenge PRNT50 titers were comparable in the group receiving sera from 
ECTV-WT primed mice (Figure 4.15). In comparison, a slight drop in the PRNT50 titers 
was detected in the post-challenge samples of the group receiving sera from ECTV-TKΔ 
infected mice. The increasing viraemia, along with preordained low neutralizing 
capacity of antibodies from ECTV-TKΔ infected mice could account for the 
sequestration of the antibody and subsequent lower PRNT50 titers. In summary, these 
findings indicate that the antibodies generated in response to a replicating viral infection 
offer better protection during a secondary exposure. 
4.2.4 Replication-competent virus generates better humoral 
memory B cell responses 
To examine the effect of viral replicative capacity on memory B cell responses, 
C57BL/6 mice were primed subcutaneously with the same dose of ECTV-WT or 
ECTV-TKΔ. At 7 weeks post-priming, the mice were sacrificed and > 95% purity 
CD19+ splenocytes were purified via FACS sorting. CD19+ cells are a heterologous 
population of naïve and memory B cells. On contact with antigen, the memory B cells 
should rapidly differentiate into ASC leading to a robust anamnestic antibody response 
to control the infection. Approximately, 5 x 104 CD19+ cells from naïve, ECTV-WT or
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Figure 4.15: Virus-neutralizing antibody titers in primary ECTV infection. 
Immune serum recipient mice were challenged as described in figure 4.13. Mice were 
bled pre- and post-challenge and serum extracted. ECTV-specific virus neutralizing 
activity was determined by PRNT. Curve-fitting of the data was done using four-
parameter non-linear regression analysis and represented as (A) % Neutralization 
following infection with ECTV-WT, (B) % Neutralization following infection with 
ECTV- TKΔ and  (C) Comparison of PRNT50 titers between the two groups. Data 
shown is from one of two independent experiments with similar results and represented 
as means ± SEM (n= 4 mice per group). No statistical difference was detected by two-
way ANOVA between pre and post-challenge samples. 	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ECTV-TKΔ primed mice were adoptively transferred into separate groups of naïve 
C57BL/6 mice. Three days post-transfer, mice were challenged with a sub-lethal dose 
of ECTV-WT to activate memory B cells.  In a preliminary experiment, we found that 
endogenous ECTV-specific IgG was only detectable in the no transfer control after day 
9 post-challenge (data not shown). Therefore in this study, mice were sacrificed at day 8 
post-challenge and ECTV-specific IgG levels were measured by ELISA. In naïve mice 
transferred with CD19+ B cells from ECTV-WT primed donors that were not 
challenged with virus, no ECTV-specific IgG was detected (data not shown). This 
finding confirmed that any ECTV-specific antibody detected post-challenge must be 
generated from the memory B cell differentiation per se and not due to contamination 
with plasma cells. ECTV-specific IgG was detected in groups of mice that received 
CD19+ B cells from ECTV-WT or ECTV-TKΔ primed donors. Although no statistical 
significance could be detected between the two groups, mean antibody levels were 
lower in mice that received memory B cells from ECTV-TKΔ primed donor mice 
(Figure 4.16A). The small number of mice used could explain the lack of statistical 
significance in this experiment. However, the ELISA titers do not reflect on the quality 
of the antibody produced and therefore virus-neutralizing capacity of the antibodies 
generated following memory B cell transfer was determined by PRNT assay. Mice 
receiving memory B cells from ECTV-WT primed donor mice generated antibodies 
with significantly higher PRNT50 titers compared to mice receiving ECTV-TKΔ primed 
memory B cells and naïve mice. (Figure 4.16B). In summary, a significantly better 
quality of memory B cell response was detected in mice infected with replication-
competent ECTV-WT compared to replication-inefficient ECTV-TKΔ infection at the 
same dose. 
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Figure 4.16: Effect of viral replicative capacity on quality of memory B cell 
response. C57BL/6 mice were primed subcutaneously with 1000 PFU of ECTV-WT or 
ECTV-TKΔ or left uninfected. At Day 50 post-priming, mice were sacrificed; 5 x 104 
CD19+ cells were sorted by flow cytometry and adoptively transferred into naïve mice. 
At 3 days post-transfer, mice were challenged with a sub-lethal dose (1000 PFU) of 
ECTV-WT. Mice were bled at day 9 post-challenge and sera used to measure (A) 
ECTV-specific IgG levels by ELISA and (B) ECTV-specific virus neutralizing activity 
by PRNT.  PRNT50 was calculated as the reciprocal of plasma dilution at which 50% of 
the virus was neutralized; means ± SEM of one experiment (n=3 mice per group). Data 
was log transformed and statistical significance determined using One-Way ANOVA 
with Holm-Sidak multiple comparison test. *P<0.05; **P<0.005;  ****P<0.0001.	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4.2.5 Replication-competent virus infection generates higher CD8 
and CD4 T memory populations 
Immune memory following either infection or vaccination is mediated by both arms of 
the adaptive immune system - the humoral memory response is mediated by memory B 
cells where as CD8 and CD4 T memory cells are key players of the cellular immune 
response arm. To understand how viral replicative capacity affects immune memory 
comprehensively, we examined the CD8 and CD4 T memory cell subsets in addition to 
memory B cells described in the previous section. C57BL/6 infected with ECTV-WT or 
ECTV-TKΔ at the same dose were sacrificed 8 weeks post-infection and the memory T 
cell subsets were analysed by flow cytometry. Though memory T cells are present in 
both lymphoid and non-lymphoid tissues, a study by Becker et al., demonstrated that 
the memory subsets on recall proliferated to a greater extent in the lymphoid tissues, 
specifically in the bone marrow (Becker et al., 2005). Therefore, CD8 and CD4 T cell 
memory subsets were evaluated both in the spleen as well in the bone marrow. 
Based on the classification system proposed by Sallusto et al., CD8 memory T cells can 
be categorized as either central (TCM; CD8
+, CD44hi, CD127hi, CD62Lhi) or effector 
(TEM; CD8
+, CD44hi, CD127 hi, CD62Llo) memory cells based on CD62L expression 
(Sallusto et al., 1999). In addition, effector CD8 T cells with potential to survive and 
form long-lived memory CD8 T cells, designated as memory precursor effector cells 
(MPEC) can be identified by flow cytometry as CD8+, CD44hi, KLRGlo, CD62Llo, 
CD127lo stained cells (Kaech et al., 2003; Joshi et al., 2007). The gating strategy used 
in the identification of memory T cell subsets is shown in Appendix Figure 4.1. In the 
bone marrow, CD8+ TEM, TCM and MPEC memory cell populations were detected in 
response to both ECTV-WT as well as ECTV-TKΔ infection. However, significantly 
higher numbers of CD8+ memory T cell population were detected in ECTV-WT 
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infected mice compared to ECTV-TKΔ infected mice (Figure 4.17A, 4.17B and 4.17C). 
Similarly, in the spleen, ECTV-WT infection induced significantly higher numbers of 
CD8+ TEM, TCM and MPEC memory cell populations compared to aged-matched naïve 
controls or ECTV-TKΔ infected mice (Figure 4.18A, 4.18B and 4.18C). Intriguingly, no 
CD8+ memory T cell population was detected in the spleen (above levels seen in age-
matched naïve controls) following ECTV-TKΔ infection. This finding is consistent with 
previous reports demonstrating a weak secondary CTL response in mice primed 
subcutaneously with ECTV-TKΔ (Panchanathan et al., 2010). 
In addition, CD4+ TEM (CD4+, CD44hi, CD62Llo, CD127hi) and TCM (CD4+, CD44hi, 
CD127hi, CD62Lhi) cells were also examined in the spleen and bone marrow 8 weeks 
after infection with ECTV-WT or ECTV-TKΔ. The gating strategy used in the 
identification of memory T cell subsets is shown in Appendix Figure 4.2. Interestingly, 
a preferential CD4 TEM population was generated in the bone marrow following 
infection with ECTV-WT virus (Figure 4.18A). In contrast, both CD4+ TEM and TCM 
cell populations were demonstrated in the spleen of ECTV-WT infected mice (Figure 
4.19C and 4.19D). Following infection with ECTV-TKΔ, no CD4 T memory population 
was elicited in both spleen and bone marrow.  
Taken together, these results indicate that replication-competent virus induced stronger 
CD8 and CD4 memory T cell populations both in the spleen and bone marrow 
compared to a poorly replicating virus.  
4.2.6 Priming with a replication-competent virus leads to better 
viral control following lethal challenge 
Hitherto, our studies have demonstrated that infection with a replicating virus elicits a 
better GC response resulting in long term antiviral immunity mediated by neutralizing
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Figure 4.17: Effect of viral replicative capacity on CD8 T memory populations in 
the bone marrow. C57BL/6 mice infected subcutaneously with 1000 PFU of ECTV-
WT or ECTV-TKΔ were sacrificed at day 70 p.i. and CD8 TEM, MPEC and TCM cell 
populations were identified in the bone-marrow (BM) as illustrated in Appendix Figure 
4.1. Shown are numbers of (A) CD8 TEM cells (B) MPEC and (C) TCM cells. Data 
shown is from one of two independent experiments with similar results and represented 
as means ± SEM (n=6 mice per group except naïve n=3). Data was log transformed and 
statistical significance determined using One-Way ANOVA with Holm-Sidak multiple 
comparison test. **P<0.005; ***P<0.0005; ****P<0.0001.  	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Figure 4.18: Effect of viral replicative capacity on splenic CD8 T memory 
populations. C57BL/6 mice infected as in figure 4.17 were sacrificed at day 70 p.i. 
and CD8 TEM, MPEC and TCM cell populations were enumerated in the spleen. 
Numbers of (A) CD8 TEM cells (B) MPEC and (C) TCM cells are presented. Data 
shown is from one of two independent experiments with similar results and 
represented as means ± SEM (n=6 mice per group except naïve n=3). Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test. *P<0.05; **P<0.005; ***P<0.0005; 
****P<0.0001.	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Figure 4.19: Effect of viral replicative capacity on CD4 T memory populations. 
C57BL/6 mice infected as in figure 4.17 were sacrificed at day 70 p.i. and CD 4 TEM 
and TCM cell populations were identified in  BM and spleen (as illustrated in appendix 
Figure 4.2). (A) BM CD4 TEM cell numbers (B) BM CD4 TCM cell numbers (C) 
Splenic CD4 TEM cell numbers and (D) Splenic CD4 TCM cell numbers. Data shown 
is from one of two independent experiments with similar results and represented as 
means ± (n=6 mice per group except naïve n=3). Data was log transformed and 
statistical significance determined using One-Way ANOVA with Holm-Sidak 
multiple comparison test. **P<0.005; ***P<0.0005; ****P<0.0001. 	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 antibodies and immunological memory. To examine the degree of immune protection 
conferred following priming with replication variant viruses, we used the prime-lethal 
challenge approach. C57BL/6 mice, though resistant to ECTV-WT, succumb to 
infection by day 8-11 p.i. at a dose of 106 PFU administered intravenously. C57BL/6 
mice were primed with either ECTV-WT or ECTV-TKΔ at the same dose and 8 weeks 
later challenged with a lethal dose (106 PFU i.v.) of ECTV-WT. Mice were ethically 
sacrificed 5 days post-challenge and organs collected to determine the viral load. At the 
time of sacrifice, 8-9 log10 PFU/g virus titer was detected in the organs of unprimed 
mice. No virus was detected in the organs of ECTV-WT primed mice. Viral titers of 3 
log10 PFU/g was detected in the lungs (Figure 4.20A) and liver (Figure 4.20B) of 
ECTV-TKΔ primed mice. ECTV-specific IgG levels were determined prior to challenge 
and at the time of sacrifice. Post-challenge, an increase in ECTV-specific antibody 
levels was detected in both ECTV-WT and ECTV-TKΔ primed mice representing the 
anamnestic memory response (Figure 4.21). In addition, antibody neutralizing titers 
were determined both pre and post-challenge. Though a trend towards higher PRNT50 
titers was observed in both the ECTV-WT and ECTV-TKΔ primed mice post-challenge, 
no statistical significance could be detected (Figure 4.22). It is note-worthy that the 
post-challenge ECTV-TKΔ primed mice demonstrated PRNT50 titers that were almost 
20-fold lower than the pre-challenge ECTV-WT primed samples.  In summary, these 
results indicate that priming with replication-competent virus leads to better viral 
control following a secondary lethal challenge. 
4.2.7 Effect of viral replicative capacity on magnitude of TFH and 
GC B cell responses in the VACV model 
Results from the ECTV model indicate that the viral replicative capacity dictates the 
quality of long-term antiviral immunity. This information is useful from a vaccine
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Figure 4.20: Viral control following challenge with a lethal dose of ECTV-WT. 
C57BL/6 mice were primed subcutaneously with 1000 PFU of ECTV-WT or ECTV-
TKΔ  or left uninfected. At 8 weeks post-priming, mice were challenged with a lethal 
dose of 106 PFU intravenously. Mice were sacrificed at day 5 post-challenge; viral load 
in (A) Lungs and (B) Liver was determined by plaque assay and expressed as means of 
log10  PFU / gram of tissue ± SEM (n=4 mice per group). (C) DNA isolated from blood 
was used to quantitate the viral load by qRT-PCR and expressed as means of log10 viral 
genome copy ± SEM. Dashed lines indicate the limit of detection. Data was log 
transformed and statistical significance determined using One-Way ANOVA test. 
**P<0.005; ****P<0.0001. 
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Figure 4.21: Viral control following challenge with a lethal dose of ECTV-WT. 
C57BL/6 mice were primed as in figure 4.20 and 8 weeks post-priming, mice were 
challenged with a lethal does of 106 PFU ECTV-WT i.v. ECTV-specific antibody levels 
were detected by ELISA and represented as means ± SEM (n=4 mice per group). (A) 
Pre-challenge and (B) Post-challenge (day 5 post-challenge). Data was log transformed 
and statistical significance determined using Two-way ANOVA test. **P<0.005; 
****P<0.0001. 
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Figure 4.22: Virus-neutralizing antibody titers following challenge with a lethal 
dose of ECTV-WT. C57BL/6 mice were primed and challenged as described in Figure 
4.20. ECTV-specific virus neutralizing activity was determined by PRNT assay. 
PRNT50 titers between the two groups were compared pre- and post-challenge (at day 5 
post-challenge); means ± SEM. No statistical difference was detected between pre- and 
post-challenge samples by Two-way ANOVA with Holm-Sidak multiple comparison 
test. 
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design perspective and would be of particular interest if these results can be extended to 
include other orthopoxviruses, specifically VACV, considered to be the prototype 
poxvirus of human significance and potential vaccine vector. 
Although VACV is not a natural mouse pathogen, it does replicate in mice, albeit, the 
replication is restricted to the site of infection after cutaneous inoculation (Tscharke et 
al., 1999). Therefore, in this study, intravenous injections were chosen as the route of 
virus administration to simulate the blood-borne systemic spread seen in ECTV 
infection. To evaluate the effect of viral replicative capacity using VACV model, 
C57BL/6 mice were infected with replication-competent VACV-WT or replication-
defective VACV-TKΔ at the same dose. At day 10 p.i., mice were ethically sacrificed 
and TFH and GC B cell populations were analyzed by flow cytometry.  
Replication-competent VACV-WT induced significantly higher TFH cell numbers 
compared with the replication-inefficient VACV-TKΔ at the same dose (Figure 4.23A). 
Analyses of the proportions of TFH and TFR cells within the parent follicular CXCR5hi 
and PD-1hi population revealed a bias towards TFH cells in response to infection with 
replication-competent VACV-WT. In comparison, infection with VACV-TKΔ at the 
same dose induced a smaller increase in TFH cell numbers with TFR proportions 
remaining high (Figure 4.23B). Accordingly, VACV-WT induced a higher splenic TFH: 
TFR ratio compared to VACV-TKΔ (Figure 4.23C), and as expected, the latter induced a 
higher TFR:TFH ratio compared to VACV-WT (Figure 4.23D).  
Next, differences in the GC TFH cell responses in the spleen and blood were evaluated. 
Compared with VACV-TKΔ, VACV-WT infection induced significantly higher 
proportions (Figure 4.24A) and numbers (Figure 4.24B) of GC TFH cells in the spleen. 
The blood TFH cell responses were consistent with the ongoing splenic TFH activity, i.e.
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Figure 4.23: Effect of viral replicative capacity on TFH cell population in primary 
VACV infection. C57BL/6 mice were infected intravenously with 1000 PFU of 
VACV-WT or VACV-TKΔ or left uninfected. At day 10 p.i., the mice were sacrificed; 
TFH and TFR cells were identified by flow cytometry as described previously and 
represented as  (A) TFH cell numbers per spleen, (B) Proportions of TFH and TFR cells 
within the parent follicular CXCR5hi, PD-1hi CD4 T cells, (C) TFH:TFR ratio and (D) 
TFR:TFH ratio. Data shown is from one of two independent experiments with similar 
results; means ± SEM (n=3 mice per group). Data was log transformed and statistical 
significance determined using One-Way ANOVA with Holm-Sidak multiple 
comparison test. **P<0.005; ***P<0.0005; ****P<0.0001. 
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Figure 4.24: Effect of viral replicative capacity on GC TFH populations in primary 
VACV infection. C57BL/6 mice infected as in Figure 4.23 were sacrificed at day 10 
p.i. GC TFH cells were identified by flow cytometry and represented as (A) % of CD4 T 
cells and (B) Total cell numbers per spleen. Data shown is from one of two independent 
experiments with similar results; means ± SEM (n=3 mice per group). Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test. *P<0.05; **P<0.005; ***P<0.0005.  
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significantly higher circulating TFH cell numbers were detected following infection with 
VACV-WT (Figure 4.25A and 4.25B). In addition, the ratio of circulating TFH cells to 
TFR cells in response to infection with VACV-WT and VACV-TKΔ was evaluated. An 
increase in blood TFH:TFR ratio was detected in both VACV-WT and VACV-TKΔ 
infected mice. Although no statistical significance could be detected between the two 
infections, a trend towards higher TFH: TFR ratio was observed with VACV-WT 
infection (Figure 4.25C). Within each infection group, splenic and blood TFH: TFR ratios 
were comparable as shown in Figure 4.25D.  
Whilst GC B cell responses were detected in mice infected with either virus, the 
magnitude of GC response was significantly higher in mice infected with VACV-WT 
(Figure 4.26). Similar results were seen with ECTV-WT and ECTV-TKΔ infected mice 
as described in the preceding sections. Collectively, these findings highlight that the 
impact of viral replication capacity on long-term antiviral immunity observed with 
ECTV infection is applicable to the VACV model. 
4.2.8 Replication-incompetent MVA induces a mild GC response  
MVA, the attenuated Ankara strain of VACV is currently being considered as a prime 
candidate in recombinant vaccine vector design against infectious agents and cancer 
(Cavenaugh et al., 2011; Garcia et al., 2011; Kantoff et al., 2010). MVA was developed 
through serial passaging of its parental virus, CVA, in primary chicken embryo cells 
(Mayr et al., 1978). After more that 570 passages, six major deletions in the CVA 
genome, led to the attenuated, host-cell restricted MVA (Meyer et al., 1991). Based on 
the results obtained with attenuated strains of ECTV and VACV, we hypothesized that 
infection with MVA would elicit a ‘mild’ GC response, thereby affecting the quality of 
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Figure 4.25: Effect of viral replicative capacity on blood TFH population in primary 
VACV infection. C57BL/6 mice were infected as described in Figure 4.23. At day 10 
p.i., the mice were sacrificed; blood TFH population was identified by flow cytometry 
and expressed as (A) % of CD4 T cells, (B) Total cell numbers per 106 CD4 T cells, (C) 
TFH:TFR ratio in blood  and (D) Comparison of splenic and blood TFH:TFR ratio. Data 
from one experiment represented as means ± SEM (n=3 mice per group).  Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test. **P<0.005; ***P<0.0005; ****P<0.0001. 
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Figure 4.26: Effect of viral replicative capacity on GC B cell responses in primary 
VACV infection. C57BL/6 mice were infected as described previously in Figure 4.23. 
At day 10 p.i., the mice were sacrificed; GC B cells were quantitated by flow cytometry 
as described previously and expressed as (A) % of B220 cells and (B) GC B cell 
numbers per spleen. Data shown is from one of two independent experiments with 
similar results; means ± SEM (n=3 mice per group).  Data was log transformed and 
statistical significance determined using One-Way ANOVA with Holm-Sidak multiple 
comparison test. **P<0.005; ***P<0.0005; ****P<0.0001.	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long-term humoral immunity. To test this, we infected C57BL/6 mice with replication-
competent parental CVA and replication-incompetent MVA at the same dose. For 
comparative analysis, intravenous administration was chosen as the route of infection. 
TFH, GC TFH and GC B cell populations were identified by flow cytometry and 
percentages as well as total splenic numbers were calculated. As hypothesized, infection 
with CVA elicited a significant four-fold increase in the GC B cell response compared 
with MVA infection (Figure 4.27). TFH cell population analysis showed significantly 
higher TFH cell numbers in CVA infected mice compared to naïve controls (Figure 
4.28A). Although a greater than two-fold increase in TFH cell numbers was 
demonstrated in CVA infected mice when compared to MVA infected animals, no 
statistical difference could be detected. This may be accounted for by the small numbers 
of animals used and the spread in numbers of TFH cells generated in individual animals 
following CVA infection. On evaluating the proportions of TFH and TFR cells within the 
follicular CXCR5hi PD-1hi activated CD4 T cells, a higher proportion of TFH cells was 
noted in response to CVA infection (Figure 4.28B). In comparison, the TFR proportions 
remained high in MVA infected mice inspite of a slight increase observed in TFH 
proportion (Figure 4.28B). As expected, a significantly higher TFH:TFR ratio was 
observed in replication-competent CVA infection. In response to MVA infection, 
although a slight increase in the TFH:TFR ratio was noted compared to naïve control, no 
statistical significance could be detected (Figure 4.28C). Conversely, a higher TFR:TFH 
ratio was observed in mice infected with MVA compared to CVA infected mice (Figure 
4.28D). Next, differences in the GC TFH cell population was evaluated. Significantly 
higher frequency (Figure 4.29A) and numbers  (Figure 4.29B) of GC TFH cells were 
demonstrated in mice infected with CVA when compared to MVA infected mice. 
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Figure 4.27: Effect of viral replicative capacity on GC TFH populations in primary 
CVA or MVA infection. C57BL/6 mice were infected intravenously with 1000 PFU of 
CVA or MVA or left uninfected. At day 10 p.i., the mice were sacrificed; GC B cells 
were quantitated by flow cytometry and expressed as  (A) % of B220 cells and (B) 
Total cell numbers per spleen. Data from one experiment represented as means ± SEM 
(n=3-4 mice per group). Data was log transformed and statistical significance 
determined using One-Way ANOVA with Holm-Sidak multiple comparison test. 
*P<0.05; ***P<0.0005; ****P<0.0001.  	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Figure 4.28: Effect of viral replicative capacity on TFH cell population in primary 
CVA and MVA infection. C57BL/6 mice were infected as described in Figure 4.27. At 
day 10 p.i, the mice were sacrificed; TFH cells were quantitated by flow cytometry as 
described previously and expressed as (A) TFH cell numbers per spleen, (B) Proportions 
of TFH and TFR cells within the parent follicular CXCR5hi, PD-1hi CD4 T cells, (C) 
TFH:TFR ratio and (D) TFR:TFH ratio. Data from one experiment represented as means ± 
SEM (n=3-4 mice per group). Data was log transformed and statistical significance 
determined using One-Way ANOVA test with Holm-Sidak multiple comparison test. 
*P<0.05 ***P<0.0005; ****P<0.0001. 
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Figure 4.29: Effect of viral replicative capacity on GC TFH populations in primary 
CVA and MVA infection. C57BL/6 mice were infected as described in Figure 4.27. At 
day 10 p.i, the mice were sacrificed; GC TFH cells were quantitated by flow cytometry 
and expressed as  (A) % of CD4 T cells and (B) Total cell numbers per spleen. Data 
from one experiment represented as means ± SEM (n=3-4 mice per group). Data was 
log transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test; means ± SEM; *P<0.05; **P<0.005; 
***P<0.0005; ****P<0.0001.  
 
 
 	    
N
ai
ve
 
C
VA
 
M
VA
 0.0
0.1
0.2
G
C
 T
FH
 
(%
 C
D
4+
 c
el
ls
) 
****
**
*
N
ai
ve
 
C
VA
 
M
VA
 0
1×104
2×104
3×104
# 
G
C
 T
FH
 / 
sp
le
en **
*** *
A B
	  	   174 
To study differences in long-term antiviral antibody immunity generated following 
infection with CVA versus MVA, virus-neutralizing capacity was determined at day 50 
p.i. At this time-point, a significantly higher neutralizing capacity (Figure 4.30A) and 
PRNT50 titers (Figure 4.30B) was detected in the CVA infected mice, as measured by 
PRNT assay. No statistical significance was observed in the PRNT50 titers between 
MVA infected mice and age-matched naïve controls. To further evaluate if the 
differences in the neutralizing antibody titers translate functionally to better protection 
during secondary challenge, we chose a prime-heterologous challenge approach. 
C57BL/6 mice primed with CVA or MVA, were challenged 8 weeks later with a lethal 
dose of ECTV-WT 106 PFU i.v. At day 5 post-challenge, mice were ethically sacrificed 
and organs collected to determine the viral load. Viral titers of 8-9 log10 PFU/g were 
detected in the organs of both unprimed as well as MVA primed mice. In contrast, 
significantly lower viral titers were detected in the spleen (Figure 4.31A), lungs (Figure 
4.31B) and liver (Figure 4.31C) of CVA primed mice. These results indicate that 
following a lethal secondary challenge, mice primed with replication-competent CVA 
control virus significantly better than mice primed with replication-incompetent MVA. 
Collectively we have demonstrated that viral replicative capacity significantly impacts 
TFH:TFR ratio which correlates with potent neutralizing antibody responses and 
protection across three orthopoxvirus infection models in mice: ECTV, VACV and 
MVA.  
4.2.9 Effect of viral replicative capacity on antibody responses in 
influenza A virus infection model 
In the preceding sections, we have demonstrated that the replication fitness of the virus 
affects long-term antiviral immunity using orthopoxviruses (double-stranded DNA).
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Figure 4.30: Replication-competent CVA induces antibodies with higher virus-
neutralizing antibody titers. C57BL/6 mice were infected intravenously with 1000 
PFU of CVA or MVA or left uninfected. Mice were bled at day 50 p.i. and VACV-
specific neutralizing activity was determined by PRNT assay. (A) Curve-fitting of the 
data was done using four-parameter non-linear regression analysis and represented as % 
neutralization (Dotted lines indicates 50% neutralization). (B) PRNT50 titers were 
calculated as the reciprocal of plasma dilution at which 50% of the virus is neutralized. 
Data from one experiment represented as means ± SEM (n=4-5 mice per group).  Data 
was log transformed and statistical significance determined using One-Way ANOVA 
with Holm-Sidak multiple comparison test; means ± SEM;  **P<0.005. 
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Figure 4.31: Viral load in primed mice following heterologous challenge with lethal 
dose of ECTV-WT. C57BL/6 mice were primed intravenously with 1000 PFU of CVA 
or MVA or left unprimed. At day 50 post-priming, mice were challenged with a lethal 
dose of ECTV-WT (106 PFU i.v.). Mice were sacrificed at day 5 post-challenge; viral 
load in (A) Spleen,  (B) Lungs and (C) Liver was determined by plaque assay and 
represented as means of log10  PFU / gram of tissue ± SEM (n=4-5 mice per group). 
Data was log transformed and statistical significance determined using one-Way 
ANOVA with Holm-Sidak multiple comparison test. ***P<0.0005; ****P<0.0001.  
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The question arises whether the impact of virus replicative capacity on induction of 
long-lived humoral immunity could apply more broadly to other viruses. We thus 
extended our studies to include influenza A viruses (single-stranded RNA genome). 
Influenza A human viruses do not naturally infect mice and therefore mouse-adapted 
influenza A/PR/8 virus were used in this study. We hypothesized that in comparison to 
live influenza A/PR/8 infection, mice infected with inactivated influenza A/PR/8 virus 
would generate a weaker antiviral humoral response. To generate inactivated viral 
stocks, live influenza A/PR/8 virus stocks were treated with formalin as described in 
section 2.2.11. Virus inactivation was confirmed by influenza viral plaque assay. 
Formalin inactivation did not affect the HA titers  (data not shown).  
To examine whether viral replicative capacity in influenza A virus infections affects the 
GC reaction, C57B/6 mice were immunized with comparable titers of live and 
inactivated influenza A/PR/8 intravenously. On day 10 p.i., mice were ethically 
sacrificed and the TFH and GC B cell populations were determined by flow cytometry. 
Live influenza A/PR/8 virus induced significantly higher TFH  (Figure 4.32A and 4.32B) 
and GC B cell populations (Figure 4.32C and 4.32D) compared to inactivated influenza 
A/PR/8 virus immunization. In addition, a significantly higher TFH:TFR ratio was 
detected in mice infected with live influenza A/PR/8 virus  compared to age-matched 
naïve controls and inactivated influenza virus immunized mice (Figure 4.32E). Whilst, a 
slight increase in the TFH:TFR ratio could be detected following inactivated influenza 
A/PR/8 virus immunization, no statistical difference was observed when compared to 
naïve control mice. On examining the TFR:TFH ratios, a significantly lower TFR:TFH ratio 
was detected following live influenza A/PR/8 virus priming compared to naïve control 
mice (Figure 4.32F). No statistical differences in the TFR:TFH ratios could be detected
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Figure 4.32: Effect of viral replicative capacity on TFH and GC B cell populations 
in primary influenza A/PR/8 infection. C57BL/6 mice infected intravenously with 105 
HAU of live influenza A/PR/8 or formalin inactivated influenza A/PR/8 were sacrificed 
at day 10 p.i. (A) TFH  as % of CD4 T cells, (B) TFH cell numbers per spleen, (C) GC B 
cells as % of B220 cells, (D) GC B cell numbers per spleen, (E) Spleen TFH: TFR ratio 
and (D) Spleen TFR: TFH ratio. Data is presented as means ± SEM. Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test. **P<0.005; ***P<0.0005; ****P<0.0001.  	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between inactivated versus live influenza A/PR/8 virus immunized mice or between 
naïve controls and inactivated virus immunized mice. 
Next, levels of serum antibody against virus HA were determined by HAI assay as 
described in section 2.2.13. Naïve age-matched controls showed HAI titers of ≤ 20. At 
day 50 p.i., anti-HA antibodies were detected in sera of mice infected with either live or 
inactivated A/PR/8 virus. However, at the comparable doses, mice immunized with live 
influenza A/PR/8 virus generated significantly higher HAI antibody titers compared to 
mice immunized with inactivated influenza A/PR/8 virus (Figure 4.33).  
WHO issues annual recommendations for influenza vaccine formulations based on 
seasonal influenza strain forecasts. To provide further evidence in support of our 
hypothesis, C57BL/6 mice were immunized with live or inactivated seasonal vaccine 
strain influenza A/SI/3/06 virus and the magnitude of TFH and GC B cell responses were 
evaluated. Significantly higher TFH (Figure 4.34A) and GC B cell numbers (Figure 
4.34B) were detected following live influenza A/SI/3/06 virus immunization at the same 
dose. Consistent with this data, higher TFH:TFR ratio was demonstrated in mice primed 
with live influenza A/SI/3/06 virus (Figure 4.34C). In contrast, a higher TFR:TFH ratio 
was detected in mice immunized with inactivated influenza A/SI/3/06 virus compared to 
mice primed with live influenza A/SI/3/06 virus (Figure 4.34D). Analysis of the 
TFH:TFR ratios in blood also revealed significantly higher values in response to live 
influenza A/SI/3/06 virus immunization compared to mice immunized with inactivated 
influenza A/SI/3/06 virus and naïve controls (Figure 4.34E). In this study, no statistical 
differences in the blood TFH:TFR ratio were noted between naïve controls  and mice 
immunized with inactivated influenza A/SI/3/06 virus. Within each group, the TFH:TFR 
ratio obtained in spleen and blood were comparable and this is shown in Figure 4.34F. 
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Figure 4.33: Effect of viral replicative capacity on HAI titers. C57BL/6 infected as 
in Figure 4.32 were bled at day 50 p.i. and HAI titers were determined by HAI assay as 
described in section 2.2.12. Data from one experiment represented as means ± SEM 
(n=4-5 mice per group). Data was log transformed and statistical significance 
determined using One-Way ANOVA test. **P<0.005; ***P<0.0005; ****P<0.0001. 
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Figure 4.34: Effect of viral replicative capacity on TFH and GC B cell populations 
in primary influenza A/SI/3/06 infection. C57BL/6 were mice infected intravenously 
with 105 HAU of live or formalin-inactivated influenza A/SI/3/06 and TFH and GC B 
cell populations were identified by flow cytometry. (A) TFH cell numbers per spleen,  
(B) GC B cell numbers per spleen, (C) Spleen TFH: TFR ratio, (D) Spleen TFR: TFH ratio, 
(E) Blood TFH: TFR ratio and (F) Comparison of spleen and blood TFH:TFR ratio. Data 
shown is from one of two independent experiments with similar results and represented 
as means ± SEM (n=4-5 mice per group). Data was log transformed and statistical 
significance determined using One-way ANOVA with Holm-Sidak multiple 
comparison test. *P<0.05; **P<0.005***; P<0.0005; ****P<0.0001.  	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Collectively, these results indicate that the GC response and long term antiviral humoral 
immunity following influenza A virus infections is strongly influenced by the 
replication fitness of the virus. 
4.3 Discussion 
Despite the development of several successful viral vaccines that elicit protective 
immune response such as smallpox, measles, rubella and chickenpox, the key input 
parameters that are critical to the induction and maintenance of long-term immunity are 
poorly understood. Moreover, much of our current understanding is based on studies 
that use non-replicating antigens or animal infection models that do not have a natural 
host-pathogen relationship. These factors have partly contributed to the high failure 
rates of vaccines that go to clinical trials. 
In this chapter, we have used ECTV infection as a model of virus-natural host 
interaction in which the correlates of protection are well understood. Protection 
following ECTV infection correlates with efficient virus control and generation of 
neutralizing antibodies. Importantly, ECTV infection is associated with life-long 
protection mediated by humoral immune responses akin to all current vaccines that are 
clinically effective (Letvin, 2007; Plotkin, 2010). In this chapter, using viruses that 
exhibit varying replication capacities, the contribution of viral replicative capacity 
towards induction and maintenance of long-term antiviral humoral immunity was 
studied. 
We have demonstrated that the replication fitness of a virus is directly co-related to the 
magnitude of TFH responses in the spleen. At the same dose, infection with a 
replication-competent ECTV-WT induces significantly higher TFH and GC TFH cell 
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numbers at the peak of the GC reaction, compared to infection with a replication-
inefficient ECTV-TKΔ. Similar observations were made with the VACV model 
(VACV-WT versus VACV-TKΔ), vaccine vector MVA model (replication-competent 
parental CVA versus replication-incompetent MVA) and influenza A RNA virus 
infection model (live influenza A/PR/8 and A/SI/3/06 viruses versus inactivated virus 
forms).  Using the LCMV model, Hale et al., demonstrated that TFH effector cells form 
a memory population and these cells have a definite propensity to continue as TFH cells 
during a recall response (Hale et al., 2013). This raises the interesting question of 
whether the significant differences in TFH cell populations observed with live and 
attenuated virus infections would translate into varying TFH memory responses and this 
warrants further investigation. We predict that after contraction of the TFH effector 
population, the differences will be maintained into the memory phase and as a result 
replication-competent viruses would elicit a better TFH memory response. To test this 
hypothesis, a future study employing adoptive transfer of congenically marked TCR7 
CD4+ transgenic cells specific for the HEL74-88 epitope (Neighbors et al., 2006) can be 
set up. Donor cells can then be tracked into the memory phase following infection with 
recombinant ECTV-WT and ECTV-TKΔ expressing HEL. Furthermore, it would be 
useful to study differences in the expansion profile and quality of B cell help provided 
by TFH memory cells generated in response to live and attenuated virus infections. 
On examining the GC B cell responses, it was found that the magnitude of the GC 
response, as determined by GC B cell numbers and virus-specific antibody levels, was 
strongly associated with replication fitness of the virus. In addition, significantly higher 
serum neutralizing antibody responses (PRNT50) were elicited following infection with 
a replication-competent virus. Passive immune serum transfer and challenge 
experiments confirmed that antibodies generated in response to replication-competent 
viral infections had higher virus neutralizing capacity and were able to better control the 
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virus during secondary challenge. These results argue for a better affinity maturation 
following infection with a replication-competent virus. In addition, results from the 
memory B cell transfer experiment (section 4.2.4) demonstrate that the functional 
capacity of the antibody generated on recall is significantly better in the group primed 
with a virus that replicates efficiently. This data further validates that the memory B 
cells have been likely generated after several rounds of affinity maturation in mice 
infected with replication-competent virus but not in those infected with replication-
inefficient virus. In this experiment, only the early recall responses, prior to the 
appearance of endogenous antiviral antibody, were studied. In order to analyse long-
term recall responses, future experiments could be setup in which memory B cell 
populations from live and attenuated virus primed mice is adoptively transferred into T 
and B cell deficient RAG-1-/- mice. Previous work from our laboratory demonstrated a 
requirement for CD4+ T cell help for sustained antibody responses during a secondary 
virus challenge (Chaudhri et al., 2015) and it is therefore important in this experiment to 
consider the accessory role of memory TFH cells in long-term recall antibody responses. 
Following antigenic stimulation, survival kinetics, viral load and antiviral antibody 
levels can then be analyzed to efficiently characterize the humoral memory B cell 
response.  
Previous studies using protein antigens have demonstrated a significant reduction in the 
frequency of somatic hyper mutation (SHM) and proportion of cells carrying the 
mutated VH gene following loss of IL-21 (Zotos et al., 2010). TFH cells are good 
producers of IL-21 and using IL-21 GFP transgenic mice in this study, more than a two-
fold difference in IL-21+ TFH cell numbers was observed between replication-competent 
and inefficient virus infections. This could be one of the factors contributing to reduced 
affinity maturation in response to attenuated virus. To further explore this possibility, in 
chapter 6 of this thesis, we have examined somatic hypermutation patterns to virus-
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expressed antigen in the context of viral replicative fitness using SWHEL transgenic mice 
in conjunction with recombinant ECTV-WT and ECTV-TKΔ expressing a variant 
version of HEL. 
The field of vaccine biology would be immensely aided by the identification of 
biomarkers that are predictive of potent long-lived antiviral immunity. In this chapter, 
we have presented data that exploits the use of TFH:TFR ratio as one such biomarker. 
Data presented in the preceding chapter, highlighted the relationship between TFH and 
TFR cells in ECTV-induced GC reaction. Our findings suggest that the TFR cells govern 
the GC reaction by limiting TFH cell numbers and TFH:TFR ratio is a good guide to 
reflect this relationship.  We have demonstrated that replication-competent ECTV-WT 
induced a higher splenic TFH:TFR ratio contemporaneous with higher serum neutralizing 
antibody responses and better humoral immune memory. However, in human vaccine 
clinical trials, use of splenic TFH:TFR ratio as a biomarker is restricted, as access to 
spleen tissue is limited. Taking this into consideration, we next analyzed the TFH and 
TFR cells in the blood compartment, for which routine access may be more readily 
available. 
Although the identity of circulating TFH cells have been well established in both humans 
and mice, only recent studies have identified TFR cells in the blood compartment. 
Studies by Sage et al., demonstrated that TFR cells in blood can home to lymphoid 
organs, inhibit TFH cells in vivo and thereby impact the quality of antibody response 
(Sage et al., 2014). Whilst the importance of TFH:TFR ratio has been hinted in these 
studies, the work presented in this study would be the first validation of its use as a 
biomarker in comparative viral model studies. We have established that blood TFH:TFR 
ratios paralleled those detected in the spleen and can reliably predict the potency of 
antiviral antibody and memory response. Furthermore, our results indicate that blood 
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TFH:TFR ratios determined within weeks of vaccination or infection can predict long-
term antiviral immunity well before they are even generated. Importantly, reliability of 
the biomarker was confirmed across various virus models: ECTV, VACV and vaccine 
vector MVA (orthpox DNA virus models) and influenza A (RNA virus model).  
It is pertinent to discuss the one caveat associated with the valid use of blood TFH:TFR 
ratio as a biomarker of long-lived antiviral immunity: It is an absolute requirement that 
the terminal TFH differentiation and GC formation steps are not affected. Circulating 
TFH and TFR cells are generated prior to terminal differentiation into lymphoid TFH and 
TFR effector cells that participate in GC response (He et al., 2013). Normal circulating 
levels of CD4+, CXCR5+ cells are present in SAP deficient humans and mice, even 
though the TFH terminal differentiation, GC formation, long-lived plasma cell and 
memory B cells responses are severely impaired. In this context, the blood TFH:TFR ratio 
would yield a false positive result of long-lived antiviral immunity and therefore 
judicious use of this ratio is recommended in animal models. 
The results presented in this chapter clearly indicate that the quality of protection 
provided by live virus vaccination was far superior compared to attenuated strains. The 
magnitude of virus replication in-vivo determines the amount of antigen available within 
the host. This raises the probability that the poor TFH and GC responses induced by 
replication-incompetent virus is due to reduced antigen availability that further impacts 
antigen presentation by DC and priming of CD4 T cells. Indeed, a three-fold difference 
in the activated CD4 T cell numbers was observed between replication-competent and 
replication-poor virus infections (Appendix Figure 4.3). To further elucidate the 
differing quality of immune response following live or attenuated virus infection, it is 
important that our future studies take into consideration the activation and cytokine 
profile of DC. In response to infection, the activation status of CD4+ CD11c+ DC can be 
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assessed by analyzing the expression of antigen presentation molecule (MHC II), co-
stimulatory molecules (B7.1/B7.2, CD40 and PDL2) and cytokine production patterns 
(IL-6, IL-12 and IL-2). Further transcriptome analyses of DC from animals infected 
with replication-variant viruses can help identify novel regulators and gene expression 
patterns associated with effective antigen-presentation by DC. By characterizing these 
patterns of DC controlled TFH priming, adjuvants can be factored into vaccine design to 
enhance TFH response to replication-incompetent virus.  
Although this study has focused primarily on the humoral arm of antiviral adaptive 
immune responses, the contribution of the innate immune responses cannot be 
overlooked. Research over the past decade has recognized innate immune sensing 
pathways as regulators of the strength and quality of immune responses (Iwasaki and 
Medzhitov, 2010; Iwasaki and Medzhitov, 2015). Numerous studies have highlighted 
the importance of pattern-recognition receptors (PRR), particularly Toll-like receptor 
(TLR) signaling in immunity to ECTV, VACV, MVA and influenza A viruses. 
(Samuelsson et al., 2008; Davies et al., 2014; O'Gorman et al., 2010; Delaloye et al., 
2009; Koyama et al., 2010; Aoshi et al., 2011). Future experiments characterizing the 
patterns of innate sensing in replicating and replication-deficient viruses will provide 
valuable clues to refining viral vaccine vector designs with adjuvants tailored to elicit 
long-lasting adaptive immune response. 
In summary, data presented in this chapter clearly indicate that the replication fitness of 
virus determines the magnitude of TFH and GC responses, long-term antibody and 
immune memory responses. Importantly, we have established that the ratio of 
circulating TFH cells to TFR cells can be used a valuable biomarker to predict long-term 
antiviral immunity. Our studies envision manipulation of TFH:TFR ratio as a vital step in 
optimizing vaccine regime to generate durable potent antiviral response. 
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5 Antigen availability influences the 
magnitude of TFH and GC B cell responses 	  
5.1 Introduction 
Replication-competent viruses such as VACV elicit excellent humoral immune 
responses and are powerful tools in the development of vaccine and immunotherapeutic 
vectors. The adverse consequences associated with use of live viruses particularly in 
immuno-compromised individuals precipitated the development of virus vectors with an 
improved safety profile, mostly at the expense of replication capacity of the virus. Our 
findings in the previous chapter, however, clearly demonstrate that replication fitness of 
virus has a significant impact on the magnitude of TFH and GC responses, long-term 
humoral memory and protection. In our studies, significant differences were observed in 
the blood viral genome copy numbers following s.c. infection with replication-
competent ECTV-WT and replication-inefficient ECTV-TKΔ (Appendix Figure 5.1). In 
contrast to the significant viral genome copy numbers in blood following replication-
competent ECTV-WT infection, no viral genomes could be detected in mice infected 
with ECTV-TKΔ (above levels seen in age-matched naïve controls). This result 
suggested that increasing virus dose, and as a consequence the concentration of viral 
antigens, in attenuated infections might provide the essential cues to the immune system 
to drive GC responses for induction of robust, long-lived antiviral humoral immunity. 
An increase in the dose of replication-inefficient virus is expected to increase antigen 
availability and augment the magnitude of TFH and GC B cell responses.  
In this chapter, we explored strategies to enhance the immunogenicity and protection 
afforded by attenuated viruses. In principle, the primary benefit conferred by the 
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replication status of the virus is an enhanced antigen concentration. If the magnitude 
and quality of humoral immune response correlates with the level of antigen expressed, 
we hypothesized that increasing the antigen availability by varying the inoculum dose 
would be an ideal strategy to augment TFH, GC B cell and antiviral antibody responses 
generated against replication-inefficient or inactivated viruses.  
Much of our current understanding of the role of antigen in TFH responses comes from 
studies using model protein antigens and persistent viral infection models (Baumjohann 
et al., 2013; Fahey et al., 2011). However, in these studies, the use of adjuvants and 
persistent antigen stimulation skew immune responses and the antigen kinetics are not 
representative of a physiological viral infection. Understanding the basic, yet important 
role of antigen in the magnitude and duration of TFH mediated GC responses, 
particularly in viral infections that induce potent, durable humoral immune responses, 
will be key to rational viral vaccine design and efficacy studies. 
In the previous chapter, the TFH:TFR ratio was found to be a reliable index of potent 
antiviral antibody response across four virus models. Using the TFH:TFR ratio as a 
biomarker in this current study, we investigated if antiviral humoral immunity to 
replication-compromised viruses can be enhanced by altering the viral inoculum dose. 
As in the previous chapter, primary studies were carried out using the natural mouse-
pathogen ECTV, followed by confirmatory work using various VACV strains and 
influenza A viruses for potential translational outcomes. 
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5.2 Results 	  
5.2.1 Subcutaneous route of infection with an increased dose of 
ECTV-TKΔ does not enhance antiviral humoral responses 
In order to test our hypothesis that increasing the initial viral inoculum dose augments 
TFH and GC response to replication-inefficient ECTV-TKΔ, C57BL6 mice were infected 
s.c. at doses varying by 1000-fold (103 PFU and 106 PFU; alternatively referred to as 
low and high dose, respectively). Mice infected with replication-competent ECTV-WT 
(103 PFU s.c.) were used as a positive control for generation of protective immunity. As 
statistical comparisons between ECTV-WT and ECTV-TKΔ at the same dose (103 PFU 
s.c.) have been discussed in detail in the previous chapter, only statistical comparisons 
involving the ECTV-TKΔ 106 PFU s.c. infection group [i.e., ECTV-TKΔ 106 PFU s.c. 
versus naïve, ECTV-WT (103 PFU s.c.) and ECTV-TKΔ (103 PFU s.c.)] have been 
discussed in this section.  
TFH cell analyses by flow cytometry did not identify any significant changes in the 
frequency  (Figure 5.1A) and total number of splenic TFH cells (Figure 5.1B) between 
low dose (103 PFU) and high dose (106 PFU) ECTV-TKΔ infection. In addition, no 
differences were observed in the proportions of TFH and TFR cells (within the parent 
CXCR5hi, PD-1hi population) between low and high dose s.c. ECTV-TKΔ infections 
(Figure 5.2A and 5.2B). Correspondingly, no statistically significant changes in the 
TFH:TFR ratio  was observed between the low and high dose ECTV-TKΔ infection 
(Figure 5.2C).  The effect of dose variations on GC TFH cell population was also 
analyzed and no differences were identified in the frequency (Figure 5.3A) and number 
of GC TFH cells (Figure 5.3B) in the spleen. Consistent with the splenic TFH responses, 
no increase in the circulating TFH cell population was observed following a 1000-fold
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Figure 5.1: Effect of virus dose on TFH cell population. C57BL/6 mice infected s.c. 
with either 103 PFU of ECTV-WT, 103 PFU of ECTV-TKΔ, 106 PFU of ECTV-TKΔ or 
left uninfected were sacrificed at day 14 p.i. and spleens harvested for flow cytometric 
analysis. TFH cell population expressed as (A) % of CD4 T cell and (B) Total cell 
numbers per spleen, Combined data from two experiments represented as means ± SEM 
(n=7 mice per group, except for naïve n=4). Data was log transformed and statistical 
significance determined using One-Way ANOVA with Holm-Sidak multiple 
comparison test; only statistical comparisons involving the ECTV-TKΔ (106 PFU) group 
are shown on the graph; *P<0.05; ****P<0.0001. 	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Figure 5.2: Effect of increased viral inoculum dose on TFH and TFR proportions. 
C57BL/6 mice were infected as described in Figure 5.1. Mice were sacrificed at day 
14p.i. and splenocytes were stained for TFH and TFR cells as described previously. (A) 
Concatenated flow cytometric plots from all samples in the experimental groups 
represented in the figure. Numbers on the plots represent percent of the parent 
CXCR5hi, PD-1hi population. (B) Graphical representation of the proportions of TFH and 
TFR cells within the follicular parent CXCR5hi PD-1hi cell population and (C) TFH:TFR 
ratio; means ± SEM (n=7 mice per group, except for naïve n=4). Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test. **P<0.005; ***P<0.0005. 	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Figure 5.3: Effect of virus dose on GC TFH cell population. C57BL/6 mice were 
infected as in Figure 5.1; GC TFH cells were identified by flow cytometry as described 
previously and expressed as (A) % of CD4 T cells and (B) Cell numbers per spleen. 
Combined data from two experiments represented as means ± SEM (n=7 mice per 
group, except for naïve, n=4). Data was log transformed and statistical significance 
determined using One-Way ANOVA with Holm-Sidak multiple comparison test; only 
statistical comparisons involving the ECTV-TKΔ (106 PFU) group are shown on the 
graph;  **P<0.005; ****P<0.0001. 	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increase in the dose of ECTV-TKΔ (Figure 5.4A and 5.4B).  The ratio of circulating TFH 
and TFR cells was evaluated and again, no statistical differences could be identified 
between the two doses (Figure 5.4C and 5.4D). As seen previously, the splenic and 
blood TFH:TFR ratio (Figure 5.5A) and TFR:TFH ratio (Figure 5.5B)  were comparable 
within experimental groups. 
Based on the poor TFH responses, we hypothesized that the increase in viral inoculum 
dose would not have any observable difference in the GC B cell response. Although 
increasing the dose of ECTV-TKΔ by a 1000-fold resulted in an approximate 2-3-fold 
significant increase in the percentage of GC B cells (Figure 5.6A), it did not translate 
into an increase in GC B cell numbers in the spleen (Figure 5.6B). The frequency and 
number of GC B cells in mice infected with a high dose of ECTV-TKΔ was significantly 
lower compared to control ECTV-WT infected mice.  
Next, we questioned whether an increase in ECTV-TKΔ inoculum dose administered 
through the s.c. route might elicit qualitatively better antiviral humoral immunity. To 
answer this, ECTV-specific IgG levels and virus-neutralizing capacity was determined 
at day 50 p.i. A significant increase in the ECTV-specific ELISA antibody level was 
detected in mice infected with high dose ECTV-TKΔ compared to a low dose infection. 
However, these levels were significantly lower than the levels observed in the control 
ECTV-WT infected mice (Figure 5.7A). As ELISA titers do not reflect on the quality of 
the antibody produced, the neutralizing capacity of the antibody was determined by 
PRNT assay. No statistical differences in the neutralizing capacity (Figure 5.7B) and 
PRNT50 titers (Figure 5.7C) were detected between low and high dose of ECTV-TKΔ 
infections. In contrast, and as expected, mice infected with replication-competent 
ECTV-WT exhibited significantly higher PRNT50 titers (~ 40-fold higher) (Figure 
5.7C). These results clearly demonstrate that despite a 1000-fold increase in the dose of  
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Figure 5.4: Effect of virus dose on blood TFH cell population. Groups of 4 C57BL/6 
mice were infected as described in Figure 5.1. Blood TFH and TFR populations were 
identified by flow cytometry and expressed as (A) % of CD4 T cells, (B) Cell numbers 
per 106 CD4 T cells, (C) TFH:TFR  ratio and (D) TFR:TFH ratio. Data from one experiment 
represented as means ± SEM. Data was log transformed and statistical significance 
determined using One-Way ANOVA with Holm-Sidak multiple comparison test; only 
statistical comparisons involving the ECTV-TKΔ (106 PFU) group are shown on the 
graph; **P<0.005; ****P<0.0001.  
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Figure 5.5: Comparison of TFH:TFR and TFR:TFH ratios in spleen and blood. 
C57BL/6 mice were infected subcutaneously with either 103 PFU of ECTV-WT, 103 
PFU of ECTV-TKΔ , 106 PFU of ECTV-TKΔ or left uninfected. Spleen and blood TFH 
and TFR populations were identified by flow cytometry and represented as (A) TFH:TFR 
ratio and  (B) TFR: TFH ratio. Combined data from two experiments represented as 
means ± SEM.  
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Figure 5.6: Effect of virus dose on GC B cell population. C57BL/6 mice infected as 
described in Figure 5.1 were sacrificed at day 14 p.i. and spleens harvested for flow 
cytometric analysis. GC B cell population expressed as (A) % of B220+ve cells and (B) 
Total cell numbers per spleen, Combined data from two experiments represented as 
means ± SEM (n=7 mice per group, except for naïve n=4). Data was log transformed 
and statistical significance determined using One-Way ANOVA with Holm-Sidak 
multiple comparison test; only statistical comparisons involving the ECTV-TKΔ (106 
PFU) group are shown on the graph;  **P<0.005; ****P<0.0001. 
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Figure 5.7: Effect of virus dose on ECTV-specific antibody levels and virus-
neutralizing capacity. C57BL/6 mice were infected s.c. with 103 PFU of ECTV-WT, 
103 PFU of ECTV-TKΔ, 106 PFU of ECTV-TKΔ or left uninfected (naïve). Mice were 
bled at day 50 p.i. and plasma extracted. (A) ECTV-specific IgG levels were determined 
by ELISA. Data is represented as means of absorbance values ± SEM (n=4 mice per 
group). Virus neutralizing activity was determined by PRNT. Curve-fitting of the data 
was done using four-parameter non-linear regression analysis and represented as (B) % 
Neutralization in indicated infections and  (C) Comparison of PRNT50 titers between the 
groups. Data shown is from one experiment and represented as means ± SEM (n=4 mice 
per group). Data was log transformed and statistical significance determined using One-
Way ANOVA; only statistical comparisons involving the ECTV-TKΔ (106 PFU) group 
are shown on the graph; **P<0.005; ****P<0.0001. 
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replication-inefficient ECTV-TKΔ used to infect mice through the s.c route, the antiviral 
antibody responses remained qualitatively inferior to responses generated by 
replication-competent ECTV-WT infection. 
Collectively, these results argue against using the s.c. route to deliver increased doses of 
attenuated viruses as an optimal strategy to improve immunogenicity and long-term 
humoral immunity. 
5.2.2 Antiviral humoral responses are significantly enhanced 
following intravenous administration of ECTV-TKΔ. 
 
 
Given that a 1000-fold increase in the dose of the replication-inefficient ECTV-TKΔ 
administered s.c. had little qualitative benefit in the antiviral humoral immune response, 
the next set of experiments investigated whether a different route of virus administration 
could augment the magnitude of TFH and GC B cell responses. A previous study from 
our laboratory found that the recall antibody responses and protection after virulent 
virus challenge in mice previously immunized with ECTV-TKΔ via the intra-dermal 
(i.d.) or s.c. routes were comparable but lower than the i.p. route of immunization 
(Panchanathan et al., 2010). The i.p. route of immunization with ECTV-TKΔ, unlike the 
i.d. or s.c. routes, results in a low systemic spread of virus.  We therefore hypothesized 
that administration of the attenuated virus i.v. to simulate haematogenous spread to 
secondary lymphoid organs might improve immunogenicity and antiviral protection.  
To examine differences in long-term antiviral humoral immunity elicited via changes in 
route of administration, C57BL/6 mice were infected either i.v. or s.c. with a high dose 
of ECTV-TKΔ (106 PFU). Mice infected with ECTV-WT (103 PFU s.c.) were used as 
controls, principally as a guide to the threshold of TFH responses associated with potent 
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antiviral humoral immunity. For the ease of description, only statistical comparisons 
involving ECTV-TKΔ (106 PFU i.v.) [i.e., ECTV-TKΔ 106 PFU i.v. versus naïve, 
ECTV-WT (103 PFU s.c.) and ECTV-TKΔ (106 PFU s.c.)] are discussed in this section.  
At the peak of ECTV-induced GC reaction, the magnitude of TFH and GC B cell 
responses were evaluated to highlight any differences at the initiation phase of humoral 
immunity. At the same dose, administration of ECTV-TKΔ i.v. induced significantly 
higher TFH cell responses compared to the s.c. route (Figure 5.8A and 5.8B). Similar 
results were observed with the GC TFH cell population, wherein a significantly higher 
percentage (Figure 5.8C) and total number (Figure 5.8D) was detected in mice infected 
i.v. with ECTV-TKΔ compared to mice infected with the same dose s.c. Both TFH and 
GC TFH responses were comparable between ECTV-WT infected mice and the high 
dose ECTV-TKΔ i.v. infected mice, with no statistically  significant differences 
detected.  
Analyses of TFH and TFR cell proportions within the parent CXCR5hi, PD-1hi population 
revealed a notable bias towards TFH cells in mice infected with ECTV-WT or ECTV-
TKΔ (Figure 5.9A and 5.9B). Although a trend towards higher TFH:TFR ratio was 
observed in mice infected i.v. compared with the s.c. route, no statistical difference 
could be detected (Figure 5.9C) which may be due to the small number of animals used 
in this experiment. The blood TFH outputs were consistent with the ongoing splenic TFH 
activity. Significantly higher proportions and numbers of circulating TFH cell 
populations were detected in mice infected i.v. compared to the s.c. route (Figure 5.10A 
and 5.10B). Importantly, the circulating TFH cell numbers were comparable between the 
replication-competent ECTV-WT-infected mice and mice infected i.v. with a high dose  
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Figure 5.8: Effect of route of virus administration on TFH and GC TFH cell 
populations. C57BL/6 mice were infected as in Figure 5.7, sacrificed at day 14p.i. and 
splenocytes were stained for TFH and TFR cells. TFH cells expressed as (A) TFH as % of 
CD4 T cells and (B) TFH cell numbers per spleen. GC TFH cells expressed as (C) % of 
CD4 T cells and (D) cell numbers per spleen. Data from one experiment represented as 
means ± SEM (n=3 mice per group, except for naïve n=2). Data was log transformed 
and statistical significance determined using One-Way ANOVA with Holm-Sidak 
multiple comparison test; only statistical comparisons involving the ECTV-TKΔ (106 
PFU i.v.) group are shown on the graph;  *P<0.05; **P<0.005; ***P<0.0005. 
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Figure 5.9: Effect of route of virus administration on TFH and TFR proportions. 
C57BL/6 mice were infected as described in Figure 5.7. Mice were sacrificed at day 
14p.i. and splenocytes were stained for TFH and TFR cells as described previously. (A) 
Concatenated flow cytometric plots from all samples in the experimental groups 
represented in the figure. Numbers on the plots represent percent of the parent 
CXCR5hi, PD-1hi population. (B) Graphical representation of the proportions of TFH and 
TFR cells within the follicular parent CXCR5hi PD-1hi cell population and (C) TFH:TFR 
ratio; means ± SEM. . Data was log transformed and statistical significance determined 
using One-Way ANOVA with Holm-Sidak multiple comparison test; only statistical 
comparisons involving the ECTV-TKΔ (106 PFU i.v.) group are shown on the graph;  
*P<0.05. 
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of ECTV-TKΔ. As expected, the circulating TFH:TFR  (Figure 5.10C) and TFR:TFH 
(Figure 5.10D) ratios detected in mice infected i.v. were significantly different from the 
observed values in the s.c. route of infection. In this present study, the blood and splenic 
TFH:TFR  ratio in control ECTV-WT infected mice were not statistically different from 
that in mice infected i.v. with a high dose of ECTV-TKΔ. These results suggested that a 
potent antiviral antibody response is likely to be generated in mice infected i.v. with 
ECTV-TKΔ. 
Next, to investigate the differences in GC B cell responses, GC B cell percentages and 
total splenic numbers were analyzed in these mice. At the same dose, a 4-fold increase 
in the frequency (Figure 5.11A) and 8-fold increase in the total number of GC B cells 
(Figure 5.11B) was observed in mice infected i.v compared to s.c. route of infection. To 
assess GC formation by immunofluorescent staining, spleen sections were stained with 
PNA, anti-IgD and anti-CD3 to visualize GC, splenic B and T cell areas respectively. 
Expectedly, GC formation was not observed in the naïve spleen sections whereas 
clearly recognizable PNA+ GC’s were detected in spleen sections of ECTV-WT 
infected mice (Figure 5.12A and 5.12B). Administration of a high dose of ECTV-TKΔ 
s.c. induced a weak GC reaction as evidenced by a few small PNA positive GC’s 
(Figure 5.12C). In contrast, administration of ECTV-TKΔ i.v. resulted in a considerable 
increase in the number and size of GC’s (Figure 5.12D). These results indicate an 
enhancement in GC formation by i.v. administration of replication-inefficient ECTV-
TKΔ. 
ECTV-specific antibody levels and virus-neutralizing capacity was determined at day 
50 p.i. to evaluate the long-term antiviral immunity generated in the above described 
experimental conditions. Whilst both routes of infection generated ECTV-specific 
antibody  measured by ELISA, mice infected i.v.  generated  significantly higher levels  
	  	   208 
 
 
 
 
 
 
Figure 5.10: Effect of route of virus administration on blood TFH cell population. 
C57BL/6 mice were infected as indicated in Figure 5.7. Blood TFH and TFR populations 
were identified by flow cytometry and expressed as (A) % of CD4 T cells, (B) cell 
numbers per 106 CD4 T cells, (C) TFH:TFR  ratio and (D) TFR:TFH ratio. Data from one 
experiment represented as means ± SEM (n=5 mice per group). Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test; only statistical comparisons with ECTV-TKΔ 
(106 PFU i.v.) group are shown on the graph; **P<0.005; ****P<0.0001.  
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Figure 5.11: Effect of route of virus administration on GC B cell population. 
Groups of C57BL/6 mice infected with a high dose (106 PFU) of ECTV TKΔ (s.c. and 
i.v.), ECTV-WT (control; 103 PFU s.c.) or left uninfected (Naïve) were sacrificed at day 
14 p.i. for flow cytometric analysis. GC B cells expressed as (A)  % of B220+ cells and 
(B) total number per spleen. Data from one experiment represented as means ± SEM 
(n=3 mice per group, except for naïve n=2). Data was log transformed and statistical 
significance determined using One-Way ANOVA with Holm-Sidak multiple 
comparison test; only statistical comparisons with ECTV-TKΔ (106 PFU i.v.) group are 
shown on the graph;  **P<0.005; ***P<0.0005, ****P<0.0001. 	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Figure 5.12: Effect of dose and route of virus administration on GC formation. C57BL/6 were infected as indicated in the figure. At day 14 p.i., 
mice were sacrificed and frozen 10µm spleen sections were stained using anti-CD4 mAb (clone: GK1.5; represented in green), anti-IgD mAb (clone: 
11-26c; represented in red) and PNA (represented in blue). Sections were imaged using Leica SP5 confocal Laser scanning microscope. Images are 
representative of multiple fields per section from 3 mice per group; Magnification 10X. Scale 500µm. 
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compared to mice infected s.c. (Figure 5.13A). The virus-specific antibody levels were 
comparable between high dose ECTV-TKΔ i.v infection and control ECTV-WT 
infection. Next, the most critical parameter in antibody-mediated virus control, the 
functional neutralizing capacity of the antibody was determined by PRNT assay. At day 
50 p.i., significantly higher neutralizing capacity and PRNT50 titers was detected in 
mice infected i.v. compared to the s.c. route of infection (Figure 5.13B and 5.13C). No 
statistically significant differences were observed in the PRNT50 titers between mice 
infected i.v. with high dose of ECTV-TKΔ and control ECTV-WT infected mice. These 
results support the idea that the i.v. route of inoculation is an alternative strategy to 
augment humoral immune responses induced by replication-inefficient viruses. In 
addition, the positive association between potent antiviral antibody responses and 
TFH:TFR ratio in these experimental manipulations are further proof that splenic and 
particularly blood TFH:TFR ratios are robust indicators of effective antiviral humoral 
immunity generation. In summary, the direct comparison of s.c. and i.v. routes of 
delivery highlight important differences in humoral immune responses to attenuated 
virus strains. 
5.2.3 Magnitude of TFH and GC B cell responses are dictated by 
the dose of virus administered through i.v. route. 
Work presented in Chapter 4 using the VACV model demonstrated that viral replicating 
capacity influences the long-term antiviral antibody response. Unlike ECTV, VACV 
replication is restricted to the site of infection after cutaneous or s.c. infection in mice 
with minimal systemic spread (Lin et al., 2013).  For these reasons, in experiments 
described in Chapter 4, VACV was administered i.v. to allow for wider blood-borne 
spread. To verify whether the dose of the attenuated VACV strain was a critical 
determinant  for antiviral  antibody  response when inoculated i.v., C57BL/6 mice were  
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Figure 5.13: Effect of route of virus administration on ECTV-specific antibody 
levels and virus-neutralizing capacity. Groups of C57BL/6 mice infected with a high 
dose (106 PFU) of ECTV TKΔ (s.c. and i.v.), ECTV-WT (control; 103 PFU s.c.) or left 
uninfected (naïve) were bled at day 50 p.i. and plasma extracted. (A) ECTV-specific 
IgG levels were determined by ELISA. Data is represented as means of absorbance 
values ± SEM (n=4 mice per group). Virus neutralizing activity was determined by 
PRNT. Curve-fitting of the data was done using four-parameter non-linear regression 
analysis and represented as (B) % Neutralization in indicated infections and  (C) 
Comparison of PRNT50 titers between the groups. Data shown is from one experiment 
and represented as means ± SEM (n=4 mice per group). Data was log transformed and 
statistical significance determined using One-Way ANOVA; only statistical 
comparisons involving the ECTV-TKΔ (106 PFU i.v.) group are shown on the graph;  
**P<0.005; ***P<0.0005. 
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infected with low (103 PFU) or high dose (106 PFU) of VACV-TKΔ. Mice infected with 
replication-competent VACV-WT (103 PFU i.v.) were used as positive controls in this 
experiment. Statistical comparisons between the control VACV-WT and replication-
inefficient VACV-TKΔ at low dose have been discussed previously in section 4.2.6 and 
therefore only statistical comparisons involving the high dose VACV-TKΔ infections 
[i.e., VACV-TKΔ (106 PFU) infection group versus naïve, VACV-WT (103 PFU) and 
VACV-TKΔ (103 PFU)] have been discussed in this section. 
Increasing the dose of VACV-TKΔ by a 1000-fold resulted in a significant 3-4-fold 
increase in the percentage (Figure 5.14A) and numbers (Figure 5.14B) of TFH cells. No 
statistically significant difference was observed in the TFH cell population between the 
control VACV-WT and high dose VACV-TKΔ infections. Correspondingly, a high dose 
VACV-TKΔ infection elicited a significantly higher splenic TFH:TFR ratio compared to 
mice infected with a 1000-fold lower dose (Figure 5.14C). Conversely, a higher TFR:TFH 
ratio was detected in mice infected with a low dose of VACV-TKΔ (Figure 5.14D). In 
addition, a significant increase in the number of GC TFH  (Figure 5.14E) and circulating 
TFH cells (Figure 5.14F) was observed in mice infected with a high dose of VACV-TKΔ 
compared to a low dose infection. Interestingly, a two-fold difference in the GC TFH and 
blood TFH cell numbers was observed between high dose VACV-TKΔ infection and 
control VACV-WT infected mice. In accordance with the TFH cell responses, a 
significant increase in the GC B cell population was detected in mice infected with a 
high dose compared to a low dose  (Figure 5.14G and 5.14H). Collectively, these results 
demonstrate that increasing the dose of the replication-incompetent VACV-TKΔ 
augmented the magnitude of the TFH and GC B cells when the virus was inoculated i.v. 
Subsequent studies to investigate the translation of these enhanced responses into 
protective  antiviral  antibody  responses  were  performed  using  the  MVA   strain of  
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Figure 5.14: Effect of virus dose on TFH and GC TFH cell populations: VACV 
model. C57BL/6 mice were infected i.v. with VACV-WT (103 PFU), VACV-TK Δ (103 
and 106 PFU) or left untreated (naïve). TFH and GC B cells were identified by flow 
cytomtery and expressed as (A) TFH cells as % of CD4 T cells, (B) TFH cell numbers per 
spleen,  (C) Splenic TFH:TFR  ratio, (D) Splenic TFR:TFH ratio, (E) GC TFH cell numbers 
per spleen, (F) Blood TFH cells as numbers per 106 CD4 T cells, (G) GC B cells as % of 
B220 cells and (H) GC B cell numbers per spleen. Data from one experiment 
represented as means ± SEM (n=3 mice per group). Data was log transformed and 
statistical significance determined using One-Way ANOVA with Holm-Sidak multiple 
comparison test; only statistical comparisons involving the VACV-TKΔ (106 PFU) 
group are shown on the graph; *P<0.05; **P<0.005; ***P<0.0005; ****P<0.0001. 
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VACV, as it is currently being trialed as a vaccine and vaccine vector of choice in 
vaccination studies. 
5.2.4 Evaluation of antiviral protection in mice primed with a 
high dose of MVA 
Prior to investigating protective long-term antibody responses, an analysis of TFH and 
GC B cell responses to dose variations of replication-incompetent MVA was first 
performed. The experiment described in this section is an extension of the one described 
in section 4.2.8 in Chapter 4. In that section, replication-competent CVA and 
replication-incompetent MVA infected mice were used to demonstrate that viral 
replicative capacity significantly impacts TFH:TFR ratio, which correlates with potent 
neutralizing antibody responses and protection. To study the effect of virus dose on the 
magnitude of TFH and GC B cell response, and subsequent antiviral antibody response, 
C57BL/6 mice were infected i.v. with a low dose (103 PFU) of CVA or MVA, or a high 
dose (108 PFU) of MVA. On account of a ‘mild’ GC reaction induced by a low dose of 
MVA, a 105–fold higher dose was used to evaluate the role of antigen dose in MVA-
induced humoral immune responses. Since statistical comparisons between low dose of 
CVA and MVA have been described in section 4.2.8, only comparisons involving the 
high dose of MVA [i.e., MVA (108 PFU) versus naïve, CVA (103 PFU) and MVA (103 
PFU) are discussed in this section.  
Analyses of TFH cell population by flow cytometry revealed a significant increase in the 
TFH cell numbers in mice infected with high dose of MVA compared to low dose 
infection (Figure 5.15A). As expected, virus dose significantly impacted on the 
proportion of TFH and TFR cells (Figure 5.15B), with the high dose of infection being 
associated with higher TFH:TFR ratio (Figure 5.15C) and low dose infection associated 
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with a higher TFR:TFH ratio (Figure 5.15D). Correspondingly, GC TFH cells were 
significantly higher in frequency (Figure 5.15E) and numbers (Figure 5.15F) in high 
dose MVA infected mice compared to the low dose. These results parallel the findings 
observed with a high dose of attenuated VACV-TKΔ. Analyses of GC B cell responses 
revealed a striking 10-fold increase in the percentage  (Figure 5.15G) and total number 
(Figure 5.15H) of GC B cells in high dose MVA infection compared to a low dose 
infection.  Notably, the GC B cell numbers in 108 PFU MVA infected mice was 
approximately 2.5-fold higher than replication-competent CVA (103 PFU) infection. 
Subsequently, the resultant ex-vivo neutralizing antibody response on schematic 
manipulation of TFH:TFR ratio was analysed. At day 50 p.i., a significantly higher 
neutralizing capacity (Figure 5.16A) and PRNT50 titers (Figure 5.16B) was detected in 
mice infected with a high dose of MVA compared to a low dose. No statistical 
significance was observed in the PRNT50 titers in sera of mice given the high dose 
MVA compared with the low dose replication-competent CVA.  
Next, the functional in-vivo protection was analyzed by a prime–heterologous challenge 
as described previously in section 4.2.8. Briefly, C57BL/6 mice primed with low dose 
CVA, low or high dose MVA were challenged 8 weeks later with a lethal dose of 
ECTV-WT 106 PFU i.v. At day 5 p.c., viral load in organs was examined by viral 
plaque assay. Mice primed i.v. with high dose MVA demonstrated significantly lower 
viral burden in the spleen (Figure 5.17A), lungs (Figure 5.17B) and liver (Figure 5.17C) 
compared to low dose MVA primed mice. In contrast, the viral burden in high dose 
MVA and control CVA primed mice were comparable, with no statistically significant 
differences observed. These findings re-affirm a direct relationship between the in-vitro 
antibody neutralizing capacity and in-vivo protection following secondary challenge. 
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Figure 5.15: Effect of virus dose on TFH and GC TFH cell populations: MVA model. 
C57BL/6 mice were infected i.v. with CVA (103 PFU), MVA (103 PFU or 106 PFU) or 
left untreated (naïve). TFH and GC B cell populations were identified by flow cytometry 
and represented as  (A) TFH cell numbers per spleen, (B) Proportions of TFH and TFR 
cells within the parent follicular CXCR5hi, PD-1hi CD4 T cells,  (C) TFH:TFR  ratio, (D) 
TFR:TFH ratio, (E) GC TFH as % of CD4 T cells, (F) GC TFH cell numbers per spleen, 
(G) GC B cells as % of B220 cells and (H) GC B cell numbers per spleen Data from 
one experiment represented as means ± SEM (n=3-4 mice per group). Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test; only statistical comparisons involving the 
VACV-TK Δ  (106 PFU) group are shown on the graph; *P<0.05; **P<0.005; 
***P<0.0005; ****P<0.0001. 
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Figure 5.16: Effect of viral dose on virus-neutralizing antibody titers: MVA model. 
C57BL/6 mice were infected i.v. with CVA (103 PFU), MVA (103 PFU or 106 PFU) or 
left untreated (naïve) were bled at day 50 p.i. and VACV-specific virus neutralizing 
activity was determined by PRNT assay. (A) Curve-fitting of the data was done using 
four-parameter non-linear regression analysis and represented as % neutralization 
(Dotted lines indicates 50% neutralization). (B) PRNT50 titers were calculated as the 
reciprocal of plasma dilution at which 50% of the virus is neutralized. Data from one 
experiment represented as means ± SEM (n=4-5 mice per group). Data was log 
transformed and statistical significance determined using One-Way ANOVA with 
Holm-Sidak multiple comparison test; only statistical comparisons involving the MVA 
(108 PFU) group are shown on the graph; ***P<0.0005 	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Figure 5.17: Viral load in primed mice following heterologous challenge with lethal 
dose of ECTV-WT. C57BL/6 mice were primed as described in Figure 5.14. At 8 
weeks post-priming, mice were challenged with a lethal dose of ECTV-WT (106 PFU 
i.v.). Mice were sacrificed at day 5 post-challenge; viral burden in (A) Spleen,  (B) 
Lungs and (C) Liver was determined by viral plaque assay.  Data from one experiment 
represented as represented as means of log10  PFU / gram of tissue ± SEM (n=4-5 mice 
per group). Data was log transformed and statistical significance determined using one-
Way ANOVA with Holm-Sidak multiple comparison test; only statistical comparisons 
involving the MVA (108 PFU) group are shown on the graph;  ***P<0.0005; 
****P<0.0001.  	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Collectively, these results indicate that administering a high dose of MVA i.v. as an 
ideal strategy to augment TFH, GC TFH and GC responses and TFH:TFR ratios for 
induction of long-lived, protective antiviral humoral immunity. This approach has 
specific implications for studies using poxviruses  as vaccine vectors. 
5.2.5 TFH and GC B cell responses to inactivated influenza A 
viruses are dependent on dose and route of immunization  
Finally, to extend our hypothesis to non-poxviral models, experiments to augment TFH 
and GC B cell responses via dose and route variations were set up using influenza 
A/PR/8 virus. The experimental strategy used was similar to that described for the 
poxviral models i.e., C57BL/6 were infected with low or high dose of non-replicating 
(inactivated) influenza A/PR/8 virus or low dose of replicating (live) influenza A/PR/8 
virus. As the viral stock titers were relatively low, the dose was varied only by 20-fold. 
Despite the relatively small increase in virus dose, a significant increase in the 
percentage (Figure 5.18A) and numbers (Figure 5.18B) of TFH cells was detected in 
mice infected with a high dose compared to the low dose infected mice. Consistent with 
the findings in poxviral models, altering the dose of inactivated virus administered 
through the i.v route resulted in significant differences in TFH:TFR ratio (Figure 5.18C) 
and TFR:TFH ratio  (Figure 5.18D) between high and low dose infection regimes. A 
parallel 3-4 fold significant rise in the frequency (Figure 5.18E) and numbers (Figure 
5.18F) of GC B cells was observed in mice infected with a high dose of inactivated 
A/PR/8 virus compared to a low dose.  
Current influenza vaccines are administered using intramuscular (i.m.) or deep s.c. route 
of administration. Based on the non-replicating nature of the inactivated virus, we 
hypothesized that the administration of a high dose i.m. would have limited benefit and  
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Figure 5.18: Effect of virus dose on TFH and GC TFH cell population: Influenza 
A/PR/8 model. C57BL/6 mice were infected i.v. with live A/PR/8 virus (105 HAU), 
formalin-inactivated A/PR/8 virus at 105 HAU (inactivated) , 2 x 106 HAU (inactivated 
↑ dose) or left untreated.  TFH and GC B cell populations were analyzed  by flow 
cytometry. (A) TFH  as % of CD4 T cells, (B) TFH cell numbers per spleen,  (C) TFH: TFR 
ratio,  (D) TFR: TFH ratio,  (E) GC B cells as % of B220 cells and (F) GC B cell numbers 
per spleen. Data from one experiment represented as means ± SEM (n=4 mice per group 
except for naïve n=2). Data was log transformed and statistical significance determined 
using One-way ANOVA with Holm-Sidak multiple comparsion test; only statistical 
comparisons involving the inactivated ↑ dose group are shown on the graph *P<0.05; 
**P<0.005***; P<0.0005; ****P<0.0001.  	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the magnitude of TFH and GC B cell responses would be significantly lower compared 
to i.v. administration. To test this hypothesis, groups of C57BL/6 mice were infected 
with a high dose (4 x 106 PFU) of inactivated seasonal vaccine strain, influenza 
A/SI/3/06 virus either through the i.v. or i.m. routes. Mice infected i.v. with live 
influenza A/SI/3/06 virus at a 40-fold lower dose were used as positive controls. The 
i.v. route of inoculation with inactivated  influenza A/SI/3/06 virus resulted in 
significant increase in the percentage and absolute numbers of TFH cells over i.m. 
administration (Figure 5.19A and 5.19B). Consistent with this data, a higher TFH:TFR 
ratio was demonstrated in mice infected by the i.v. route (Figure 5.19C). In contrast, a 
high TFR:TFH ratio was detected in mice infected i.m. compared to the i.v, route of 
infection (Figure 5.19D).  A corresponding, 6-8 fold significant increase in the 
frequency (Figure 5.19E) and numbers (Figure 5.19F) of GC B cells was detected in 
mice infected i.v. compared to the i.m. route. The magnitude of TFH and GC B cell 
responses were comparable between mice infected with low dose of live virus and high 
dose non-replicating, inactivated virus-infected mice. Similar results were obtained with 
route variations using influenza A/PR/8 virus and these results are shown in Figure 
5.20. 
Data presented in the previous chapter as well as preceding sections of this chapter have 
demonstrated a positive correlation between TFH responses, GC responses and TFH:TFR 
ratios with induction of protective antiviral antibody responses. Although long-term 
humoral responses were not evaluated, based on the TFH and GC B cell responses along 
with the TFH:TFR ratios in the experiments described in this section, and in addition to 
data presented on the influenza model in Chapter 4, we predict a strong neutralizing 
antibody response is likely to be induced in mice receiving a high dose of inactivated 
virus i.v. 
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Figure 5.19: Effect of route of virus administration on TFH and GC TFH cell 
populations: Influenza A/SI/3/06 model. C57BL/6 mice were infected with live 
A/SI/3/06 virus (105 HAU, i.v.), formalin-inactivated A/S1/3 virus at 4 x 106 HAU i.v. 
or i.m. (inactivated ↑ dose i.v. or inactivated ↑ dose, i.m. respectively); TFH and GC B 
cell populations were analyzed by flow cytometry (A) GC B cells as % of B220 cells, 
(B) GC B cell numbers per spleen,  (C) TFH as % of CD4 T cells,  (D) TFH cell numbers 
per spleen,  (E) TFH: TFR ratio and (F) TFR: TFH ratio. Data from one experiment 
represented as means ± SEM (n=4 mice per group). Data was log transformed and 
statistical significance determined using One-way ANOVA with Holm-Sidak multiple 
comparison test; only statistical comparisons involving the group inactivated ↑ dose i.m. 
are shown on the graph *P<0.05; **P<0.005***; P<0.0005; ****P<0.0001.  
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Figure 5.20: Effect of route of virus administration on TFH and GC TFH cell 
populations: Influenza A/PR/8 model. C57BL/6 were mice infected with live A/PR/8 
virus (105 HAU, i.v.), formalin-inactivated A/PR/8 virus at 4 x106 HAU i.v. or i.m. 
(inactivated ↑ dose i.v. and inactivated ↑ dose, i.m.); TFH and GC B cell populations 
were analyzed by flow cytometry (A) GC B cells as % of B220 cells, (B) GC B cell 
numbers per spleen,  (C) TFH as % of CD4 T cells,  (D) TFH cell numbers per spleen,  
(E) TFH: TFR ratio and (F) TFR: TFH ratio. Data from one experiment represented as 
means ± SEM (n=4 mice per group). Data was log transformed and statistical 
significance determined using One-way ANOVA with Holm-Sidak multiple 
comparison test; only statistical comparisons involving the group inactivated ↑ dose i.m. 
are shown on the graph *P<0.05; **P<0.005***; P<0.0005; ****P<0.0001	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Collectively, the results using the influenza model confirm manipulation of antigen 
availability, particularly a hematogenous spread of the antigen, as an effective strategy 
to enhance antiviral-humoral responses to non-replicating viruses. 
5.3 Discussion 
TFH and B cell interactions are indispensable for the establishment of GC reactions in 
the generation of long-term humoral immunity that forms the fundamental basis for 
vaccination. Although there has been a recent surge in publications concerning TFH and 
GC B cell responses in humoral immunity, very few studies have examined the 
deterministic capacity of antigen in TFH responses, particularly in the realm of viral 
infections and vaccines. Evidence supporting antigen-dose dependent TFH 
differentiation comes from studies using protein antigens and animal models using 
persistent viral infection or bacteria. Using the protein antigen ovalbumin (OVA), 
Baumjohann et al. demonstrated that the magnitude of TFH responses is dictated by the 
amount of available antigen (Baumjohann et al., 2013). An elegant study by Tubo et al., 
that followed the fate of individual CD4 T cells in recombinant Listeria monocytogenes 
infection established that increasing the antigen dose favored TFH and GC TFH 
production (Tubo et al., 2013). Furthermore, persistent viral infection following 
LCMV-clone13 inoculation revealed progressive differentiation of TFH cells driven by 
sustained TCR stimulation (Fahey et al., 2011). Although the models used in these 
studies are not reflective of generalized acute viral infections, the data suggests a TFH 
differentiation program influenced by antigen availability. 
With an improved safety profile, viral vaccines are predominantly generated on a 
platform of attenuated viruses; however our findings in the previous chapter 
undoubtedly established that replication-compromised viruses have significantly 
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reduced potential to generate long-term humoral immunity. We hypothesized 
modulating antigen availability in attenuated viral infections as a strategy to augment 
the magnitude of TFH responses and ensuing antiviral immune responses. In a 
replication-competent virus infection, even at a relatively low dose1 the virus replicates 
in the host to provide sufficient levels of antigen for ‘optimal’ TFH responses. However, 
attenuated viruses are disadvantaged by their replication capability and the antigen 
levels required have to be delivered by altering the inoculum dose.  
In the current study, varying doses of replication-compromised viruses were used to 
examine the contribution of the initial viral input dose towards the antiviral humoral 
immune responses. Following a 1000-fold increased dose of replication-inefficient 
ECTV-TKΔ via the s.c. route of administration, no significant changes were detected in 
the magnitude of TFH and GC B responses. Importantly, no changes in the TFH:TFR ratio 
and long-term virus neutralizing antibody responses were observed between low and 
high dose infections. These findings argue against our hypothesis that an increase in the 
initial viral dose per se (of attenuated viruses) would translate to higher antigenic load 
and thereby improve immunogenicity and long-term antiviral humoral immunity. An 
explanation for these findings can be found in the pathogenesis of mousepox. Upon s.c. 
infection of ECTV-WT, extensive replication at the site of inoculation and migration to 
draining lymph node is followed by step-wise dissemination to blood and secondary 
lymphoid organs (Fenner, 1947b; Fenner, 1948). Attenuation of ECTV-TKΔ restricts 
replication at the site of infection thereby limiting subsequent haematogenous spread to 
secondary lymphoid organs (Kochneva et al., 1994). The low titer and poor quality of 
antiviral antibodies generated even at a 1000-fold increase in the ECTV-TKΔ dose 
administered s.c. suggests predominant localization of antigen with limited systemic 
spread. 	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Based on these findings, we predicted that inoculation of attenuated viruses i.v. should 
overcome the dissemination barrier and augment immunogenicity and antiviral 
protection. The reduced pathogenesis of ECTV-TKΔ allows administration of a high 
dose such as 106 PFU i.v. without inducing any clinical signs of disease or morbidity. 
Upon i.v. inoculation, a significant increase in the TFH and GC B cell responses were 
observed compared with the s.c. route of infection. The magnitude of the responses 
were comparable to that detected in the replication-competent virus infection. 
Concordantly, long-term ECTV-specific antibody levels and neutralizing capacity 
elicited via i.v. inoculation was greater than the s.c. infected group. These results 
corroborate our revised hypothesis that optimal antigen availability in the secondary 
lymphoid organs, particularly the spleen is critical for the induction of protective 
antiviral responses. 
The question still remains whether the antigen levels in the secondary lymphoid organs 
impact the GC reaction and subsequent antiviral humoral responses. In order to answer 
this question, C57BL/6 mice were infected with a 1000-fold higher dose of VACV-TKΔ 
i.v. An increase in the viral inoculum dose resulted in a significant increase in the 
magnitude of TFH and GC B cell responses. By manipulating the input dose of the 
attenuated TKΔ virus, an increase in the TFH:TFR ratio was observed at a high dose;  
nearly identical to the responses detected in mice infected with a replication-competent 
virus. These results suggest that the dose of the antigen via i.v. inoculation influences 
the magnitude of the TFH response contrary to the limited effect seen in s.c. infection. 
The strategy to enhance antiviral humoral immunity by increasing the inoculum dose 
i.v. was next tested with the vaccine vector of choice, MVA. Consistent with findings in 
ECTV and VACV infection models, an increase in the initial viral dose elicited a higher 
TFH and GC response. Accordingly, elevated TFH:TFR ratio in high dose i.v. inoculation 
	  	   231 
was associated with qualitatively better neutralizing antibody response. Prime-challenge 
studies confirmed enhanced protection against lethal mousepox infection in mice 
primed with a high dose of MVA i.v. compared to a low dose. Previous studies using 
MVA-based expression vectors have required multiple immunizations or combination 
with prime-boost regimes involving different vector systems to induce protective 
immunity against various pathogens (Earl et al., 2004; Grandpre et al., 2009). Single 
i.m. immunization regimes using 108 PFU of MVA vector encoding influenza H7 have 
been shown to protect ferrets from a lethal challenge with the H7N9 influenza virus in 
short-term studies (Kreijtz et al., 2015) Nonetheless, whether antibody responses 
induced by any of these approaches are long-lived is not known. Although the induction 
of long-lived antiviral antibodies by MVA via the different routes of immunization has 
not been undertaken in this study, we predict that the i.v. route would be superior and 
possibly require only a single immunization. As discussed, the i.v. route of 
immunization will result in haematogenous spread to secondary lymphoid organs, 
including the spleen, whereas MVA given via the i.m., i.d. or s.c. route will be confined 
to the local draining lymph nodes. 
Although poxviral models have been a primary focus in this study, experiments were 
performed with influenza A viruses to investigate if the hypothesis holds true in other 
viral models. Using influenza A/PR/8 and A/SI/3/06 viruses, we demonstrated that both 
the dose and the route of administration influence the magnitude of TFH and GC B cell 
responses. Irrespective of the virus model used, plotting the number of GC B cells and 
TFH cells revealed a direct correlation between antigen availability and the magnitude of 
responses (Appendix Figure 5.2). 
The results presented in this study indicate that attenuated or inactivated viruses can 
generate robust antiviral humoral responses provided that an optimal antigen threshold 
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is delivered to the spleen. Attenuated TKΔ viruses can replicate locally, albeit less 
efficiently and it is therefore essential in these viral infections to consider that in 
addition to the initial viral dose, the duration of the virus (viral antigen) persistence can 
play an amplifying role in host humoral response. Post TFH differentiation, we 
hypothesize a temporal requirement for antigen availability along with B cell 
interactions in TFH proliferation. Further studies are required to tease out whether initial 
viral input dose or duration of virus persistence or both influence the magnitude of TFH 
responses. Future experiments including dose variation of attenuated viruses with or 
without antiviral treatment (after peak viraemia) will provide insights into the 
contribution of dose versus antigen persistence towards antiviral humoral response. In a 
study evaluating vaccination side-effects following co-administration of an antiviral 
drug (Cidofovir) along with Dryvax (a first generation replicating VACV vaccine), a 
significant decrease in vaccine-specific humoral and adaptive immune responses was 
observed, suggesting that virus antigen persistence could indeed play an important role 
in antiviral immune response and protective immunity (Wei et al., 2009). In replication-
incompetent viral infections, such as MVA and inactivated influenza A viruses (in 
which mature infectious virions cannot be generated), the antigen availability is 
predominantly determined by the inoculum dose. The lack of antigen persistence could 
reflect on the relatively short-term duration of protection and the need for prime-boost 
strategies to achieve optimal immune responses.  
In addition to the duration of virus persistence discussed above, another important factor 
to acknowledge is virus tropism. A study by Puig et al., employing recombinant viruses 
expressing GFP (VACV and MVA, with their TKΔ counterparts) report differing 
cellular bias in virus infections (Sanchez-Puig et al., 2004). Although a strong 
preference towards non-T cells (monocytes and DC) was maintained in both VACV and 
MVA infections, B cells and NK cells were more efficiently infected by VACV (and its 
	  	   233 
TKΔ counterpart) than MVA. Despite studies showing increased apoptosis of VACV 
and MVA infected cells, particularly DC and B cells, cross-presentation of viral 
antigens via bystander cells has been reported, highlighting the complex nature of 
antiviral immune responses (Liu et al., 2008b; Joffre et al., 2012). The ability to infect 
B cells can be further harnessed to augment the antigen-presenting properties of B cells 
in TFH cell program initiation (Barnett et al., 2014), thereby supporting a potent antiviral 
antibody response which is discussed further in the final conclusion chapter. 
In summary, data presented in this chapter indicates that the magnitude of TFH and GC 
B cell responses are antigen dose and route dependent. Our findings reveal modulation 
of antigen availability as an optimal strategy to augment antiviral antibody responses to 
attenuated virus vaccines. Collectively, the results provide a rationale for i.v. 
inoculation of attenuated virus vectors or inactivated vaccines for antibody-mediated 
immunotherapeutics. 
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6 Affinity maturation in antigen-specific B 
cells during viral infection 	  
6.1 Introduction 
High affinity neutralizing antibodies are a critical component of the host immune 
defense against viral infection and the mechanism by which all clinically effective viral 
vaccines work to provide protection. Despite the unquestioned importance of 
antibodies, the fundamental aspects regarding the generation of affinity-matured 
antibodies to viral antigens during the course of an infection remains elusive.  
To date, antibody affinity maturation to T cell-dependent antigens have been primarily 
studied using model protein antigens involving protein-hapten conjugates (Jacob et al., 
1991; Jacob and Kelsoe, 1992; Jacob et al., 1993; Griffiths et al., 1984; Gearhart et al., 
1981). These studies employing differing combination of haptens (2-phenyl oxazolone, 
phosphorylcholine, [4-hydroxy-3- nitrophenyl] acetyl) and carrier proteins (ovalbumin, 
chicken gamma globulin, keyhole limpet haemocyanin, HEL) are confounded by the 
valence of the haptens and size of the carrier proteins (Oda et al., 2004). With the recent 
development of SWHEL transgenic mice, it is now possible to evaluate antigen-specific 
GC responses including differentiation to GC B cells, plasma cells and memory B cells, 
class-switching and affinity maturation (Phan et al., 2003). Studies utilizing this model, 
have thus far employed HEL covalently coupled to SRBC; since HEL alone fails to 
elicit a T helper response. Data from these protein immunization models indicate that 
the initial affinity of BCR to antigen, antigen receptor engagement and antigen dose, 
combinatorially affect antigen-specific B cell responses and affinity maturation (Phan et 
al., 2006; Paus et al., 2006; Brink et al., 2008).  
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Pertinent to these experiments is the obvious differences between antigens encountered 
in protein immunization versus viral infections. In a viral infection, as opposed to 
protein immunization, the virus interacts with the various arms of the innate immune 
system and the viral antigen availability increases over time (depending on the 
replication fitness of the virus). In addition, the virus exhibits a range of antigens in 
various forms (envelope, soluble and membrane) and correspondingly, antibodies 
against all forms of viral antigens have been detected in immune responses (Davies et 
al., 2005). With these critical differences, the question arises as to whether the findings 
from protein immunization models are reflective of antibody responses generated in the 
physiological context of a viral infection. It is therefore, imperative that the parameters 
leading to high affinity anti-viral antibody production are substantiated with appropriate 
viral models.  
This chapter aims to establish a model to examine antigen-specific B cell responses and 
affinity maturation during the course of a viral infection. Generation of recombinant 
ECTV-WT expressing HEL in the viral envelope will allow us to take advantage of the 
well-established SWHEL transgenic system to study affinity maturation under 
physiological conditions of an infection. In the previous chapters, we have presented 
data to show that the replication fitness of virus affects virus-specific antibody levels 
and to confirm these results, we additionally generated recombinant ECTV-TKΔ 
expressing HEL in the viral envelope. Tracking of adoptively transferred congenic 
SWHEL B cells in recipient mice during infection with recombinant ECTV-WT or 
ECTV-TKΔ encoding HEL will allow the study of affinity maturation in antigen-
specific B cells under varying experimental conditions. Preliminary findings 
demonstrating the effectiveness of the ECTVHEL: SWHEL model along with class-
switching and somatic hypermutation patterns in antigen-specific GC B cells are also 
discussed. 
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6.2 Results 	  
6.2.1 Generation of recombinant viruses expressing HEL 
In this chapter, we aimed to study affinity maturation during infection with replication-
competent and replication-inefficient viral infections using recombinant ECTV-WT / 
TKΔ expressing HEL in conjunction with the SWHEL system. In SWHEL mice, a 
proportion of the B cells (~10-20%) carry the specificity of the HyHEL10 anti-HEL 
mAb (Brink et al., 2008; Chan et al., 2009). The HyHEL10 anti-HEL mAb binds to 
wild-type HEL (HELWT) with very high affinity (association constant [Ka]: 2 x 1010 M-
1), comparable to the theoretical ceiling threshold for affinity maturation (Batista and 
Neuberger, 1998). Therefore, to study the process of affinity maturation, we generated 
recombinant viruses expressing HEL variants that have reduced affinity to HyHEL10. 
HEL variants designated as HEL2X and HEL3X have two (HEL2X; R73E and D101R) or 
three (HEL3X; R73E, D101R and R21Q) amino acid substitutions that reduce the 
binding affinity to either intermediate (HEL2X; Ka: 8 x 107 M-1) or low (HEL3X; Ka: 1.5 
X 106 M-1) (Paus et al., 2006; Brink et al., 2008) (Appendix Figure 6.1). 
B5R, a VACV viral envelope protein, is essential for the production of extracellular 
enveloped form of the virus (EEV) and is responsible for cell-to-cell and long-range 
spread of virus within the host (Engelstad and Smith, 1993; Wolffe et al., 1993). 
Modest levels of long-lasting anti-B5R antibody responses have been detected in 
individuals vaccinated against smallpox (Putz et al., 2005; Bell et al., 2004). The B5R 
gene contains an N-terminal signal peptide followed by 4 SCR regions and a trans-
membrane domain. In a previous study, Newsome et al., found that the production of 
EEV and cell-to-cell spread of the virus was not affected by removal of the SCR regions 
1-3 (Newsome et al., 2004). In ECTV, the ECTV155 gene is a homologue of VACV 
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B5R (Bratke et al., 2013). Thus, to study antigen-specific B cell responses during ECTV 
infection, the variant HEL epitope was inserted in the first three SCR regions of the 
ECTV155 gene (Figure 2.1). To determine whether insertion of the gene encoding 
variant HEL epitope in the ECTV genome affected virus replication, C57BL/6 mice 
were infected s.c. with either ECTV-WT or recombinant ECTV-WT expressing HEL3X 
(rECTV-WT-HEL3X) at the same dose. At day 5 after infection, animals were sacrificed 
and the viral load in the spleen and liver was determined by viral plaque assay. Both 
WT and recombinant viruses replicated to comparable levels in the organs (Figure 6.1). 
These results indicate that the virus replicative capacity was not affected by the 
insertion of the HEL epitope into the ECTV155 region. 
6.2.2 Antigen-specific B cell responses in rECTV-WT-HEL3X 
infection 
The experimental strategy used here for studying antigen-specific B cell responses 
during the course of ECTV infection is schematically represented in Appendix Figure 
6.2. SWHEL splenocytes (CD45.1) were adoptively transferred into WT (CD45.2) 
congenic recipients (SWHEL B cell recipient mice) followed by infection with the 
recombinant virus 24 hours later. The number of transferred HEL-binding SWHEL B 
cells were maintained at ~ 3-5 x 104 cells per mouse to ensure that their frequency was 
similar to the physiological repertoire of antigen specific B cells (Sigal et al., 1987; 
Shokrgozar and Shokri, 2001; Klinman et al., 1976). Antigen-specific, donor-derived B 
cell responses can be tracked by flow cytometric analysis of CD45.1+, HEL-binding B 
cells (Appendix Figure 6.2B). 
The process of affinity maturation is ideally studied using low affinity antigen (HEL3X), 
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Figure 6.1: Replicative capacities of ECTV-WT and rECTV-WT-HEL3X in-vivo. 
C57BL/6 mice infected subcutaneously with 1000 PFU of ECTV-WT or rECTV-WT-
HEL3X were sacrificed at day 5 p.i. Viral load in liver and spleen was determined by 
viral plaque assay and expressed as means of log10 PFU / gram of tissue ± SEM (n=4 
mice per group). No statistical difference in the viral load was observed by Two-Way 
ANOVA test.  	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and therefore to establish the ECTVHEL:SWHEL model, experiments were performed 
using rECTV-WT-HEL3X. Foremost, we sought to confirm that the donor B cells in the 
ECTVHEL: SWHEL model responded to ECTV-encoded HEL3X. SWHEL splenocytes 
containing 3 x 104 HEL-binding B cells were injected i.v. into CD45.2 congenic WT 
recipient mice, followed by s.c. infection with either ECTV-WT or rECTV-WT-HEL3X 
24 hours later. Using the gating strategy illustrated in Figure 6.2A, CD45.1+, HEL-
binding donor B cells were analyzed 14 days later. Expansion of CD45.1+, HEL binding 
B cells was evident in SWHEL B cell recipient mice infected with rECTVWT-HEL3X. 
The expansion was clearly antigen specific since it was not detected in SWHEL B cells 
recipient mice infected with ECTV-WT control (Figure 6.2B). 
The next step was to characterize the donor-derived B cell response in rECTV-WT-
HEL3X infection. Following adoptive transfer of SWHEL splenocytes into congenic WT 
recipients, mice were either infected with rECTV-WT-HEL3X or immunized with SRBC 
conjugated to HEL3X (as a positive experimental control). Mice were ethically 
sacrificed 7, 14, 21 and 28 days later and the donor B cell response kinetics were 
analyzed using the gating strategy illustrated in Figure 6.2A. The expansion kinetics of 
the positive experimental control (HEL3X-SRBC) was similar to the previous published 
results, with peak proliferation detected early (day 7 post-immunization in our time-
course analysis), followed by a gradual reduction back to baseline levels (Appendix 
Figure 6.3). The antigen-specific responses observed in rECTV-WT-HEL3X infection 
were different, with no expansion in the donor SWHEL population detected at day 7 p.i. 
However, between days 7 and 14 p.i., a six-fold expansion in the proportion of donor 
HEL-binding cells was observed. At day 14 p.i., HEL-binding cells accounted for 
approximately 50% of the donor population. Following this peak proliferative response, 
the proportion of the donor derived   HEL-binding  B  cells  gradually  declined  (Figure  
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Figure 6.2: Gating strategy used to study donor SWHEL B cell responses to viral 
infection. SWHEL B cell recipient mice infected subcutaneously with either ECTV-WT 
or rECTV-WT-HEL3X were sacrificed at day 14 p.i. and the donor-derived B cell 
responses were examined by flow cytometry. (A) FSC and SSC gates were applied to 
lymphocytes and doublets excluded by FSC area-height scaling. Autofluorescent cells 
were gated out in the next step using an unstained fluorescent parameter. Donor-derived 
SWHEL cells were identified by gating on donor allotype (CD45.1), HEL-binding cells. 
(B) Lack of expansion of HEL-binding donor B cells in ECTV-WT infected mice 
indicates that the expansion is antigen-specific. Numbers represent the percentage of 
parent population within the gate. Data is representative of pooled samples from three 
mice in each group. 
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6.3A) and is represented as % of single lymphocytes, % of donor CD45.1+ cells and 
total splenic numbers in Figure 6.3B, 6.3C and 6.3D respectively.   
The differentiation of SWHEL donor B cells into GC B cells in response to rECTV-WT-
HEL3X infection was next examined. Antigen-specific, donor-derived GC B cell were 
identified by flow cytomtery as CD45.1+, HEL-binding B cells that were GL7 and Fas 
double positive, express B220 but lack Syndecan-1 (CD138) expression (Figure 6.4A). 
FMO controls were used at each step to set precise gating boundaries. Analyses of the 
donor GC B cell responses to virus-expressed HEL3X revealed the GC B cell 
differentiation to peak at day 14 p.i. (Figure 6.4B). This data is consistent with the 
polyclonal GC B cell kinetics described in Chapter 3, Figure 3.5. 
Together, these findings indicate that the maximal antigen-specific B cell proliferation 
and GC B cell differentiation to a viral envelope-expressed antigen is elicited at day 14 
p.i. 
6.2.3 Class-switching patterns elicited in rECTV-WT-HEL3X 
infection 
Previous studies have reported SWHEL B cell responses to HEL3X-SRBC to be 
dominated by IgG1 class switching, both in the GC and plasma cell compartment (Phan 
et al., 2006; Phan et al., 2005)(Appendix Figure 6.4). To study immunoglobulin class 
switching patterns elicited in response to viral envelope-HEL3X antigen, donor GC B 
cells were stained with flurochrome-conjugated antibodies to detect surface expression 
of all IgG heavy chain isotypes. By day 14 p.i., donor GC B cells of all IgG isotypes 
could be detected, albeit at varying frequencies. The highest frequency of switched 
SWHEL donor GC B cells were of the IgG2c subclass (53%) followed by IgG2b 
(approximately 7%) and IgG3 (approximately 7%). IgG1 was the least switched isotype  
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Figure 6.3: Antigen-specific donor B cell proliferation kinetics during rECTV-WT-
HEL3X infection.  SWHEL B cell recipient mice were infected subcutaneously with 
rECTV-WT-HEL3X and spleens harvested for flow cytometric analysis on days 7, 14, 
21 and 28 p.i. (A) Pseudocolor FACS plots showing the expansion profile of donor 
HEL-binding B cells at time-points indicated. The data shown are gated on lymphocytes 
after doublet and autofluorescent cell exclusion as in Figure 6.2A. Numbers indicate the 
percentage of CD45.1+ cells that bound HEL. Donor-derived HEL-binding cells 
expressed as (B) % of single lymphocytes, (C) % CD45.1+ donor cells and (D) Absolute 
cell numbers per spleen. Data is representative of pooled samples from three mice at 
each time-point. 
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Figure 6.4: Antigen-specific GC B cell differentiation kinetics in rECTV-WT-
HEL3X infection.  SWHEL B cell recipient mice were infected as in Figure 6.3 and 
spleens harvested for flow cytometric analysis at time-points indicated. (A) Pseudocolor 
concatenated FACS plots showing the gating strategy employed for GC B-cell 
identification. Following FSC-SSC gating, doublet and autofluorescent cell exclusion, 
donor-derived GC B-cells were identified as of CD45.1+, HEL-binding, GL7+, Fas+ 
cells with B220hi and Sydecan-1lo expression. Donor-derived GC B-cells expressed as 
(B) % of single lymphocytes, (C) % CD45.1+ donor cells and (D) Absolute cell 
numbers per spleen. Data is representative of pooled samples from three mice at each 
time-point. 
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representing only about 5% of the donor GC B cells (Figure 6.5). At day 28 p.i., the 
IgG2c subclass continued to be the major contributor (64%) to the antigen-specific, 
donor-derived GC B cell compartment (data not shown).  
Subsequently, the contribution of the IgG isotypes to the plasma cell compartment was 
analysed. Donor-derived plasma cells were identified by flow cytometry as CD45.1+ 
cells with high intracellular HEL expression. At day 14 p.i., IgG subclass analysis 
revealed that the IgG2c subclass was the major contributor (88%) to the plasma cell 
compartment. Donor plasma cell populations of the IgG2b and IgG3 subclasses 
accounted for only about 5% and 3%, respectively. Less than 1% of the donor-derived 
plasma cells expressed IgG1 (Figure 6.6).  
Next, we sought to confirm the class switching patterns observed in flow cytometry by 
ELISA. SWHEL B cell recipient mice either infected with rECTV-WT-HEL3X or 
immunized with HEL3X-SRBC were bled at day 14 p.i. Differences in the IgG subclass 
switching patterns between the two experimental groups were confirmed by examining 
the circulating anti-HEL IgG2c and IgG1 antibody levels using HEL3X binding ELISA. 
In response to rECTV-WT-HEL3X, high levels of anti-HEL IgG2c antibody were 
detected, but anti-HEL IgG1 antibody titers were minimal. Conversely, high levels of 
anti-HEL IgG1 but minimal IgG2c antibody subclasses were detected in response to 
HEL3X-SRBC immunization (Figure 6.7).  
Collectively, these results indicate that the antibody response to viral HEL3X envelope 
protein is characterized by a predominant IgG2c subclass switching both in GC as well 
as plasma cell compartments. 
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Figure 6.5: IgG subclass-switching of donor-derived GC B cells in rECTV-WT-HEL3X infection.  SWHEL B cell recipient mice infected with 
rECTV-WT-HEL3X were sacrificed at day 14p.i. and spleens harvested for FACS analysis. Donor-derived CD45.1+, HEL-binding GC B cells were 
stained separately for (A) IgG1, (B) IgG2b, (C) IgG2c and (D) IgG3 subclasses. Numbers within the gates indicate the frequency of donor-derived GC 
B-cells positive for the specific IgG subclass. Data is representative of pooled samples from three mice. 
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Figure 6.6: IgG subclass-switching of donor-derived plasma cells in rECTV-WT-HEL3X infection.  SWHEL B cell recipient mice infected with 
rECTV-WT-HEL3X were sacrificed at day 14p.i. and spleens harvested for FACS analysis. Donor-derived CD45.1 intermediate, intracellular HEL-
binding cells were stained separately for (A) IgG1, (B) IgG2b, (C) IgG2c and (D) IgG3 subclasses. Numbers within the gates indicate the frequency of 
donor-derived GC B-cells positive for the specific IgG subclass. Data is representative of pooled samples from three mice.	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Figure 6.7: Antigen-specific IgG2c and IgG1 antibody responses. SWHEL B cell 
recipient mice were either infected with rECTV-WT-HEL3X or immunized with HEL3X-
SRBC and bled 14 days later. Serum extracted was used in the detection of anti-HEL 
(A) IgG2c and (B) IgG1 in HEL3X binding ELISA. Data from three mice per group, 
expressed as means of absorbance values ± SEM. 	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6.2.4 Induction of SHM during rECTV-WT-HEL3X infection: 
silent versus replacement mutations. 
To study the process of SHM during the course of a viral infection, SWHEL B cell 
recipient mice infected with rECTV-WT-HEL3X were ethically sacrificed on days 7, 14, 
21 and 28 p.i. and single cells of the most prevalent IgG2c class switched donor derived 
GC B cells were isolated. IgG heavy chain variable region exon was PCR amplified and 
the amplicons were sequenced as described in section 2.10 in Chapter 2. To identify 
somatic mutations, translated sequences were aligned with the original germline 
HyHEL10 sequence used in the generation of the SWHEL mice. Preliminary analysis of 
donor-derived GC B cells at day 7 p.i. revealed mutations in only 3 of the total 21 
amplicons sequenced (Appendix Figure 6.5). In addition, IgG2c class-switched donor 
derived GC B cells accounted for less than 0.00003% of the total splenocyte population 
at this time-point (data not shown), making it an extremely difficult population to 
perform single cell sorts. Therefore this time-point was excluded from future analysis.  
During the time-course of infection, a progressive increase in the number of amino acid 
substitutions per amplicon was detected in the VH exon region of IgG2c switched GC B 
cells (Figure 6.8A).  The average number of mutations per clone increased from 1.8 at 
day 14 p.i. to 4.6 at day 28 p.i. During the process of affinity maturation, antibodies 
typically accumulate mutations in the complementarity determining regions (CDRs) that 
come in contact with the antigen. Therefore the number of mutations, particularly in the 
CDRs was analyzed. As expected, an increase in the number of mutations was detected 
over the time course studied (Figure 6.8B). In addition, the number of mutations at the 
nucleotide and protein level was compared to determine the proportion of silent 
(synonymous) and replacement (non-synonymous / substitution) mutations. As the 
infection progressed a decrease in the number of silent mutations was detected along 
	  	   253 
with a concurrent increase in the number of replacement mutations (Figure 6.8C). 
Replacement mutations accounted for approximately 17%, 70% and 80% of the total 
mutations in the CDR at days 14, 21 and 28 p.i. respectively. The average ratio of 
replacement to silent mutations (R/Savg) increased progressively from 1.3 at day 14 p.i. 
to 4.2 at day 28 p.i. (Figure 6.8C). These findings indicate that the affinity maturation 
process in response to rECTV-WT-HEL3X is dominated by replacement mutations in 
the CDRs, consistent with previous published literature that the CDR regions are more 
prone to replacement mutations than framework regions (Chang and Casali, 1994; 
Shlomchik et al., 1987). 
6.2.5 SHM patterns elicited in GC B cells following rECTV-WT-
HEL3X infection. 
To gain further insight, the patterns of SHM in the IgG2c subclass switched donor-
derived GC B cells and in particular the VH amino acid residues that come in contact 
with the antigen were analyzed. Ten HyHEL10 residues make contact with the antigen 
(Figure 6.9), of which three are located in CDR1 (Ser-31, Asp-32 and Tyr-33), six in 
CDR2 (Tyr-50, Ser-52, Tyr-53, Ser-54, Ser-56 and Tyr-58) and one in CDR3 (Tyr-
95)(Padlan et al., 1989). At days 14, 21 and 28 p.i., the percentage of clones that 
showed mutations in these ten contact residues were determined. The highest frequency 
of mutations was detected at Tyr-53 (>90% of amplicons) followed by Ser-56 and 
Tyr58 (approximately 40% of the amplicons). These mutation hotspots Tyr-53/ Ser-56 
and Tyr-58 make contact with the antigen at position 101 and 21 respectively (mutated 
in HEL3X variant; D101R and R21Q). In addition, only one of the above mentioned 
HyHEL10 residues, Ser-31, makes contact with the antigen at the position 73, which is 
the third mutated position in HEL3X; R73E. Accordingly, Tyr-53, Ser-56, Tyr-58 and
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Figure 6.8: Somatic mutations in IgG2c class-switched donor-derived GC B cells. 
SWHEL B cell recipient mice were infected as described for Figure 6.3. IgG2c donor-
derived GC B-cells were single cell sorted and the VH region was PCR amplified and 
sequenced. (A) Absolute numbers of replacement mutations in the VH region (FRs + 
CDRs) detected per cell at the time-points indicated. (B) Total number of amino acid 
substitutions per cell in CDRs at time-points indicated. Data points represent a single 
cell / amplicon and the bar represents the mean. (C) Frequency of silent and 
replacement mutations in the CDRs at time-points indicated. The numbers within the 
inner circles represent R/Savg. Clones analyzed at each time-point: D14p.i., n=24; 
D21p.i., n=25; D28p.i., n=25. 	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 Ser-31 VH contact residues were considered for further SHM analysis (Figure 6.9 and 
6.10) 
6.2.5.1 Amino acid substitution patterns of tyrosine residues at position 53 
and 58 
IgG2c switched donor-derived GC B cells were single cell sorted, VH region sequenced 
and the amino acid substitution patterns of Tyr-53 in CDR2 was analyzed. At day 14 
p.i., >80% of the cells did not show any mutations at this position (Figure 6.11). Only 3 
of a total of 24 amplicons showed a point mutation leading to its substitution with 
aspartate (Y53D), However, by day 21 p.i. Y53D substitution was detected in all 
amplicons analyzed. Previous studies using HEL3X-SRBC reveal that the Y53D 
mutation increases the affinity of the SWHEL HyHEL10 BCR to HEL3X by ~ 85 fold 
(Ka: 3.5 x 109 M-1)(Phan et al., 2006). Y53D mutation remained dominant at day 28 p.i., 
with the substitution detected in 22 of the 25 amplicons. 
The patterns of amino acid substitution at position 58 in CDR2 region were next 
examined. The substitution of tyrosine at this position with phenylalanine (Y58F) 
increases the affinity of HyHEL10 to HEL3X (Ka: 4.2 x 107 M-1) albeit at levels lower 
than the Y53D substitution (Chan et al., 2012). At day 14 p.i., Y58F substitution was 
identified in only approximately 8% of the amplicons. However, the frequency of this 
substitution increased progressively during the time-course studied, with a 4-fold 
increase detected at day 28 p.i. (Figure 6.12A). The presence of both Y53D and Y58F 
mutations significantly increases the affinity of HyHEL10 to HEL3X (Ka: 1.4 x 1010 M-
1)(Chan et al., 2012). During the time-course examined, we detected an increase in the 
number of amplicons with both Y53D and Y58F mutations (Figure 6.12B). By day 28 
p.i., 40% of the amplicons with Y53D substitutions exhibited a concurrent Y58F 
mutation. 
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Figure 6.9: SHM analysis of VH residues in direct contact with the antigen. VH regions of IgG2c switched donor-derived GC B-cells were 
sequenced as in Figure 6.8. Single cell SHM analysis of the VH residues that come in contact with the antigen was performed. At each time-point, the 
columns represent the percentage of amplicons with substitutions for the amino acid residues indicated. The residues with the highest frequency of 
mutations that are considered for further analysis are boxed in red. Clones analyzed at each time-point: D14p.i., n=24; D21p.i., n=25; D28p.i., n=25. 
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Figure 6.10: SHM patterns in IgG2c switched GC B cells in response rECTV-WT-
HEL3X infection. At time-points indicated, VH regions of IgG2c switched donor-
derived GC B cells were sequenced as in Figure 6.8 and the SHM patterns were 
examined. FR and CDR regions are separated by vertical lines. Colored bars represent 
the amino acid residues that were identified in Figure 6.9 for further analysis. 
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Figure 6.11: Amino acid substitutions at position 53. VH region of IgG2c switched 
donor-derived GC B cells were sequenced as in Figure 6.8 and the amino acid 
substitution patterns at position 53 were examined. Each colored sector represents the 
proportion of cells with the indicated amino acid substitution. The numbers of clones 
analyzed at each time-point are indicated in the inner circles. 	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Figure 6.12: Amino acid substitutions at position 58. VH region of IgG2c switched donor-derived GC B-cells were sequenced as in Figure 6.8 and 
the amino acid substitution patterns at position 58 were examined. At time-points specified, representation of cell proportions with (A) Indicated amino 
acid substitutions and (B) Indicated combinations of Y53D and Y58F substitutions. The numbers of clones analyzed at each time-point are indicated in 
the inner circle. 	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6.2.5.2 Amino acid substitution patterns of serine residues at position 56 
and 31  
At day 14 p.i., amino acid substitution analysis of CDR2 residue, Ser-56 was not 
mutated in ~75% of the amplicons analyzed (Figure 6.13A). In the remaining 25% of 
the sequences, varying amino acid substitutions were detected at this position and a 
dominant pattern could not be identified. However, this changed by day 28 p.i., when 
>50% of the amplicons with mutations at this position were dominated by an 
Asparagine substitution (S56N). Subsequently, we analyzed if the S56N mutations were 
associated with the dominant Y53D mutation described earlier. In the time-course 
analyzed, a progressive increase in the frequency of clones with both Y53D and S56N 
substitutions was detected and by day 28 p.i., ~20% of the amplicons with Y53D 
substitution exhibited a concurrent S56N substitution (Figure 6.13B).  
In addition to the mutation hotspots in CDR2, somatic mutations induced at position 31 
of CDR1 was also examined. Although the frequency of mutations at Ser-31 were 
relatively low, by day 28 p.i., a preferential Arginine substitution (S31R) was detected 
in ~75% of the clones with point mutations at this position (Figure 6.14A). In addition, 
all amplicons with the S31R substitution exhibited an Y53D substitution (Figure 
6.14B). Although a quantitative measurement of antibody affinity was not carried out in 
this study, nevertheless, S56N and S31R substitutions have been identified to increase 
the affinity of HyHEL10 BCR to HEL3X (S31R > S56N) (personal communication with 
Dr. Tyani Chan, B cell Biology laboratory, Garvan Institute of Medical Research, 
Sydney).  
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Figure 6.13: Amino acid substitutions at position 56. VH region of IgG2c switched 
donor-derived GC B-cells were sequenced as in Figure 6.8 and the amino acid 
substitution patterns at position 56 were examined. At time-points specified, 
representation of cell proportions with (A) Indicated amino acid substitutions and (B) 
Indicated combinations of Y35D and S56N substitutions. The numbers of clones 
analyzed at each time-point are indicated in the inner circle. 	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Figure 6.14: Amino acid substitutions at position 31. VH region of IgG2c switched 
donor-derived GC B cells were sequenced as in Figure 6.8 and the indicated 
combinations of Y35D and S31R substitutions were examined at (A) Day 14 p.i, (B) 
Day 21 p.i. and (C) Day 28 p.i. The numbers of clones analyzed at each time-point are 
indicated in the inner circle. 	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With a comprehensive understanding of the substitution patterns in the mutation 
hotpots, the selection patterns of combinatorial affinity enhancing substitutions was next 
investigated. Association of the dominant Y53F substitution with either Y58F / S56N / 
S31R (i.e. Y53D +) was restricted to less than 5% at day 14 p.i. (1 of total 25 clones 
analyzed). At the later time-points analyzed, i.e. at days 21 and 28 p.i., Y53D+ clones 
increased, representing 20% and 35% respectively of the total population. In addition, at 
day 28 p.i., at least 12% of the clones had two of the affinity enhancing mutations 
(combination of Y58F, S56N, S31R) in addition to Y53D substitution (designated as 
Y53D++) (Figure 6.15). These results imply active selection of the high affinity clones 
in the GC compartment. 
Collectively, these results show that SWHEL GC B cells affinity maturation to virus-
expressed HEL3X is dominated by Y53D and Y58F substitutions with smaller 
contributions by S56N and S31R (in order of frequency: Y53D > Y58F > S56N > 
S31R). 
6.2.6 SHM patterns elicited in plasma cells following rECTV-
WT-HEL3X infection 
During a GC response, B cells accumulate mutations that increase the affinity to foreign 
antigens and are actively selected to contribute to the plasma cell pool. Although the 
serum antibody affinity is a direct reflection of the antibody-secreting plasma cell 
repertoire, the half-life of both plasma cells and circulating antibodies could affect the 
read-outs in a short time-course analysis as in this study. Therefore we attempted to 
study the somatic mutation patterns in plasma cells. However, due to time constraints, a 
complete time-course could not be carried out and mutation analyses of plasma cells 
was carried out only at day 14 p.i.. At this time-point, ~ 90% of the GC B cell  
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Figure 6.15: Y53D accompaniment mutations: VH region of IgG2c switched donor-
derived GC B cells were sequenced as in Figure 6.8 and association of Y53D mutation 
with other affinity increasing mutations (Y58F, S56N, S31R) was examined at (A) Day 
14 p.i, (B) Day 21 p.i. and (C) D28 p.i. The numbers of clones analyzed at each time-
point are indicated in the inner circle. 
None: No somatic mutations at position Y53. 
Single: Y53other: Substitution at position 53 with amino acid other than Aspartate. 
Single: Y53D: Substitution at position 53 with Aspartate (Y53D). 
Double: Y53D+: Presence of one Y53D accompaniment mutation (either Y58F, S56N 
or S31R) 
Triple: Y53D++: Presence of two or more Y53D accompaniment mutation 
(combinations of Y58F, S56N or S31R) 	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amplicons and 70% of the plasma cell amplicons show at least one mutation (Figure 
6.16A).  About 28% of the GC B cells show the affinity increasing Y53D mutation. In 
contrast, ~40% of the plasma cells show the affinity enhancing Y53D substitution 
(Figure 6.16B). These results indicate that as the GC reaction progresses, somatic 
mutations of the BCR generating higher affinity clones are selected into the plasma cell 
compartment. Although, we did not detect any plasma cells with Y53D accompaniment 
mutations  (Y58F, S56N and S31R), we predict that these clones would dominate the 
plasma cell repertoire by day 28 p.i. 
6.2.7 Binding capacity of serum anti-HEL IgG2c  
Serological maturation of anti-HEL IgG2c elicited in response to rECTV-WT-HEL3X 
was examined by HELWT and HEL3X binding ELISA. No anti-HEL IgG2c response 
could be detected in naïve or ECTV-WT infected mice, indicating that the HEL-specific 
circulating IgG2c antibody response was generated in response to virus-encoded 
HEL3X. With the accumulation of HEL3X-affinity enhancing mutations, we would 
expect a reduction in the serum anti-HEL antibody binding to HELWT along with a 
parallel increase in binding to HEL3X. In the time-course studied, the serum anti-HEL 
IgG2c from SWHEL B cell recipient mice infected with rECTV-WT-HEL3X showed 
progressively reduced binding to HELWT (Figure 6.17A). By day 14 p.i., the serum anti-
HEL IgG2c showed similar binding to HELWT and HEL3X suggesting maturation of the 
antibody response specific to HEL3X (Appendix Figure 6.6). Intriguingly, we observed a 
slight drop in the binding to HEL3X at days 21 and 28 p.i. (Figure 6.17B) and this 
warrants further investigation. 
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Figure 6.16: SHM patterns in donor-derived GC B cells and plasma cells. SWHEL 
B-cell recipient mice infected with rECTV-WT-HEL3X were sacrificed at day 14 p.i. 
and donor-derived GC B-cells (CD45.1+, HEL-binding, GL7+, Fas+, B220+) and plasma 
cells (CD45.1+, HEL-binding, B220lo) were single cell sorted. Ig VH loci were PCR 
amplified and sequenced for SHM analysis. (A) Frequency of clones with indicated 
number of mutations and (B) SHM patterns in donor-derived GC and plasma cells. The 
numbers of clones analyzed at each time-point are indicated in panel A. Residues Y53, 
S56 and Y58 are highlighted in red, yellow and orange respectively. 
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Figure 6.17: HEL3X binding capacity of IgG2c antibody response in rECTV-WT- 
HEL3X infection. SWHEL B-cell recipient mice infected subcutaneously with rECTV-
WT-HEL3X were bled on days 14, 21 and 28 p.i., and sera collected. At each time-point, 
serial dilutions of serum from individual mice was used to analyze the IgG2c binding 
ability to (A) HELWT and (B) HEL3X in parallel ELISA’s. Data shown are the means of 
absorbance values ± SEM from three mice per time-point (done in duplicate). 	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6.2.8 Affinity maturation in replicating and non-replicating viral 
infections 
Results from chapter 3 of this thesis demonstrated that the replication fitness of the 
virus impacts the antiviral humoral responses. In the subsequent chapter, we showed 
that the antiviral antibody response in replication-incompetent viral infections could be 
improved by manipulating the antigen availability. Although the main focus of this 
chapter is to establish an experimental model to track affinity maturation in antigen-
specific B cells during a viral infection, we have extended this work to examine somatic 
hypermutation patterns in context of viral replication fitness. We generated replication-
inefficient recombinant ECTV-TKΔ expressing HEL variants: HEL2X and HEL3X. On 
account that we were initially successful in generating rECTV-TKΔ-HEL2X, the effect of 
viral replicative fitness on affinity maturation was examined using recombinant WT and 
TKΔ expressing HEL2X. Although the affinity of HyHEL10 BCR to HEL2X is 50 fold 
higher than HEL3X, it is still below the ceiling threshold for affinity maturation (Batista 
and Neuberger, 1998) and previous studies have successfully demonstrated affinity 
maturation of donor SWHEL B cells on challenge with HEL2X-SRBC (Paus et al., 2006). 
6.2.8.1 Antigen-specific B cell responses and SHM patterns in rECTV-
HEL2X infection. 
Prior to comparative affinity maturation analysis in replicating and non-replicating viral 
infection, a preliminary analysis of the donor SWHEL B cell responses to rECTV-WT-
HEL2X was performed. Foremost, the ability of the donor SWHEL B cells to expand in 
response to viral-HEL2X was examined. At day 14 p.i., extensive expansion of the donor 
SWHEL B cells was evident, with the HEL-binding B cells accounting for approximately 
45% of the donor population. Although the degree of expansion was two-fold lower 
compared to rECTV-WT-HEL3X (Figure 6.18), nevertheless, the donor SWHEL B cells  
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Figure 6.18: Donor-derived GC and plasma differentiation in rECTV-WT-HEL3X 
and rECTV-WT-HEL2X. SWHEL B cell recipient mice infected subcutaneously with 
either rECTV-WT-HEL3X or rECTV-WT-HEL2X were sacrificed at day 14 p.i. and the 
spleens harvested for flow cytometric analysis. Pseudocolor FACS plots showing the 
expansion profile of donor HEL-binding B cells followed by GC B cells and plasma cell 
differentiation in (A) rECTV-WT-HEL3X infection and (b) rECTV-WT-HEL2X 
infection. Donor HEL-binding B cells are gated on lymphocytes after doublet and 
autofluorescent cell exclusion as in Figure 6.2A. Numbers indicate the percentage of 
parent population within the gate. Data is representative of pooled samples from three 
mice in each group. 	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responded efficiently to HEL2X expressed as a viral envelope protein. Next, the ability 
of SWHEL donor B cells to differentiate into GC B cells and plasma cells was examined. 
Whilst the overall frequency of differentiation into GC B cells  (CD45.1+, GL7+, 
CD138-ve) and plasma cells (CD45.1+, GL7-ve, CD138+) was maintained in rECTV-WT-
HEL2X and rECTV-WT-HEL3X infections (Figure 6.18), the two-fold difference in 
expansion of donor SWHEL B cells resulted in reduced GC and plasma cell numbers 
following rECTV-WT-HEL2X infection (data not shown). Within the CD138+ donor-
derived cell population, a higher proportion of plasmablasts (B220+, CD138+) was 
detected in mice infected with rECTV-WT-HEL2X infection compared to rECTV-WT-
HEL3X infection (Figure 6.18). This result suggests a plasmablast bias in response to 
high affinity antigen and warrants further investigation with additional markers to 
precisely delineate plasma and memory B cells populations. 
 Subsequently, somatic mutation patterns of SWHEL donor GC B cells elicited in 
response to rECTV-WT-HEL2X were examined at day 14 and 28 p.i. The average 
number of mutations per clone increased from 2.3 at day 14 p.i. to 4.3 at day 28 p.i., 
similar to the results observed with viral-HEL3X (Figure 6.19A).  The tyrosine residues 
at positions 53 and 58 as well as the serine residue at position 56 continued to be the 
major CDR2 mutation hotspots (Figure 6.19B). Considering that Tyr-53 and Ser-56 of 
HyHEL10 make contact with D101R of HEL2X antigen, the mutation patterns at these 
positions are discussed together. Y53D substitution was detected in 40% of the donor-
derived GC B cells at day 14 p.i. Intriguingly, we did not detect any further increase in 
the number of donor-derived GC B cells with Y53D substitution at day 28 p.i. Other 
amino acid substitutions were however identified at this time-point (12% phenylalanine, 
5% asparagine, 4% serine) (Figure 6.20A). These results contrast with the 90% 
frequency of Y53D substitution observed at day 28 p.i. in response to viral-HEL3X.  At  
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Figure 6.19: SHM patterns of donor-derived GC B cells in rECTV-WT-HEL2X 
infection. SWHEL B cell recipient mice infected with rECTV-WT-HEL2X were 
sacrificed at day 14 and 28 p.i. and donor-derived GC B-cells were single cell sorted. Ig 
VH loci were PCR amplified and sequenced for SHM analysis. At time-points indicated, 
(A) Frequency of clones with indicated number of mutations and (B) SHM patterns in 
donor-derived GC B cells. Residues Y53, S56 and Y58 are highlighted in red, yellow 
and orange respectively. The numbers within the inner circles represent the average 
mutations per clone. 25 clones were analyzed at each time-point. Data is representative 
of pooled samples from three mice in each group. 
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Ser-56 residue, asparagine (S56N) and threonine (S56T) substitutions were found in 
equal proportions (16% each) (Figure 6.20B). Similar trends were seen in the IgG2C 
switched GC B cells at position 53 and 56 (data not shown). 
Although phenylalanine substitution continued to be dominant at the Tyr-58 residue, 
Y58F could be detected in only about 12-16% of the donor-derived GC B cells at day 
14 and 28 p.i. (Figure 6.20C). Residue 58 (of HyHEL10) makes contact with the 
antigen at position 21. In HEL3X, this position is mutated (R21Q) validating the 
appearance of Y58F mutations to increase the affinity to HEL3X. Position 21 is not 
mutated in HEL2X and this could explain the low frequency of Y58F mutations seen in 
rECTV-WT-HEL2X infection. As observed previously in response to viral-HEL3X, the 
frequency of mutations at Ser-31 of HyHEL10 that makes contact with R73E of HEL3X 
/ HEL2X variants remained low (less than 10%). 
These results together indicate that donor SWHEL B cells respond efficiently to HEL2X 
expressed as a viral envelope protein and although the amino acid substitutions at 
mutation hotspots were similar compared to viral-HEL3X responses, the frequency of 
mutation were altered (Y53D > S56N=S56T > Y58F > S31R). 
6.2.8.2. Antigen availability significantly affects affinity maturation 	  
6.2.8.2.1. Antigen-specific B cell responses and GC B cell differentiation 
In the previous chapters, we have demonstrated that the viral replicative fitness, 
inoculum dose and route of infection influence the magnitude of the GC response and 
the quality of the subsequent antibody response. To study affinity maturation in this 
context, SWHEL B cell recipient mice were infected with either ECTV-WT (control; 
1000 PFU s.c.), rECTV-WT-HEL2X (1000 PFU s.c.), rECTV-TKΔ-HEL2X (1000 PFU  
	  	   276 
 
 
 
 
Figure 6.20: Amino acid substitution patterns in rECTV-WT-HEL2X infection. Ig 
VH region of donor-derived GC B cells were sequenced as in Figure 6.19. At time-
points indicated, amino-acid substitution patterns at (A) Position 53, (B) Position 56 and 
(C) Position 58 were examined. Each colored sector represents the proportion of cells 
with the indicated amino acid substitution. For each time-point, the numbers of clones 
analyzed are indicated in the inner circles. Data is representative of pooled samples 
from three mice in each group. 	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s.c.), rECTV-TKΔ-HEL2X (106 PFU s.c.) or rECTV-TKΔ-HEL2X (106 PFU i.v.). Using 
the experimental strategy described earlier in this chapter (section 6.2.2), donor-derived 
SWHEL B cell expansion and GC B cell differentiation was studied at the peak of the GC 
reaction, i.e., at day 14 p.i. Compared to SWHEL recipient mice infected with control 
ECTV-WT, a 40-fold expansion of HEL-binding cells was observed in mice infected 
with rECTV-WT-HEL2X (Figure 6.21A). In contrast, infection with replication-
inefficient rECTV-TKΔ-HEL2X at 103 or 106 PFU s.c. resulted in only an approximate 
two-fold expansion of the SWHEL B cell population over the control (Figure 6.21B and 
6.21C). Increasing the antigen availability in spleen by administration of rECTV-TKΔ-
HEL2X at 106 PFU i.v. led to an efficient expansion of the HEL-binding cells (20-fold 
expansion over the control) (Figure 6.21D). In the experimental conditions discussed 
above, antigen-specific responses were quantified and represented in Figure 6.21E.  
Next, the differentiation of SWHEL donor B cells into GC B cells was examined. At the 
peak of GC response on day 14 p.i., 60% of the HEL-binding cells had differentiated 
into GC B cells in rECTV-WT-HEL2X infection (Figure 6.22A). Following infection 
with rECTV-TKΔ-HEL2X at the same dose (1000 PFU s.c.), only about 6% of the donor 
HEL-binding B cells differentiated into GC B cells; an approximate 10-fold reduction 
compared to rECTV-WT-HEL2X responses (Figure 6.22B). Increasing the dose of the 
virus to 106 PFU, but maintaining the s.c. route of administration led to only a two-fold 
increase in GC B cell differentiation (Figure 6.22C). However, administration of 106 
PFU of rECTV-TKΔ-HEL2X i.v. led to a substantial increase in the donor-derived GC B 
cell populations with approximately 50% of the adoptively transferred HEL-binding B 
cells differentiating into GC B cells (Figure 6.22D). A representation of these 
differences is provided in Figure 6.22E. 
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Figure 6.21: Effect of virus dose and route of administration on donor-derived 
HEL-binding B cells at day 14 p.i.  SWHEL B cell recipient mice were infected with 
the various recombinant viruses as indicated in the figure and spleens harvested for flow 
cytometric analysis 14 days later. Pseudocolor FACS plots showing the expansion 
profile of donor HEL-binding B cells in (A) rECTV-WT-HEL2X (1000 PFU s.c.) 
infection, (B) rECTV-TKΔ-HEL2X (1000 PFU s.c.) infection, (C) rECTV-TKΔ-HEL2X 
(106 PFU s.c.) infection and (D) rECTV-TKΔ-HEL2X (106 PFU i.v.) infection. The data 
shown are gated on lymphocytes after doublet and autofluorescent cell exclusion as in 
Figure 6.2A. Numbers indicate the percentage of CD45.1+ cells that are HEL-binding. 
(E) Donor-derived HEL-binding cells expressed as % of single lymphocytes, % 
CD45.1+ donor cells and total cell numbers per spleen. Data is representative of pooled 
samples from three mice at each time-point. 
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Figure 6.22: Effect of virus dose and route of administration on antigen-specific 
GC B differentiation: SWHEL B cell recipient mice were infected as indicated in the 
figure and spleens harvested for flow cytometric analysis 14 days later. Pseudocolor 
FACS plots showing the GC B cell populations, gated on CD45.1+, HEL-binding B 
cells (A) rECTV-WT-HEL2X (1000 PFU s.c.), (B) rECTV-TKΔ-HEL2X (1000 PFU s.c.), 
(C) rECTV-TKΔ-HEL2X (106 PFU s.c.) and (D) rECTV-TKΔ-HEL2X (106 PFU i.v.) 
infection. Numbers indicate the percentage of GC B cells within the parent CD45.1+, 
HEL-binding population. (E) Donor-derived GC B-cells expressed as % of single 
lymphocytes, % CD45.1+ donor cells and total cell numbers per spleen. Data is 
representative of pooled samples from three mice at each time-point.
	  	   281 	    
	  	   282 
Collectively, these results clearly indicate that the antigen-specific B cell proliferation 
and GC differentiation is impacted by the replicative fitness of the virus. However, 
increasing the antigen availability via i.v. administration can augment the splenic 
antigen-specific responses during replication-inefficient viral infections. 
6.2.8.2.2. SHM pattern analyses  
To compare SHM patterns under the experimental conditions discussed above, donor-
derived GC B cells were single cell sorted at day 28p.i. and the Ig heavy chain variable 
region was PCR amplified and amplicons sequenced for SHM analysis. In response to 
rECTV-WT-HEL2X infection, an average of 4.2 mutations was detected per clone 
(Figure 6.23A). Administration of rECTV-TKΔ-HEL2X   s.c. at the same dose or a 1000-
fold higher dose resulted in an average of 2 mutations per clone (Figure 6.23B and 
6.23C). In contrast, i.v. administration of rECTV-TKΔ-HEL2X   at 106 PFU increased the 
number of mutations per clone to 4.12, similar to the mutation rates detected in response 
to rECTV-WT-HEL2X infection (Figure 6.23D). 
Although the mutation rates are a good indicator of the affinity maturation process, the 
resultant somatic mutation pattern is the key deciding factor in antibody affinity. 
Therefore, patterns of amino acid substitutions elicited in response to the infections 
were next examined at day 28 p.i. (Figure 6.24). Specifically, mutations in the dominant 
hotspot Tyr-53 residue were examined. As described previously in section 6.8.1, the 
response to rECTV-WT-HEL2X was characterized by tyrosine substitution (40%), with 
smaller proportions of phenylalanine (12%), asparagine (5%) and serine (4%) 
substitutions (Figure 6.25A). Surprisingly, we did not detect any clones with affinity 
increasing Y53D substitution in s.c. infections of rECTV-TKΔ-HEL2X  (both at 103 and 
106 PFU). Under these conditions, substitutions (phenylalanine or serine) were detected 
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Figure 6.23: Effect of virus dose and route of administration on mutation rates in donor-derived GC B-cells. SWHEL B-cell recipient mice 4	  
infected as in Figure 6.21 were sacrificed at day 28 p.i. and donor-derived GC B-cells were single cell sorted. Ig VH loci were PCR amplified and 5	  
sequenced for SHM analysis. Frequency of clones with indicated number of mutations in (A) rECTV-WT-HEL2X (1000 PFU s.c.) infection, (B) 6	  
rECTV-TKΔ-HEL2X (1000 PFU s.c.), (C) rECTV-TKΔ-HEL2X (106 PFU s.c.) and (D) rECTV-TKΔ-HEL2X (106 PFU i.v.) infection. Data is 7	  
representative of pooled samples from three mice, with 25 amplicons analyzed in each group. 8	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Figure 6.24: Effect of virus dose and route of administration on SHM patterns in 8	  
donor-derived GC B-cells. Ig VH regions of donor-derived GC B-cells were sequenced 9	  
as in Figure 6.23 and the SHM patterns were examined (A) rECTV-WT-HEL2X (1000 10	  
PFU s.c.) infection, (B) rECTV-TKΔ-HEL2X (1000 PFU s.c.), (C) rECTV-TKΔ-HEL2X 11	  
(106 PFU s.c.) and (D) rECTV-TKΔ-HEL2X (106 PFU i.v.). FR and CDR regions are 12	  
separated by vertical lines. Colored bars represent the amino acid residues that were 13	  
identified in Figure 6.9 for further analysis. Residues Y53, S56 and Y58 are highlighted 14	  
in red, yellow and orange respectively. Data is representative of pooled samples from 15	  
three mice, with 25 amplicons analyzed in each group. 16	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in only 2-3 of the total 25 clones analyzed (Figure 6.25B and 6.25C). With i.v. 
administration of rECTV-TKΔ-HEL2X (106 PFU), Y53D substitution was detected in 
76% of the clones analyzed (Figure 6.25D). In addition, approximately 10% and 20% of 
clones with Y53D substitution in rECTV-WT-HEL2X (103 PFU s.c.) and rECTV-TKΔ-
HEL2X  (106 PFU i.v.) infection respectively, were associated with other affinity 
enhancing mutations described previously (Figure 6.26). These results suggest that 
antigen availability plays a key role in the appearance of affinity enhancing Y53D 
substitution. 
The SHM findings were subsequently confirmed by examining the antigen-specific 
antibody responses. Similar to the flow cytometric findings in viral-HEL3X responses, 
IgG2c continued to be the major subclass elicited in response to viral-HEL2X, both in 
replication-competent and replication-inefficient viral infections (data not shown). 
Therefore, under the experimental conditions described above, serum anti-HEL IgG2c 
responses were analyzed by HEL2X-binding ELISA at day 28 p.i. Anti-HEL IgG2c in 
rECTV-WT-HEL2X and rECTV-TKΔ-HEL2X (106 PFU i.v.) infections showed relatively 
higher binding to plate bound soluble recombinant HEL2X in comparison to mice 
infected s.c. with rECTV-TKΔ-HEL2X at 103 PFU or 106 PFU (Figure 6.27).  
Taken together, the results in this section indicate that affinity maturation to an 
envelope-expressed antigen during infection with replication-inefficient virus can be 
augmented by administration of a high dose through the i.v. route. 
6.3 Discussion 
T cell-dependent B cell responses are essential for the generation of long-lived high 
affinity antibodies that provide a powerful defense against infectious organisms, 
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Figure 6.25: Effect of virus dose and route of administration on amino acid substitution patterns at position 53. Ig VH region of donor-derived 
GC B-cells were sequenced as in Figure 6.23 and the amino acid substitution patterns at position 53 were examined in (A) rECTV-WT-HEL2X (1000 
PFU s.c.), (B) rECTV-TKΔ-HEL2X (1000 PFU s.c.), (C) rECTV-TKΔ-HEL2X (106 PFU s.c.) and (D) rECTV-TKΔ-HEL2X (106 PFU i.v.) infection. Each 
colored sector represents the proportion of cells with the indicated amino acid substitution. The numbers of clones analyzed in each group are indicated 
in the inner circles. Data is representative of pooled samples from three mice in each group. 
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Figure 6.26: Effect of virus dose and route of administration on Y53D accompaniment mutations: Ig VH region of donor-derived GC B cells 
were sequenced as in Figure 6.23 and association of Y53D mutation with other affinity increasing mutations (Y58F, S56N and S31R) was examined in 
(A) rECTV-WT-HEL2X (1000 PFU s.c.), (B) rECTV-TKΔ-HEL2X (1000 PFU s.c.), (C) rECTV-TKΔ-HEL2X (106 PFU s.c.) and (D) rECTV-TKΔ-
HEL2X (106 PFU i.v.) infection. The numbers of clones analyzed in each group are indicated in the inner circle.  
 
None: No somatic mutations at position Y53. 
Single: Y53other: Substitution at position 53 with amino acid other than Aspartate. 
Single: Y53D: Substitution at position 53 with Aspartate (Y53D). 
Double: Y53D+: Presence of one Y53D accompaniment mutation (either Y58F, S56N or S31R) 
Triple: Y53D++: Presence of two or more Y53D accompaniment mutation (combinations of Y58F, S56N or S31R) 	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Figure 6.27: Effect of virus dose and route of administration on HEL2X binding 
capacity of IgG2c antibody response. SWHEL B cell recipient mice infected with 
rECTV-WT-HEL2X (1000 PFU s.c.), rECTV-TKΔ-HEL2X (1000 PFU s.c.), rECTV-
TKΔ-HEL2X (106 PFU s.c.) or rECTV-TKΔ-HEL2X (106 PFU i.v.) were bled on day 28 
p.i. and sera collected. Serial serum dilutions from individual mice were used to analyze 
the IgG2c binding ability to HEL2X. Data shown is the mean of absorbance values ± 
SEM from three mice per time-point (done in duplicate). 	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including ECTV. The production of antigen-specific antibodies requires crosstalk 
between several immune cell-types: antigen-presenting cells, T helper cells and B cells. 
Whilst the previous chapters have examined the roles of host (TFH:TFR ratio) and viral 
factors (replication fitness and antigen availability) in generation of polyclonal antiviral 
antibody responses, this chapter has focused on examining the antibody responses to a 
single viral envelope-expressed antigen.  
Upon exposure to a novel antigen, the process of affinity maturation refines a naïve B 
cell response by selecting mutations in the antibody variable domains that enhance 
antigen binding. Recent technical advances make it possible to isolate antigen-specific 
B cells and sequence the variable regions to study the process of affinity maturation. 
However, affinity maturation has been studied extensively using protein-antigen 
immunizations and the current study is the first, to our knowledge, to systematically 
examine antigen-specific B cell responses and affinity maturation to a virus-expressed 
antigen during infection of a natural host under physiological conditions. 
The experimental model described in this chapter utilizes the SWHEL transgenic system 
in conjunction with rECTV expressing the HEL transgene. The rationale for using the 
ECTV-155 (B5R) gene to insert the HEL transgene was two-fold: Firstly, anti-B5R 
antibodies are responsive for the EEV neutralizing capacity of vaccine immune 
globulin, which is used to treat complications of smallpox vaccination (Bell et al., 
2004). Secondly, the expression of HEL in the viral envelope is the closest analogy in a 
viral system to SRBC conjugated to HEL, which has been previously used in affinity 
maturation studies with the SWHEL model (Phan et al., 2005; Phan et al., 2006; Chan et 
al., 2012). The SWHEL BCR has 1000 -10,000 fold lower affinity to HEL variants; 
HEL2X and HEL3X respectively, and the expression of these in the viral envelope allows 
	  	   291 
detailed serological and cellular affinity maturation analysis during the course of 
infection. 
In response to viral-HEL3X, HEL-binding donor SWHEL B cells proliferate extensively 
with peak expansion apparent at day 14 p.i. This expansion was antigen-specific, as it 
was not detected in SWHEL B cell recipient mice infected with ECTV-WT (Figure 6.2 
and 6.3). The donor HEL-binding B cell expansion kinetics elicited in response to viral-
HEL3X is in sharp contrast with the findings from studies using HEL3X-SRBC [(Paus et 
al., 2006) as well as in the current study; Appendix Figure 6.7]. These contrasting 
findings highlight the fundamental differences in antigen availability as well as T helper 
and B cell activation kinetics between protein immunization models and viral 
infections.   
Viral-HEL3X-specific donor-derived GC B cell differentiation peaked at day 14 p.i. 
(Figure 6.4), which is consistent with the polyclonal GC responses described in Chapter 
3, section 3.2.2. Upon examining the subclass distribution of the switched donor-
derived GC B cells at this time-point, IgG2c was found to be the dominant isotype 
followed by IgG2b and IgG3 (Figure 6.5). The class switching patterns (Ig2C > IgG2b 
> IgG3> IgG1) were maintained in the plasma cell compartment, albeit at slightly 
varying frequencies (Figure 6.6). The subclass distribution patterns elicited in response 
to viral-HEL3X differ markedly from the patterns identified using HEL3X-SRBC (IgG1 > 
IgG2b > IgG2C > IgG3; Appendix Figure 6.4). Two possibilities could account for the 
observed differences in subclass switching patterns between viral-HEL3X and HEL3X-
SRBC: One, the subclasses induced post-immunization or infection depends on the 
cytokine milieu and is an indirect measure of the relative contribution of Th1 versus 
Th2 cytokines (Finkelman et al., 1990). The preponderant switching to IgG1 in HEL3X-
SRBC response can be explained by an increased Th2 component of the anti-SRBC T 
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cell help (Ismail et al., 2005; Phan et al., 2005; Shinall et al., 2000). ECTV infection of 
resistant C57BL/6 mice predominantly elicits a Th1 response with IFN-γ production 
directing an IgG2c subclass-specificity (Chaudhri et al., 2004; Karupiah et al., 1993a; 
Snapper and Paul, 1987). Compared to IgG1, IgG2c subclass antibodies are efficient 
mediators of both CDC and ADCC (Klaus et al., 1979; Heusser et al., 1977; Kipps et 
al., 1985), triggering elimination of virus particles as well as infected cells and thus 
providing a more suitable line of defense in ECTV infection. The second possibility is 
that the form of the antigen might play a role in subclass switching and should be 
considered for future experiments. Using different subclass-switched versions of anti-
B5R antibody, it was demonstrated that in-vitro neutralization and in-vivo protection 
was heavily dependent on the antibody subclass-effector function (Benhnia et al., 
2009a; Benhnia et al., 2009b). Recombinant ECTV expressing HEL in soluble and 
trans-membrane forms are currently being generated to further evaluate the role of 
antigen form in class switching and long-term antiviral protection. 
To identify the spectrum of mutations associated with the maturation of anti-viral 
HEL3X antibodies, single donor-derived IgG2c switched GC B cells were sorted from 
rECTV-WT-HEL3X infected mice and Ig heavy chain variable region was sequenced. 
Time-course analysis of nucleotide mutations frequencies revealed an initial 
preponderance of synonymous mutations that was gradually superseded by non-
synonymous mutations (Figure 6.8). At various time-points during the course of the 
infection, a dataset of 25 amplicons were analyzed, excluding sequences with insertions 
or deletions. Somatic mutations were preferentially located in the CDR regions, 
principally around CDR2. Among the total 116 amino acid residues in the VH region, 
four residues stand out as mutational hotspots: Tyr-53 and Tyr-58 followed by Ser-56 
and Ser-31 (Figure 6.9). Substitution pattern analysis of Tyr-53 revealed a previously 
described aspartate substitution associated with increasing affinity to HEL3X. This 
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substitution resolves a steric conflict between the arginine side-chain of HEL3X 
(D101R) and the phenol group of Tyr-53 (Phan et al., 2006), thereby increasing the 
affinity of the SWHEL BCR for HEL3X by approximately 85 fold (illustrated in 
Appendix Figure 6.8). The removal of the hydroxyl group from HyHEL10 Tyr-58 as a 
result of the phenylalanine substitution increases the affinity of the SWHEL BCR to 
HEL3X. This is perhaps due to a conformational change allowing favorable contact of 
the aromatic ring of phenylalanine residue (Y58F) with the glutamine side chain (R21Q; 
HEL3X) (illustrated in Appendix Figure 6.9). Protein modeling of the asparagine 
substitution at Ser-56 shows an enhanced hydrogen bond interaction with arginine 101 
(illustrated in Appendix Figure 6.10).  
Across the infection time-points analyzed in this chapter, donor-derived B cells with 
Y53D substitution were actively selected into the GC such that by day 21p.i., the 
mutation was evident in > 90% of the clones analyzed (Figure 6.11). Subsequently, at 
days 21 and 28 p.i., a further selection of Y53D+ / Y53D++ clones with co-occurring 
Y58F/ S56N/ S31R substitutions was evident (Figure 6.15). Although the Y53D+ 
/Y53D++ clones are theoretically calculated to have higher affinity to the antigen, they 
fail to dominate the GC reaction, at least in the time-course analyzed. This result points 
to a stochastic undercurrent to the affinity based selection model, probably based on T 
cell help. Moreover, in the experiments outlined in this chapter, donor-derived IgG2c 
switched GC B cells were gated on HELWT binding. Therefore, the cells with extremely 
high affinity to HEL3X could have low HELWT binding and as a result, may have been 
lost from the analysis. A strategy to get around this problem, particularly at later time-
points, would be to use fluorochrome conjugated HEL3X protein to identify cells with 
strong HEL3X binding followed by single cell sorting to evaluate somatic hypermutation 
patterns. Recent studies have highlighted a role of somatic mutations in the 
immunoglobulin framework regions in the generation of neutralizing antibodies (Klein 
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et al., 2013; Zhou et al., 2010). Accordingly, future experiments could extend the 
analysis to the framework regions to get a comprehensive understanding of somatic 
mutation patterns associated with increased affinity. 
Although a time-course analysis of cells selected into the plasma cell compartment was 
not performed in the current study, we can, nevertheless, indirectly examine this by 
analyzing the serological maturation of antiviral-HEL3X antibodies. With the 
appearance of affinity enhancing mutations in the GC B cells, one would expect 
selection into the plasma cell compartment and consequent increase in the antibody 
binding affinity to HEL3X. Although, we detected an increase in HEL3X binding 
capacity between day 7 and 14 p.i., intriguingly, we did not detect any further increase 
in the binding capacity at day 21 and day 28 p.i.  In contrast to the polyclonal antibody 
responses described in the previous chapters, this study primarily focused on affinity 
maturation of one epitope (viral envelope HEL3X) amongst a myriad of other viral 
antigens. The HEL3X binding levels at later time-points can be explained by active 
selection of plasma cells specific for other viral antigens to maintain plasma cell 
diversity. In addition, the half-life of both plasma cell as well as circulating IgG2c 
antibodies should be taken into account while interpreting the serological maturation 
results.  The slight decrease in HEL3X binding capacity does not reflect on the affinity 
of the antibody, which was not measured in this study. We predict that the appearance 
of double (Y53D+) and triple (Y53D++) HEL3X affinity enhancing mutations in the 
antigen-specific GC B cells at day 21 and 28 p.i will correlate with increasing affinity of 
the antibody. If not, one possible explanation is the preferential selection of the Y53D+ 
and Y53D++ clones into the memory pool rather than the plasma cell compartment. 
Somatic mutation analysis of plasma cells and memory B cells at the later time-points 
will help reconcile any differences between the cellular and serological maturation 
patterns. 
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Data presented in previous chapters have confirmed a role for replication fitness of the 
virus and antigen availability in generation of anti-viral neutralizing antibodies. With 
the availability of WT and TKΔ viruses expressing the transgene of interest, we have 
sought to provide proof of principle epitope-specific antibody maturation in this 
context. Viral-HEL2X envelope antigen in a replicating virus infection elicits a 10-fold 
larger donor-derived GC B cell population compared to replication-inefficient virus at 
the same dose. Maintaining the s.c. route of administration, but increasing the dose of 
the virus by a 1000-fold led to a small two-fold increase in antigen specific GC B cell 
response. In contrast, administration of virus through the i.v. route resulted in a 
substantial 8-fold increase in antigen-specific GC B cell differentiation (Figure 6.22). 
These differences in antigen-specific GC B cell populations are likely to be a reflection 
of the amount of antigen available. In our experimental model, we can assume that the 
epitope (HEL2X) density remains the same in both recombinant WT and TKΔ viruses 
and therefore any changes in the antigen availability is likely to be brought about by 
replication of the virus or variation in virus dose. During infection with the replicating 
rECTV-WT-HEL2X, the host encounters increasing concentration of viral antigens 
(including HEL2X). This increasing antigen availability augments antigen presentation, 
activation of T and B cells and increased antigen deposition in the form of immune 
complexes on FDCs. The antigen repositories on FDCs promote affinity maturation 
resulting in a diverse high-affinity antibody response. Administration of replication-
inefficient rECTV-TKΔ-HEL2X through the s.c. route will stimulate responses in the 
local draining lymph node, but further increases in antigen concentration and potential 
spread to secondary lymphoid organs is limited due to restricted replication capacity. 
On the other hand, i.v. infection leads to direct deposition of the antigen in the lymphoid 
organs, particularly the spleen and this possibly explains the increase in antigen-specific 
B cell proliferation observed. 
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The somatic mutation rates observed are in accordance to the antigen availability; with a 
greater than two-fold increase evident in infection conditions that result in optimal 
antigen availability within the spleen (rECTV-WT-HEL2X; 1000 PFU s.c. and rECTV-
TKΔ-HEL2X; 106 PFU i.v.). Notably, preferential mutations in the CDR2, particularly 
Y53D mutation were identified. The appearance of additional mutations (double; 
Y53D+ and triple; Y53D++) in experimental conditions with increased antigen 
availability suggests selection followed by additional cycles of hypermutation. It is 
likely that the amount of antigen present stochastically determines the number of 
selection: mutation cycles, thereby regulating affinity maturation. 
The results presented in this chapter further our understanding of envelope-antigen 
driven proliferation, somatic hypermutation and class switching during the process of 
affinity maturation in the context of a physiological viral infection. The utility of 
ECTVHEL: SWHEL model extends far beyond the detailed GC somatic hypermutation 
analysis discussed in this chapter. In combination with HEL-specific CD4 T cells 
(TCR7 transgenic cells), the model can also be used to evaluate T and B cell fate 
decisions in poxviral infections. Recombinant viruses with varying antigenic forms 
(soluble and membrane) have been generated and can be used to address the role of 
antigen form in the induction and maintenance of long-lived humoral immunity. 
Antigenic specific memory B cell and LLPC studies using this viral model will make 
significant contributions towards approaches in augmenting vaccine efficacy. Finally, 
based on the protective antiviral responses elicited in this physiological model, 
comprehensive computer modeling can be used to rationally design vaccines against 
epitopes that are poorly immunogenic such as in malaria, HIV and RSV infections. 
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7 Conclusion and future directions 
7.1 Introduction 
Arguably, the vast majority of licensed viral vaccines available today have harnessed 
the power of humoral immunity to provide protection against viral diseases. This is best 
evidenced in smallpox survivors and vaccinees in whom potent neutralizing antiviral 
antibodies and long-term memory B cells responses could be detected 7-8 decades later. 
This long-term protective immunity against smallpox has been established as a 
benchmark for the functional attributes of an effective vaccine (Hammarlund et al., 
2003; Crotty et al., 2003a; Putz et al., 2005). Furthermore, the unprecedented success of 
live poxvirus vaccines in smallpox eradication has prompted further use of recombinant 
poxviral vectors as vaccine delivery systems. Poxviruses have a large genome allowing 
insertion and high-level expression of foreign genes making them an ideal choice to use 
as vaccine vector (Smith and Moss, 1983). Despite its widespread trials in human and 
veterinary infectious disease vaccines and cancer immunotherapy, the fundamental 
aspects pertaining to the long-lived humoral immunity to poxviruses remain elusive. 
The pathogenesis of smallpox infection in humans is mirrored by ECTV infection in the 
mouse. Both viruses infect their respective hosts at low doses (Nicas et al., 2004; Parker 
et al., 2009; Mavian et al., 2014), cause systemic infection and induce life-long 
protective immunity. Using mousepox as a surrogate model for smallpox, the 
contribution of different immune cell subsets to long-lived humoral immune responses 
was evaluated. The immune response to mousepox is a highly orchestrated process 
involving innate effectors as well as cellular and humoral adaptive mediators. However, 
efficient virus control and protection from re-infection are largely dominated by long-
lived virus-specific antibodies and memory B cell responses, which are generated by 
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engagement of the GC reaction. Very little is known about the dynamics of GC 
mediators that are associated with potent and durable antiviral immune responses seen 
in mousepox. 
7.2 Cellular players of GC: TFH, TFR and GC B cell 
dynamics in poxvirus infection 	  
In Chapter 3, we aimed to understand the dynamic interplay between GC mediators, i.e., 
TFH, TFR and GC B cells in the generation of long-lived antibody responses such as that 
seen in ECTV-infected mice. Surprisingly, a comprehensive kinetic analysis of the GC 
response has not yet been reported in the best surrogate model for smallpox. Time-
course analyses over a period of 4-5 weeks p.i. revealed that the magnitude of the TFH 
and GC B cells responses were correlated, with peak responses observed at day 14 p.i. 
From this point onwards, as observed by GL7 expression, 50% of the TFH cells localized 
within the GC and possibly engaged with cognate GC B cells. However, recent reports 
have established that GC TFH cells are highly plastic and can temporarily give up their 
GC status to reside as TFH cell outside the GC or develop into a memory TFH cell 
(Kitano et al., 2011; Shulman et al., 2013). Nonetheless, the GC TFH: GC B cell 
interactions are critical in humoral immune response as evidenced by reduced antiviral 
antibody response in SAP-deficient mice. Interactions between antigen-specific TFH/GC 
TFH cells and cognate GC B cells in poxvirus infections can be directly examined by 
intravital microscopy using the ECTVHEL:SWHEL model described in Chapter 6. This 
will provide valuable insight into the contribution of these interactions to the life-long 
humoral immunity associated with poxvirus infections. 
During the GC response, maximal numbers of TFR cells were detected at days 18-21 
p.i., after the peak of the GC responses. The balance of TFH /TFR evolved through the 
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course of infection, with major changes in pattern detected early through to the peak of 
the reaction followed by a gradual return to baseline. Modulating the TFH / TFR balance 
represents one of the axes along which the quality and duration of antibody responses 
may be controlled. Whilst the role of TFR cells in controlling the magnitude of GC 
responses has been confirmed by different experimental strategies (Linterman et al., 
2011; Chung et al., 2011; Wollenberg et al., 2011), the mechanism is yet to be precisely 
defined. Our study of the TFR dynamics in ECTV-induced GC response presented with 
two mechanistic possibilities. A fall in the TFR numbers was observed early in the GC 
response and adoptive transfer of TFR cells to negate the drop seemed to reduce the 
magnitude of the GC response. Linterman et al., in their study demonstrated an 
outgrowth of non-antigen specific clones in the germinal center in the absence of TFR 
cells; however the TFR cells were depleted at the peak of the GC reaction (Linterman et 
al., 2011). These findings suggest that any strategy to regulate the TFR cells for optimal 
GC responses must also consider the timing of modulation.  
In addition, our studies detected an increase in the CD25 TFR cells through the 
contraction of the GC response suggesting a role for IL2:IL2Rα signaling in the 
suppressive activity of TFR cells. It would be of particular interest to examine the 
suppressive activity of CD25+ve and CD25-ve TFR cells in in-vitro TFH and B cell co-
cultures. Although IL-2 has been shown to inhibit early TFH differentiation within the 
GC (Ballesteros-Tato et al., 2012), the cytokine could play a context dependent 
paradoxical role in TFH regulation via TFR cells. In addition to IL2:IL2Rα-mediated IL-
10 production, TFR cells can possibly deprive the TFH cells of metabolic survival signals, 
by acting as an IL-2 sink, similar to the mechanism of cytokine deprivation adopted by 
TREG cells (Pandiyan et al., 2007). TFR cells originate from TREG cells and may have 
retained several molecular suppressive mechanisms used by TREG cells such as CTLA-4 
mediated trans-endocytosis and granzyme A/B dependent cytolysis (Gondek et al., 
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2005; Wing et al., 2008; Qureshi et al., 2011). Further research into the molecular 
mechanisms of TFR-mediated suppression in poxvirus-induced GC responses will be 
beneficial in augmenting antibody responses to foreign antigens expressed by poxvirus 
based vaccine vectors. 
7.3 Requirement of SAP in protective immune 
responses against poxvirus infection 	  
Another axis that has been studied extensively to enhance antibody-mediated vaccine 
protection is SAP dependent T:B interactions. Interestingly, our findings with the SAP-
deficient mice vary from other viral model studies. In the absence of SAP, we observed 
impaired TFH differentiation post-ECTV infection, which is consistent with the TFH 
differentiation pattern in the LCMV model, but contrasts with findings reported for the 
influenza model in which TFH differentiation was not affected by SAP deficiency 
(Kamperschroer et al., 2008; Yusuf et al., 2010). Contrary to the progressive loss of 
antiviral antibody responses seen in LCMV infection (Crotty et al., 2003b), the anti-
ECTV responses were maintained long-term similar to the anti-influenza antibody 
responses (Kamperschroer et al., 2006; Crotty et al., 2003b). In a recent study, using 
inducible SAP-deficient mice, Zhong et al., demonstrated that SAP is not required for 
the long-term maintenance of antigen-specific memory B cells or long-lived plasma 
cells (Zhong and Veillette, 2013). Futhermore, in our ECTV model, primed SAP-
deficient mice were able to control a lethal secondary challenge as opposed to the 
susceptibility reported in the influenza model (Kamperschroer et al., 2006). These 
results highlight that in ECTV infection, the contribution of SAP-independent pathway 
to protective immune responses (both primary and secondary), is much more substantial 
than has been previously perceived. An extension of these findings to other 
orthopoxvirus models such as VACV would confirm if both SAP-dependent and SAP-
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independent pathways are amenable for modulation to augment antiviral antibody 
responses to poxviral vaccine vectors. If the SAP-independent pathway is indeed found 
to play a significant role in induction and maintenance of antibody responses to VACV 
in humans, it could explain, at least in part, why humoral immunity to smallpox 
vaccination persists for decades even despite waning CD4 T responses (Hammarlund et 
al., 2003)  
The most notable defect in SAP-deficient mice is the inability to maintain sustained 
contact between TFH and B cells, particularly in the T:B area and the interfollicular area 
(Qi et al., 2008). However, intra-vital microscopy results show that SAP-deficient T 
cells continue to make preferential contact with cognate B cells rather than non-cognate 
B cells (Qi et al., 2008). In ECTV infected SAP-deficient mice, it is possible that the 
presence of abundant antigen and co-stimulatory CD40 signaling allows a partial rescue 
of the conjugate stability, resulting in GC localization and exchange of signals 
promoting class switching and affinity maturation.  It is important to note that within 
the GC, the duration of T:B interactions are predominantly short and the requirement of 
SAP in this process is yet unknown. This model suggests that the contribution of the 
SAP-independent pathway to protective immune response hinges on antigen availability 
and will therefore be impacted significantly by the choice of the vaccine vector; i.e. 
replication-competent or replication-inefficient. 
7.4 Viral replicative fitness and host immune response 
in poxvirus infection 
The final outcome of an immune response to a viral infection or vaccination is not only 
dependent on a range of host factors as described above, but is also influenced by 
several viral factors (or viral vaccine vector factors). With the safety of the vaccine a 
	  	   303 
primary concern, all the viral vaccines are currently used on an attenuated platform. For 
example; although smallpox was eradicated with a live virus vaccine, the vaccine is not 
considered safe by contemporary standards and subsequent generation of vaccines 
(against smallpox as well as recombinant vaccine vectors) have been developed with an 
improved safety profile, particularly at the expense of the replication capacity of the 
virus. Although recent studies have provided a better understanding of the GC events 
and the host factors governing the quality and quantity of antiviral immune responses, 
very little is however known about the contribution of the replication-fitness of the virus 
to the process. Based on a good understanding of correlates of protection in poxvirus 
infection, a thorough evaluation of the immune responses elicited by attenuated viruses 
will provide opportunities for manipulation in order to augment protective efficacy. 
This knowledge will guide the transition from empirical vaccine development to 
rational design of vaccine. 
Our understanding of the mechanism of immune protection provided by attenuated 
viruses is confounded by the use of varying doses, routes, animal models and challenge 
strategies reported in the scientific literature. In chapter 4 of this thesis, the antiviral 
humoral immune responses elicited by replication-competent and attenuated viruses 
were compared, with a deliberate attempt to ensure that the comparisons were carried 
out under similar conditions. At the same dose and route of administration, enhanced 
TFH differentiation was observed during infection with replication-competent virus 
compared to replication-inefficient virus. This finding can be primarily attributed to the 
differences in antigen levels based on the replication fitness of the virus and are 
consistent with recent studies examining the role of antigen dose in TFH differentiation 
fate. Using pMHCII tetramers to track single antigen specific CD4 T cells, Tubo et al., 
demonstrated that in the presence of an increasing antigen dose, TFH generation 
increased progressively in response to higher TCR signaling (Tubo et al., 2013). In 
	  	   304 
addition to its key role in early TFH differentiation, antigen is critical for further rounds 
of TFH proliferation and terminal differentiation to GC TFH (Choi et al., 2013b; Tubo et 
al., 2013). The results from the current study as well as previous findings suggest that a 
sustained level of antigen and not just an initial burst is critical to determine the total 
duration of TFH and B cell interactions within the GC, which directly impacts the 
affinity of the antibody generation. Accordingly, antibodies with lower neutralizing 
capacity were generated during replication-inefficient virus infection. We were able to 
demonstrate via passive transfer-challenge experiments, that these antibodies were not 
as effective in controlling a secondary challenge as compared to antibodies generated 
following infection with a replication-competent virus. Using the novel 
ECTVHEL:SWHEL model, we were able to demonstrate at an antigen-specific level, that 
infection with a replication-inefficient virus infection resulted in impaired antibody 
affinity maturation. 
7.5 Affinity maturation in poxvirus infection – 
ECTVHEL: SWHEL model 
The generation of high affinity antibodies is a complex multistep process with iterative 
cycles of SHM and selection that is governed via antigen driven selection by FDC and 
TFH: B cell interaction. Only GC B cells with relatively high affinity BCR are able to 
survive the competition for antigen reserves and progress thorough additional cycles of 
SHM: selection or differentiation to long-lived plasma cells and memory B cells. The 
antigen levels are reduced more rapidly in attenuated virus infection compared to 
replicating virus infection, thereby impacting the number of SHM: selection cycles. 
This was reflected in the varying SHM patterns of GC B cells observed in replication-
competent and replication in-efficient virus infections. Whilst a progressive 
accumulation of mutations associated with higher affinity to the antigen was identified 
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in replicating virus infection, none could be detected in the replication-inefficient virus 
infection.  
Differentiation of somatically mutated GC B cells into plasma cells and memory B cells 
is fundamental to antiviral humoral immune responses. Although the SHM patterns of 
plasma cells later in the GC responses was not examined in this study, we were 
nevertheless able to confirm the differentiation of the somatically mutated GC B cells 
into plasma cells based on the analysis of antigen specific circulating antibody 
responses. The precise differentiation cues for the GC B cells fate decisions are not well 
understood. Whilst IL-2 and CD40 ligation have been observed to drive a memory 
phenotype (Siepmann et al., 2001; Roy et al., 2002), IL-10 and PD-1 signaling have 
been implicated in plasma cell differentiation (Choe and Choi, 1998; Good-Jacobson et 
al., 2010). A temporal differentiation pattern has also been proposed in which GC B 
cells differentiate into memory B cells early in the GC response, and long-lived plasma 
cells are preferentially generated late in the GC reaction; reports of fewer affinity 
increasing somatic mutations in the memory B cells compared to long-lived plasma 
cells in protein immunization studies support this theory (Smith et al., 1997). A study 
using West Nile virus was able to demonstrate a more stringent affinity based selection 
into the plasma cell compartment compared to the memory B cell compartment based 
on the ability to neutralize a viral escape mutant (Purtha et al., 2011). Future 
experiments using the ECTVHEL:SWHEL model described in this thesis will allow direct 
examination of the mutation patterns prevalent in antigen-specific plasma cells and 
memory B cells at various stages after infection and provide valuable insights into the 
temporal and affinity based differentiation of GC B cells into plasma cells and memory 
B cells. In addition, earlier studies using protein immunization have observed 
phenotypically discrete subsets of memory B cells with variations in mutation patterns 
(Tomayko et al., 2010; Zuccarino-Catania et al., 2014) and the relevance of these 
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subsets in physiological virus infections can be investigated using the ECTVHEL:SWHEL 
model. Furthermore, the cognate interactions between memory TFH cells and memory B 
cells have previously been shown to be important in recall responses (Locci et al., 2013; 
Ise et al., 2014). The use of the rECTV-WT-HEL3X to study antigen specific T and B 
cell interactions (using TCR7 and SWHEL B cells) in appropriate animal models will be 
beneficial to further understand the regulatory mechanisms that play a role in recall 
memory responses. It would also be of interest to investigate the role of bystander or 
antigen-independent memory B cell differentiation into plasma cells (Bernasconi et al., 
2003; Bernasconi et al., 2002; Crotty et al., 2004) by adoptive transfer experiments 
using the ECTVHEL:SWHEL model. This will provide valuable insight into the 
maintenance of long-lived immunological memory in poxvirus infections. 
7.6 TFH: TFR ratio - a valuable predictor of protective 
immune response 
A major goal for vaccine design is the induction of long-lasting immunity with high 
protective efficacy. The ability to prospectively determine the magnitude, potency and 
durability of immune response to vaccination has been a major challenge in vaccine 
biology. Several studies have attempted to identify universal molecular signatures 
associated with vaccine efficacy; however the transcriptional signatures of antibody 
responses have been shown to be dependent on the class of vaccine (Li et al., 2014). 
Identification of a correlate that within days or weeks of vaccination can predict long-
term antiviral immunity will be of great value in reducing the time-frame between 
vaccine design and clinical trials. Our findings indicate that TFH:TFR ratio in the spleen 
as well as in the blood compartment can predict the quality of long-term antibody 
responses, before they are even generated. The reliability of the correlate was 
demonstrated across varying vaccination regimes in four virus models: ECTV, VACV, 
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MVA and influenza. Based on the results from these experiments, we predict that the 
TFH:TFR ratio will be valuable in predicting antibody response outcomes in virus 
infection models that mediate protection through T-dependent antibody responses. 
However, it is important to remember that the use of TFH:TFR ratio as a biomarker of 
long-lived potent antibody responses is dependent on normal terminal TFH 
differentiation and GC formation (as discussed in Chapter 4, section 4.3).  Although the 
ability of TFH:TFR ratio to predict vaccine efficacy in non-viral models and clinical trials 
remain to be tested, these findings provide a basis for further studies into the molecular 
signatures associated with this correlate. 
7.7 Antigen availability and immunogenicity  
Attenuated recombinant poxvirus vectors targeting diseases such as influenza, malaria, 
HIV-1 and cancer are currently in various stages of clinical trails to establish vaccine 
efficacy. Despite an excellent safety profile, reports of limited efficiency such as in the 
RV144 phase II clinical trials for HIV-1 (Rerks-Ngarm et al., 2009) has prompted 
research towards a better understanding of the virus-host factors critical for vaccine 
efficacy and strategies to enhance immunogenicity of attenuated poxvirus vectors. Data 
presented in chapter 5 and 6 of this thesis show that the dose of the attenuated virus has 
a limited effect on the quality of the antibody response when given s.c. than when the 
virus was administered i.v. These findings suggest that the dose and the route of 
administration govern the GC responses by essentially altering the amount of antigen 
reaching the secondary lymphoid organs. Intravenous administration leads to efficient 
trapping of the virus particles in the spleen, directly influencing the magnitude of TFH 
differentiation and consequent affinity maturation of the antiviral antibody response. 
Indeed, several recent studies have explored the use of intra-splenic delivery of antigen 
as an immunotherapeutic modality (Munoz-Montesino et al., 2004; White et al., 2000). 
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However, in addition to high antigen dose and presence of antigen in the lymphoid 
organs, the kinetics of the antigen availability significantly impacts the quality of the 
immune response. Johansen et al., in their studies using peptide antigen, demonstrate 
that an exponential increase in the peptide antigen to simulate the antigen kinetics in 
viral replication, results in enhanced antiviral immunity on challenge (Johansen et al., 
2008). Whilst live virus vaccines produce a temporally escalating concentration of 
antigen, replication-inefficient viruses have a reduced antigen profile and in inactivated 
or non-replicating virus infections, the antigen available is restricted to the dose 
administered. Antigen availability significantly impact the quality and duration of long-
lived antiviral immunity, thereby necessitating multiple doses of attenuated and 
inactivated virus vaccines to improve immunogenicity and achieve long-term protective 
immunity. Whilst current viral vaccines widely practice homologous boosting to 
enhance humoral immune responses, heterologous prime-boost regimes are also being 
trialed to augment cellular immune responses (Reyes-Sandoval et al., 2010; Lu, 2009). 
7.8 Rational design of vaccines 
With a better understanding of the virus-host interactions in orthopoxvirus infections, 
we can transition from empirical towards rational design of poxviral vaccine vectors to 
achieve long-lived potent and durable antiviral immune response. Previous studies have 
shown that insertion of co-stimulatory molecules such as CD40L (Lauterbach et al., 
2013; Liu et al., 2008a; Gomez et al., 2009) and GM-CSF (Chavan et al., 2006; 
Nemeckova et al., 2007; Lai et al., 2011) can augment the immunogenicity of poxvirus 
vaccine vectors. Data presented in this thesis suggest that the TFH/TFR interactions, as 
evidenced by the ratio, govern the magnitude of the GC response (chapters 4 and 5). 
Therefore modulation to augment the TFH differentiation or dampen the TFR responses 
can be used to enhance the potency and duration of long-lived antiviral humoral 
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immune responses. Sage et al., demonstrated that PD-1 signaling via PD-L1 impacts the 
TFR cell numbers (Sage et al., 2013), indicating that modulating the TFR response by 
PD-L1 can effectively augment the TFH response by skewing the ratio of TFH and TFR 
cells. Modification of the cytokine milieu to promote TFH differentiation is another 
strategy to augment T-dependent humoral immune responses. IL-21, the main effector 
cytokine of TFH cells is emerging as a useful vaccine adjuvant in tumor model studies 
and cancer immunotherapy. The function of IL-21 in immune response is multifaceted 
with established roles in TFH differentiation, antibody responses, CD8+ CTL activity, 
TREG homeostasis and NK cell mediated ADCC (Bauquet et al., 2009; Ozaki et al., 
2002; Sutherland et al., 2013; Attridge et al., 2012; Watanabe et al., 2010). The 
pleiotropic effects of IL-21 suggest that the incorporation of IL-21 in viral vaccine 
vectors can be used to augment cellular immune responses as well as long-lived high 
affinity-matured antibody responses. Another complementary strategy to augment TFH 
cell differentiation and consequent protective antibody responses is to enhance antigen 
presentation by DC. Poxviruses, such as VACV, have been shown to induce DC 
apoptosis and suppress antigen presentation (Engelmayer et al., 1999; Li et al., 2005; 
Rehm et al., 2009). Incorporation of CD74 in the viral vector has been shown to 
partially ameliorate the virus inhibition of MHCII antigen presentation promoting 
antiviral antibody response (Walline et al., 2014). We hypothesize that CD74, PD-L1 
and IL-21 as potential candidates for incorporation in poxviral vaccine vectors to 
augment vaccine efficacy through induction of potent humoral immune responses. 
7.9 Concluding remarks 
In conclusion, the work described in this thesis has substantially progressed our 
understanding of the virus and host factors that influence the generation of potent and 
durable antibody responses. Defining the contribution of SAP-independent CD4 T cell 
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help pathways in neutralizing antiviral antibody responses opens additional avenues to 
further enhance vaccine mediated protective antibody responses. The use of TFH:TFR 
ratio in blood as a signature of potent, durable antiviral antibody response generated 
after infection / vaccination is of particular significance and can be potentially used as a 
screening parameter to test various vaccine designs. Although reduced pathogenicity of 
attenuated vaccine vectors is considered an appealing attribute, our studies indicate that 
the replicative fitness of the viral vector governs the induction of long-lived antiviral 
humoral immune responses by influencing the antigen availability. Of additional novel 
contribution is the study of envelope-antigen driven, antigen-specific B cell 
proliferation and affinity maturation in the context of replication-competent or 
replication-inefficient viral infections. The ability to track the induction of antigen-
specific immune memory during a physiological virus infection using the 
ECTVHEL:SWHEL model characterized in this thesis will provide valuable insights into 
the rational design of poxviral vaccine vectors to achieve an efficacious induction of 
long-lasting immune memory. 
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                  Appendix Figures 
 	   	  	  	  	  	  	  	  
	  	  
Appendix Figure 3.1: Long-term virus-specific antibody levels following primary 
ECTV infection in C57BL/6 mice: C57BL/6 mice infected with 1000 PFU of ECTV-
WT via the s.c. route were bled at times indicated. ECTV-specific IgG levels were 
measured at a plasma dilution of 1:200 using ELISA. Data from one of two independent 
experiments represented as means of absorbance values ± SEM (n=3 mice per group). 
No statistical difference was detected using One-way ANOVA test. 	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Appendix Figure 3.2: Virus-Neutralizing antibody titers in primary ECTV 
infection. C57BL/6 mice infected with 1000 PFU of ECTV-WT via the s.c. route were 
bled at times indicated and ECTV-specific neutralizing activity was determined by 
PRNT (A) Curve-fitting of the data was done using four-parameter non-linear 
regression analysis to evaluate the neutralizing capacity (Dotted line indicates 50% 
neutralization). (B) PRNT50 was calculated as the reciprocal of plasma dilution at which 
50% of the virus is neutralized. Data shown are from one of two independent 
experiments with similar results and represented as means ± SEM (n=3 mice per group). 
No statistical difference was detected using the Holm- Sidak One-way ANOVA test. 	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Appendix Figure 3.3: TFH response in C57BL/6 following exogenous transfer of 
TFR cells: Two Groups of 3 C57BL/6 were infected with 1000 PFU of ECTV-WT. On 
day 6 p.i., 5 x 103 TFR cells were adoptive transferred into one group of infected 
C56BL/6 mice. At day 14 p.i.,  mice were sacrificed and the TFH responses were 
examined by flow cytometry (A) Flow cytometric contour plots of TFH cells with or 
without exogenous TFR transfer, (B) TFH cells represented as % of CD4 T cells and (C) 
Total splenic TFH cell numbers. Data from one experiment represented as means ± 
SEM. No statistical difference was observed using Mann Whitney t-test. 	  
	  	   314 
	  	  	  	  	  	  	  	  
	  	  
Appendix Figure 3.4: GC B cell response in C57BL/6 following exogenous transfer 
of TFR cells: C57BL6 were infected and TFR cells transferred as described in Appendix 
Figure 3.3. (A) Flow cytometric contour plots of GC B cells (B) GC B cells represented 
as % of B220+cells and (C) Total splenic GC B cell numbers with or without TFR 
transfers. Data from one experiment represented as means ± SEM. No statistical 
difference was observed using Mann Whitney t-test. 	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Appendix 3.5: CD25 expression in TFR population following primary ECTV 
infection. Groups of 3 C57BL/6 mice were infected subcutaneously with 1000 PFU of 
ECTV-WT at various times and all sacrificed on the same day such that each group had 
been infected for the period indicated. CD25 expression on TFR cells was determined by 
flow cytometry (A) Naïve, (B) Day 7 p.i., (C) Day 10 p.i., (D) Day 14 p.i., (E) Day 18 
p.i., (F) Day 21 p.i., (G) Day 28p.i. and (H) CD25 MFI calculated from concatenated 
files at the indicated time-points. 
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Appendix Figure 4.1: Gating strategy for identification of CD8 MPEC, TEM and TCM cell populations:  C57BL/6 mice infected subcutaneously 
with 1000 PFU of ECTV-WT were sacrificed at day 70 p.i. and memory populations were identified by flow cytometry as described below: 
TEM cell phenotype: CD8
+, CD44hi, CD62Llo, CD127 (IL-7Rα)hi 
MPEC phenotype: CD8+, CD44hi, CD62Llo, CD127lo 
TCM cell phenotype: CD8
+, CD44hi, CD62Lhi, CD127hi 	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Appendix Figure 4.2: Gating strategy for identification of CD4 TEM and TCM cell populations:  C57BL/6 mice infected subcutaneously with 1000 
PFU of ECTV-WT were sacrificed at day 70 p.i. and memory populations were identified by flow cytometry as described below: 
TEM cell phenotype: CD4
+, CD44hi, CD127hi, CD62Llo 
TCM cell phenotype: CD4
+, CD44hi, CD127hi,  CD62Lhi  
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Appendix Figure 4.3: Effect of viral replicative capacity on activated CD4 T cell 
numbers. C57BL/6 mice were infected with live or attenuated strains of ECTV or 
VACV as described previously. Activated CD4 T cell numbers were calculated and 
represented as means ± SEM. Data was log transformed and statistical significance 
determined using Two-Way ANOVA with Holm-Sidak’s multiple comparison test; 
****P<0.0001. 	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Appendix Figure 5.1: Blood viral titers in ECTV-WT and ECTV-TKΔ infection: 
C57BL/6 mice were infected s.c. with 1000 PFU of ECTV-WT or ECTV-TKΔ. Mice 
were bled at times indicated and DNA isolated was used to quantitate the viral load by 
real time quantitative PCR. Data from one experiment represented as log10 viral genome 
copy numbers ± SEM (n=4-5 mice per group). Dotted line indicates the basal level of 
detection (20 viral genome copy numbers). Data was log transformed and statistical 
significance determined using Holm-Sidak’s Two-Way ANOVA test; ****P<0.0001. 	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Appendix Figure 5.2: Correlation between virus dose and magnitude of TFH and GC B cells. C57BL/6 mice were infected i.v. with low or high 
dose of  attenuated virus as discussed in Chapter 5. Mice were sacrificed at the peak of the GC reaction, and the GC B cell and TFH cells were 
enumerated. Data from one experiment each group is represented in the graph. The Pearson correlation co-efficient (r) and p values were calculated 
using Prism. 
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Appendix Figure 6.1: HEL variant proteins. (A) Schematic model of HyHEL10-HEL 
complex. HyHEL10 VL and VH chains are represented in blue and yellow; HEL antigen 
in white. R21, R73 and D101 residues in HEL protein are highlighted in red, green and 
orange respectively, (B) HELWT antigen structure, (C) HEL3X antigen structure with 
D101R, R73E and R21Q mutations and (D) Table listing the mutations and binding 
affinities of HyHEL10 to HEL variant proteins. Images were generated using Swiss Pdb 
viewer (Pdb file: 3HFM). 
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Appendix Figure 6.2:  Strategy used to study antigen-specific B cell responses. (A) SWHEL donor (CD45.1) splenocytes containing 3x104 HEL-
binding B cells were adoptively transferred into WT congenic (CD45.1) congenic mice. After 24 hrs, the mice were infected subcutaneously with 1000 
PFU of rECTV-WT-HEL3X. (B) Antigen-specific B cell responses were studied by tracking the HEL-binding, CD45.1+ cells. The plot is gated on 
lymphocytes after doublet and autofluorescent cell exclusion. Number within the gate indicates the percentage of the parent population. 
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Appendix Figure 6.3: Antigen specific donor B cell proliferation kinetics elicited in 
response to HEL3X-SRBC.  SWHEL B cell recipient mice were immunized with HEL3X-
SRBC and spleens harvested for flow cytometric analysis on 7, 14, 21 and 28 days later 
(A) Pseudocolor FACS plots showing the expansion profile of donor HEL-binding B 
cells at time-points indicated. The data shown are gated on lymphocytes after doublet 
and autofluorescent cell exclusion as in Figure 6.2A. Numbers indicate the proportion 
of CD45.1+ cells that were HEL-binding. Donor-derived HEL-binding cells expressed 
as (B) % of single lymphocytes, (C) % CD45.1+ donor cells and (D) Absolute cell 
numbers per spleen. Data is representative of pooled samples from three mice at each 
time-point. 
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Appendix Figure 6.4: IgG subclass-switching in HEL3X-SRBC challenge.  SWHEL B-cell recipient mice immunized with HEL3X-SRBC were 
sacrificed 14 days later and spleens harvested for FACS analysis. Donor-derived CD45.1+, HEL-binding GC B cells were stained separately for (A) 
IgG1, (B) IgG2b, (C) IgG2c and (D) IgG3 subclasses. Numbers within the gates indicate the frequency of donor-derived GC B-cells positive for the 
specific IgG subclass. 
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Appendix Figure 6.5: SHM analysis of single SWHEL GC B in response to viral-
HEL3X at day 7 p.i.  SWHEL B cell recipient WT congenic mice infected with rECTV-
WT-HEL3X were sacrificed at day 7 p.i. and the donor-derived GC B cells were single 
cell sorted. Ig VH chain exon region was PCR amplified and sequenced as described in 
section 2.10. Translated sequences were aligned with the original HyHEL10 sequence 
using MacVector. Figure shows only the amino acid substitutions detected, synonymous 
mutations are not shown. Data is representative of 21 clones analyzed from 3 mice. 
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Appendix Figure 6.6: HELWT and HEL3X binding capacity of IgG2c antibody 
elicited in response to viral-HEL3X. SWHEL B-cell recipient mice were infected as 
described for figure 6.17. At day 14 p.i., the ability to bind both HELWT and HEL3X was 
analyzed. Serum anti-HEL IgG2c showed similar binding to HELWT and HEL3X 
indicating that the affinity maturation had indeed occurred. Data shown is the mean of 
absorbance values ± SEM from three mice done in duplicate. 	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Appendix Figure 6.7: Antigen specific donor B cell proliferation kinetics in 
response to HEL3X-SRBC and viral-HEL3X. SWHEL B cell recipient mice infected 
with rECTV-WT-HEL3X or immunized with HEL3X-SRBC were sacrificed at times 
indicated. Donor-derived HEL-binding B cells were enumerated by flow cytometry and 
expressed as percentage of CD45.1+cells. Data is representative of pooled samples from 
three mice at each time-point. 	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Appendix Figure 6.8: Schematic model of interactions between D101R (HEL3X) and Y53/ Y53D (HyHEL10). Part of CDR2 (position 53-58) is 
shown in white, with the residue of interest (Tyr-53) highlighted in red. Position 101 of HEL3X is shown in green. (A) Complex showing the steric 
conflict between the arginine side-chain (D101R) of HEL3X with the phenol ring of Y53 (HyHEL10). (B) Complex showing resolution of steric 
conflict by aspartate substitution (Y53D). The computed hydrogen bonds are shown as green dashed lines and steric clashes as purple dashed lines. . 
Images were generated using Swiss Pdb viewer (Pdb file: 3HFM). 	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Appendix Figure 6.9: Schematic model of interactions between R21Q (HEL3X) and Y58/ Y58F (HyHEL10). Part of CDR2 (residues 53-58) is 
shown in white, with Tyr-58 highlighted in red. Position 21 of HEL3X (R21Q) is shown in green. (A) Complex showing the interaction between the 
aromatic ring of Tyr-58 (HyHEL10) with the amine side side-chain of glutamine (R21Q; HEL3X). (B) Phenylalanine substitution leads to a 
conformational change allowing favourable contact with the amine side side-chain of R21Q (HEL3X). Images were generated using Swiss Pdb viewer 
(Pdb file: 3HFM). 
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Appendix Figure 6.10: Schematic model of interactions between D101R (HEL3X) and S56/ S56N (HyHEL10). Part of CDR2 (residues 53-58) is 
shown in white, with the residue of interest (Ser-56) highlighted in red. Position 101 of HEL3X is shown in green. (A) Complex showing the interaction 
between Ser-56 of HyHEL10 with D101R (HEL3X). (B) Arginine substitution (Y58F) leads to enhanced hydrogen bond interaction with D101R. The 
computed hydrogen bonds are shown as green dashed lines. Images were generated using Swiss Pdb viewer (Pdb file: 3HFM). 
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